haloperidol has been researched along with olanzapine in 822 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 75 (9.12) | 18.2507 |
| 2000's | 458 (55.72) | 29.6817 |
| 2010's | 244 (29.68) | 24.3611 |
| 2020's | 45 (5.47) | 2.80 |
| Authors | Studies |
|---|---|
| Choudhary, MS; Craigo, SC; Meltzer, HY; Monsma, FJ; Roth, BL; Shen, Y; Sibley, DR; Uluer, A | 1 |
| Bregna, DE; Burgher, KL; Corbett, R; Hartman, HB; Hrib, NJ; Jurcak, JG; Kafka, S; Kerman, LL; Kongsamut, S; Roehr, JE; Szewczak, MR; Woods-Kettelberger, AT | 1 |
| De Loore, K; Gommeren, W; Janssen, PF; Lesage, AS; Leysen, JE; Luyten, WH; Schotte, A; Van Gompel, P | 1 |
| Cai, J; Hartman, HB; Kerman, LL; Kongsamut, S; Roehr, JE; Sandrasagra, A; Tang, L; Weissensee, P | 1 |
| Audinot, V; Chaput, C; Conte, C; Gavaudan, S; Millan, MJ; Newman-Tancredi, A; Touzard, M; Verrièle, L | 1 |
| Birch, AM; Bradley, PA; Gill, JC; Kerrigan, F; Needham, PL | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Butini, S; Cagnotto, A; Campiani, G; Carminati, P; Castorina, M; Catalanotti, B; Di Cesare, MA; Fattorusso, C; Galletti, B; Gemma, S; Ghirardi, O; Giorgi, G; Goegan, M; Mastroianni, D; Mennini, T; Minetti, P; Nacci, V; Pacifici, L; Scafetta, N; Stasi, MA; Tinti, O | 1 |
| Boulton, DW; DeVane, CL; Liston, HL; Markowitz, JS | 1 |
| Ernsberger, P; Hufeisen, SJ; Jayathilake, K; Kroeze, WK; Meltzer, HY; Popadak, BA; Renock, SM; Roth, BL; Steinberg, S | 1 |
| Keserü, GM | 1 |
| Butini, S; Cagnotto, A; Campiani, G; Carli, M; Carminati, P; Castorina, M; Catalanotti, B; Di Cesare, MA; Di Serio, S; Fattorusso, C; Galletti, B; Gemma, S; Ghirardi, O; Mastroianni, D; Mennini, T; Mereghetti, I; Minetti, P; Morelli, E; Nacci, V; Pacifici, L; Scafetta, N; Stasi, MA; Tinti, O; Vertechy, M | 1 |
| Wermuth, CG | 1 |
| Butini, S; Cagnotto, A; Campiani, G; Carminati, P; Catalanotti, B; Di Cesare, MA; Di Serio, S; Fattorusso, C; Fiorini, I; Gemma, S; Ghirardi, O; Mennini, T; Mereghetti, I; Minetti, P; Nacci, V; Stasi, MA; Tinti, O; Trotta, F | 1 |
| Alonso, JM; Andrés, JI; Cid, JM; Díaz, A; Fernández, J; Gil, P; Iturrino, L; Megens, A; Sipido, VK; Trabanco, AA | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Huang, AS; Kim, SF; Snowman, AM; Snyder, SH; Teuscher, C | 1 |
| Abraham, MH; Acree, WE; Ibrahim, A | 1 |
| Coolen, HK; Glennon, JC; Kruse, CG; Lange, JH; Reinders, JH; Tolboom, JT | 1 |
| Shahid, M; Walker, GB; Wong, EH; Zorn, SH | 1 |
| Jia, L; Sun, H | 1 |
| Ablordeppey, SY; Altundas, R; Bricker, B; Jackson, T; Khan, A; Kumar, EV; Roth, BL; Zhu, XY | 1 |
| Andreasen, JT; Bernetti, M; Borriello, M; Brindisi, M; Butini, S; Cagnotto, A; Campiani, G; Ceres, N; Coccone, SS; De Angelis, M; Fattorusso, C; Fiorini, I; Franceschini, S; Gemma, S; Mennini, T; Mikkelsen, JD; Nacci, V; Novellino, E; Ros, S; Sandager-Nielsen, K; Scheel-Kruger, J; Trotta, F | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Giordanetto, F; Leach, AG; Zachariae, U | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Pettersson, F; Pontén, H; Sonesson, C; Waters, N; Waters, S | 1 |
| Borrelli, G; Butini, S; Campiani, G; Fattorusso, C; Fiorini, I; Franceschini, S; Gemma, S; Guarino, E; Jacobsen, TA; Kumar, V; Madsen, K; Novellino, E; Orteca, N; Persico, M; Sandager-Nielsen, K; Scheel-Kruger, J; Trotta, F | 1 |
| Sen, S; Sinha, N | 1 |
| Breslin, MJ; Coleman, PJ; Cox, CD; Fandozzi, C; Fuerst, J; Hill, N; Huszar, S; Kandebo, M; Kim, SH; Ma, B; McGaughey, G; Raheem, IT; Renger, JJ; Schreier, JD; Sharma, S; Smith, S; Uslaner, J; Yan, Y | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Beard, JD; Davis, RE; Hendrick, JP; Lee, T; Li, P; Mates, S; Peng, Y; Robichaud, AJ; Snyder, GL; Tomesch, J; Vanover, KE; Wennogle, LP; Yao, W; Zhang, Q; Zhu, H | 1 |
| Bienkowski, P; Bucki, A; Jaśkowska, J; Kazek, G; Kowalski, P; Kołaczkowski, M; Marcinkowska, M; Mierzejewski, P; Mitka, K; Pawłowski, M; Siwek, A; Wasik, A; Wesołowska, A | 1 |
| Ablordeppey, SY; Bricker, B; Lamango, NS; Peprah, K; Roth, BL; Sampson, D; Setola, V; Zhu, XY | 1 |
| Andreassi, M; Brindisi, M; Brogi, S; Butini, S; Cagnotto, A; Campiani, G; Casagni, A; Franceschini, S; Gemma, S; Gorelli, B; Mikkelsen, JD; Novellino, E; Ros, S; Salmona, M; Sandager-Nielsen, K; Saponara, S; Scheel-Kruger, J; Trotta, F; Weikop, P | 1 |
| Bojarski, AJ; Bucki, A; Kazek, G; Kołaczkowski, M; Partyka, A; Pawłowski, M; Satała, G; Siwek, A; Wesołowska, A; Zagórska, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bączek, T; Belka, M; Bojarski, A; Herold, F; Kleps, J; Kozioł, AE; Król, M; Nowak, G; Siwek, A; Ślifirski, G; Stachowicz, K; Szewczyk, B; Turło, J; Ulenberg, S | 1 |
| Bączek, T; Belka, M; Bojarski, A; Herold, F; Kleps, J; Kozioł, AE; Król, M; Nowak, G; Podsadni, P; Siwek, A; Ślifirski, G; Stachowicz, K; Szewczyk, B; Turło, J | 1 |
| Agard, DA; Ashworth, A; Barrio-Hernandez, I; Batra, J; Beltrao, P; Bennett, MJ; Bohn, M; Bouhaddou, M; Braberg, H; Broadhurst, DJ; Cai, Y; Cakir, M; Calviello, L; Cavero, DA; Chang, JCJ; Chorba, JS; Craik, CS; d'Enfert, C; Dai, SA; Eckhardt, M; Emerman, M; Fabius, JM; Fletcher, SJ; Floor, SN; Foussard, H; Frankel, AD; Fraser, JS; Fujimori, DG; Ganesan, SJ; García-Sastre, A; Gordon, DE; Gross, JD; Guo, JZ; Haas, K; Haas, P; Hernandez-Armenta, C; Hiatt, J; Huang, XP; Hubert, M; Hüttenhain, R; Ideker, T; Jacobson, M; Jang, GM; Jura, N; Kaake, RM; Kim, M; Kirby, IT; Klippsten, S; Koh, C; Kortemme, T; Krogan, NJ; Kuzuoglu-Ozturk, D; Li, Q; Liboy-Lugo, J; Lin, Y; Liu, X; Liu, Y; Lou, K; Lyu, J; Mac Kain, A; Malik, HS; Mathy, CJP; McGregor, MJ; Melnyk, JE; Memon, D; Meyer, B; Miorin, L; Modak, M; Moreno, E; Mukherjee, S; Naing, ZZC; Noack, J; O'Meara, MJ; O'Neal, MC; Obernier, K; Ott, M; Peng, S; Perica, T; Pilla, KB; Polacco, BJ; Rakesh, R; Rathore, U; Rezelj, VV; Richards, AL; Roesch, F; Rosenberg, OS; Rosenthal, SB; Roth, BL; Roth, TL; Ruggero, D; Safari, M; Sali, A; Saltzberg, DJ; Savar, NS; Schwartz, O; Sharp, PP; Shen, W; Shengjuler, D; Shi, Y; Shoichet, BK; Shokat, KM; Soucheray, M; Stroud, RM; Subramanian, A; Swaney, DL; Taunton, J; Tran, QD; Trenker, R; Tummino, TA; Tutuncuoglu, B; Ugur, FS; Vallet, T; Venkataramanan, S; Verba, KA; Verdin, E; Vignuzzi, M; von Zastrow, M; Wang, HY; Wankowicz, SA; Wenzell, NA; White, KM; Xu, J; Young, JM; Zhang, Z; Zhou, Y | 1 |
| Benvenga, MJ; Leander, JD | 1 |
| Beasley, CM; Hamilton, S; Sanger, T; Satterlee, W; Tollefson, G; Tran, P | 1 |
| Busatto, GF; Costa, DC; Ell, PJ; Kerwin, RW; Nohria, V; Pilowsky, LS; Sharma, T; Sigmundsson, T; Taylor, M | 1 |
| Beasley, CM; Graffeo, KA; Krueger, JA; Street, JS; Tamura, RN; Thieme, ME; Tollefson, GD; Tran, PV | 1 |
| Sanger, TM; Tollefson, GD | 2 |
| Gleason, SD; Shannon, HE | 1 |
| Beasley, CM; Beuzen, JN; Blin, O; Crawford, AM; Dellva, MA; Hamilton, SH; Tollefson, GD; Tran, PV | 1 |
| Beasley, CM; Dellva, MA; Kiesler, GM; Potvin, JH; Tollefson, GD; Tran, PV | 1 |
| Borsini, F; Cerutti, M; Fodritto, F; Monferini, E; Volonté, M | 1 |
| Beasley, CM; Tollefson, GD; Tran, PV | 2 |
| Nemeroff, CB | 1 |
| Glazer, WM; Johnstone, BM | 1 |
| Casey, DE | 1 |
| Beasley, CM; Potvin, JH; Tamura, RN; Tollefson, GD; Tran, PV | 1 |
| Beasley, CM; Crawford, AM; Tollefson, GD | 1 |
| Beasley, CM; Genduso, LA; Hamilton, SH; Revicki, DA | 1 |
| Mattes, JA | 1 |
| Hillard, JR | 1 |
| Berman, A; Greaney, JJ; Madrid, A; Narendran, R; Pike, S; Tohen, M; Zarate, CA | 1 |
| Lu, Y; Sanger, TM; Thieme, ME; Tollefson, GD | 1 |
| Bymaster, FP; Li, XM; Perry, KW; Wong, DT | 1 |
| Allan, ER; Alpert, M; Connolly, B; Crichton, J; Sison, CE | 1 |
| Beasley, CM; Sanger, TM; Tollefson, GD; Tran, PV | 1 |
| Bartko, JJ; Conley, RR; Gounaris, C; Hegerty, J; Lingle, J; Love, R; Peszke, M; Richardson, C; Tamminga, CA; Zaremba, S | 1 |
| Dai, J; Ichikawa, J; Kuroki, T; Meltzer, HY | 1 |
| Bailey, RK; Dralle, PW; Eschmann, AJ; Strauss, AJ; Wagner, RB | 1 |
| Licht, RW | 1 |
| Almeida, OP | 1 |
| Koch, T; Korf, J; Sebens, JB; Ter Horst, GJ | 1 |
| Nemeroff, CB; Owens, MJ; Radke, JM; Ritchie, JC | 1 |
| Gao, XM; Sakai, K; Tamminga, CA | 1 |
| Beasley, CM; Dellva, MA; Tollefson, GD; Tran, PV; Wentley, AL | 1 |
| Depoortere, R; Perrault, G; Sanger, DJ | 1 |
| de Boer, P; de Vries, JB; Kruse, CG; Long, SK; Westerink, BH | 1 |
| Beasley, C; Grundy, S; Lieberman, JA; Sanger, TM; Tohen, M; Tollefson, GD | 1 |
| Arrang, JM; Morisset, S; Sahm, UG; Schwartz, JC; Tardivel-Lacombe, J; Traiffort, E | 1 |
| Asenbaum, S; Barnas, C; Brücke, T; Fischer, P; Kasper, S; Küfferle, B; Pezawas, L; Tauscher, J; Tauscher-Wisniewski, S | 1 |
| Abraham, D; Kissling, W; Leucht, S; Pitschel-Walz, G | 1 |
| Haack, M; Hinze-Selch, D; Kraus, T; Kühn, M; Pollmächer, T; Schuld, A; Uhr, M | 1 |
| De Bittencourt, PR; Hanel, RA; Kranich, M; Sandmann, MC | 1 |
| Breier, A; Hamilton, SH | 1 |
| Cooper, M; Passik, SD | 1 |
| Brown, RE; Genduso, LA; Hamilton, SH; Palmer, CS; Revicki, DA | 1 |
| Breier, A | 1 |
| Beasley, CM; Berg, PH; Lu, Y; Sanger, TM; Tollefson, GD; Tran, PV | 1 |
| Beasley, CM; Dellva, MA; Ferguson, K; Glazer, WM; Morgenstern, H; Tamura, RN; Tollefson, GD | 1 |
| Kapur, S; Remington, G | 2 |
| Gomberg, RF | 1 |
| Alsayegh, L; Backstrom, JR; Berry, SA; Friedman, L; Roth, BL; Sanders-Bush, E; Willins, DL | 1 |
| Crismon, ML; Dorson, PG; Lee, JW | 1 |
| Berisford, MA; Goldstein, D; Kysar, L; Marder, SR; Mintz, J; Pashdag, J; Wirshing, DA; Wirshing, WC | 1 |
| Carboni, E; Di Chiara, G; Rolando, MT; Silvagni, A | 1 |
| Croghan, TW; Heilman, DK; Johnstone, BM; Obenchain, RL; Tunis, SL | 1 |
| Bruggeman, R; den Boer, JA; Heijmen, M; Timmerman, W; Westerink, BH | 1 |
| Berk, M; Brook, S; Trandafir, AI | 1 |
| Beasley, CM; Ganoczy, D; Genduso, LA; Hamilton, SH; Revicki, DA | 1 |
| Beuzen, JN; Taylor, N; Wesnes, K; Wood, A | 1 |
| Yui, K | 1 |
| Dulisse, BK; Gibson, PJ; Johnstone, BM; Loosbrock, DL; Tunis, SL | 1 |
| Kaplan, GB; Keith, DJ; Leite-Morris, KA | 1 |
| Edgell, ET; Genduso, LA; Hamilton, SH; Revicki, DA; Tollefson, G | 1 |
| Fukuda, K; Hondo, H; Kuroki, T; Nakahara, T; Tsutsumi, T; Uchimura, H; Yao, H | 1 |
| Bedwell, J; Gochman, P; Hamburger, SD; Lenane, MC; Nicolson, R; Rapoport, JL; Spechler, L; Wudarsky, M | 1 |
| Heal, DJ; Kilpatrick, IC; Needham, PL; Rowley, HL | 1 |
| Addington, D; Breier, A; David, SR; Jones, BD; Labelle, A; Purdon, SE; Stip, E; Tollefson, GD | 1 |
| Hashimoto, K; Hirano, M; Hondo, H; Kuroki, T; Motomura, K; Nakahara, T; Tsutsumi, T; Uchimura, H; Ueki, H | 1 |
| Hawk, RM; Karson, CN; Komoroski, RA; Lindquist, DM | 1 |
| Glazer, WM | 2 |
| McCallum, SE; Porter, JH; Vann, RE; Varvel, SA | 1 |
| Devoto, P; Diana, M; Flore, G; Gessa, GL; Melis, M; Pistis, M | 1 |
| Woods, SW | 2 |
| Fujimura, M; Hashimoto, K; Yamagami, K | 1 |
| Gómez, JC; Gregor, KJ; Montejo, AL; Sacristán, JA; Vieta, E | 1 |
| Coutureau, E; Di Scala, G; Gosselin, O | 1 |
| Lu, Y; Rollema, H; Schmidt, AW; Sprouse, JS; Zorn, SH | 1 |
| Almond, S; O'Donnell, O | 2 |
| Breier, A; Edgell, ET; Hamilton, SH; Revicki, DA | 1 |
| Arvanov, V; Jardemark, KE; Liang, X; Wang, RY | 1 |
| Breier, A; David, SR; Kinon, BJ; Taylor, CC | 1 |
| Roberts, RC | 1 |
| Robinson, KA | 1 |
| Klein, HE; Müller, JL | 1 |
| Shulman, RW | 1 |
| Feifel, D | 1 |
| Gao, XM; Hashimoto, T; Sakai, K; Tamminga, CA | 1 |
| Damodaran, SS; Thankamma, JK | 1 |
| Hägg, S; Lindqvist, L; Mjörndal, T | 1 |
| Marsh, C; Preskorn, SH; Shad, MU | 1 |
| Hilger, E; Kasper, S | 1 |
| Bhana, N; Foster, RH; Olney, R; Plosker, GL | 1 |
| Kapur, S; Seeman, P | 1 |
| Hill, AL; Kinon, BJ; Milton, DR; Roychowdhury, SM | 1 |
| Jones, B; Meehan, K; Taylor, CC | 1 |
| Basson, BR; Crawford, AM; Jones, B; Kinon, BJ; Walker, DJ | 1 |
| Crawford, AM; Gomez, JC | 1 |
| Basson, BR; Gilmore, JA; Kinon, BJ; Tollefson, GD | 1 |
| Mujica, R; Weiden, P | 1 |
| Gundlapalli, SP; Iqbal, MM; Passman, TE; Ryals, T; Ryan, WG | 1 |
| Beasley, CM; Berg, PH; Czekalla, J; Dellva, MA; Grundy, S | 1 |
| Hatzimanolis, J; Lykouras, L; Markianos, M; Oulis, P | 1 |
| Basson, BR; Gilmore, JA; Kinon, BJ; Szymanski, KA; Taylor, CC; Tollefson, GD | 1 |
| Agarwal, V; Kumar, P | 1 |
| Basturk, M; Esel, E; Kula, M; Saffet Gonul, A; Sofuoglu, S; Tayfun Turan, M; Yabanoglu, I | 1 |
| Alaka, KJ; Bernardo, M; Birkett, M; Bradley, P; Breier, A; David, SR; Ferchland, I; Krueger, J; Meehan, K; Reinstein, M; San, L; Saunders, JC; Wright, P | 1 |
| Deslandes, M; Edwardes, MD; Laporta, M; Ricard, N; Sauriol, L; Suissa, S | 1 |
| Inada, T; Ishigooka, J; Miura, S | 1 |
| Alvarez, N; Costa e Silva, JA; Cousins, L; Gattaz, WF; Larach, V; Mazzotti, G; Oliva, D; Ospina, J; Starkstein, S; Taylor, CC; Tohen, M; Tran, PV; Wang, J | 1 |
| Cater, J; Choudhury, MS; Delaney, MA; Malone, RP; Sheikh, RM | 1 |
| Howard, HR; Lebel, LA; Schmidt, AW; Zorn, SH | 1 |
| Reuss, B; Unsicker, K | 1 |
| Copolov, DL; Dean, B; Hussain, T; Pavey, G; Scarr, E | 1 |
| Bernardo, M; Catafau, AM; Font, M; Gómez, JC; Gutiérrez, F; Lomeña, F; López-Carrero, C; Parellada, E; Pavía, J; Salamero, M | 1 |
| Andersen, MP; Pouzet, B | 1 |
| Atkins, A; Cilia, J; Foxton, R; Hagan, JJ; Heidbreder, CA; Hughes, ZA; Hunter, AJ; Jones, DN; Shah, AJ | 1 |
| Infante, M; Khandat, A; Singh, A; Smith, RC | 1 |
| Badía, X; Gómez, JC; Kind, P; Sacristán, JA | 1 |
| Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J | 1 |
| Hatzimanolis, J; Lykouras, L; Markianos, M | 1 |
| Bauzon, D; Bymaster, FP; Cohen, ML; DeLapp, NW; Falcone, JF; Kennedy, JS; Schenck, K | 1 |
| Cohen, H; Kotler, M; Loewenthal, U; Matar, M | 1 |
| de Boer, A; Herings, RM; Jansen, PA; Leufkens, HG; Roos, RA; Schillevoort, I | 1 |
| Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J | 3 |
| Aloj, L; Ambesi-Impiombato, A; Barone, P; Bravi, D; Caracò, C; de Bartolomeis, A; Muscettola, G | 1 |
| Edgell, E; García-Cabeza, I; Gómez, JC; González de Chavez, M; Sacristán, JA | 1 |
| Dai, J; Fowler, WL; Ichikawa, J; Meltzer, HY; O'Laughlin, IA | 1 |
| Breier, A; Feldman, PD; Keck, PE; Risser, RC; Tohen, M; Tran, PV; Zhang, F | 1 |
| Philibin, SD; Porter, JH; Vann, RE; Varvel, SA; Wise, LE | 1 |
| Apter, A; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Phillip, M; Ratzoni, G; Reidman, J; Weizman, R | 1 |
| Berg, PH; Glick, ID | 1 |
| Yatham, LN | 1 |
| Nomikos, GG; Rodriguez, DE; Shirazi-Southall, S | 1 |
| Klein, HE; Müller, JL; Röder, C; Schuierer, G | 1 |
| Birkett, M; Breier, A; Brook, S; David, S; Dossenbach, M; Ferchland, I; Kiesler, G; Meehan, K; Palmer, R; Sutton, V; Taylor, CC; Wright, P | 1 |
| Klein, H; Müller, JL; Röder, CH; Schuierer, G | 1 |
| Andersen, S; Cohen, LS; Crawford, A; Goldstein, JM; Horton, NJ; Lee, H; Tohen, M; Tollefson, G | 1 |
| Breese, GR; Moy, SS | 1 |
| Bilder, RM; Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Goldman, RS; Hoptman, M; Horowitz, TL; Kunz, M; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J | 1 |
| Apter, A; Constantini, N; Falk, B; Frishman, S; Gothelf, D; Kairi, M; Phillip, M; Poraz, I; Singer, P; Weizman, A; Zalsman, G; Zigel, L | 1 |
| Le Pen, G; Moreau, JL | 1 |
| Christodoulou, GN; Hatzimanolis, J; Lykouras, L; Markianos, M | 1 |
| Chiu, FC; Mahadik, SP; Wakade, CG; Waller, JL | 1 |
| Quartermain, D; Rosengarten, H | 1 |
| Breier, A; Edgell, ET; Gandhi, G; Haro, JM; Namjoshi, MA; Shi, L; Tohen, M; Zhang, F | 1 |
| Alfaro, CL; Gochman, P; Lenane, M; Nicolson, R; Rapoport, JL; Sporn, A; Wudarsky, M | 1 |
| Alkhouri, I; Champine, D; Fluent, T; Ghaziuddin, M; Ghaziuddin, N; Quinlan, P | 1 |
| Inada, T; Miura, S; Yagi, G | 1 |
| König, F; Raape, J; Truöl, S; Von Hippel, C | 1 |
| Dean, B; Parkin, FM; Pavey, G; Scarr, E | 1 |
| Douyon, K; Franco, K; Hadi, F; Hermida, T | 1 |
| Ballon, JS; Boyd, JA; Marder, SR; Meng, LR; Wirshing, DA; Wirshing, WC | 1 |
| Bilici, M; Cakirbay, H; Guler, M; Tan, U; Tosun, M; Ulgen, M | 1 |
| de Haan, L; van Amelsvoort, T | 1 |
| Barak, Y; Mirecki, I; Shamir, E; Toren, P; Weizman, R; Zemishlani, H | 1 |
| Hägg, S; Hedenmalm, K; Mortimer, O; Spigset, O; Ståhl, M | 1 |
| Evans, DR; Hill, WD; Mahadik, SP; Parikh, V; Terry, AV; Waller, JL | 1 |
| Bai, O; Bowen, R; Chlan-Fourney, J; Keegan, D; Li, XM | 1 |
| Alvarez, E; Bobes, J; Cañas, F; Carrasco, JL; Gascón, J; Gibert, J; Gómez, JC; Gutiérrez, M; Sacristán, JA | 1 |
| Beasley, CM; Inada, T; Tanaka, Y; Walker, DJ | 1 |
| Duncan, GE; Lieberman, JA; Marx, CE; Morrow, AL; VanDoren, MJ | 1 |
| Daniel, DG | 1 |
| Aguglia, E; De Vanna, M; Ferrara, D; Onor, ML | 1 |
| Atmaca, M; Gecici, O; Kuloglu, M; Tezcan, E; Ustundag, B | 1 |
| Booij, J; de Haan, L; Dingemans, PM; Lavalaye, J; Linszen, D; van Bruggen, M | 1 |
| Kalkman, HO; Loetscher, E | 1 |
| Meibach, RC | 1 |
| Messori, A | 1 |
| Gupta, S | 2 |
| Duncan, GE; Lieberman, JA; Miyamoto, S | 1 |
| Jardemark, KE; Ninan, I; Wang, RY | 1 |
| Gilmore, JA; Halbreich, UM; Kinon, BJ; Liu, H | 1 |
| Clifton, PG; Hartfield, AW; Moore, NA | 1 |
| Fischer-Barnicol, D; Koch, HJ; Szecsey, A; Vogel, M | 1 |
| Brown, CM; Gibson, PJ; Opolka, JL; Rascati, KL | 2 |
| Cherkerzian, S; Cohen, BM; Lange, N; Ma, J; Wager, C; Ye, N | 1 |
| Leander, JD; Wolff, MC | 1 |
| Apter, A; Bloch, Y; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Ratzoni, G; Reidman, J; Tyano, S; Weizman, R | 1 |
| Bedogni, F; Fossati, C; Fumagalli, F; Gennarelli, M; Molteni, R; Racagni, G; Riva, MA; Roceri, M; Santero, R | 1 |
| Kreilgaard, M; Mow, T; Pouzet, B; Velschow, S | 1 |
| Bobes, J; Fernández, I; Garcia-Garcia, M; García-Portilla, MP; Hernández, G; Rejas, J; Rico-Villademoros, F | 1 |
| Gaisler-Salomon, I; Green, A; Joel, D; Schiller, D; Weiner, I | 1 |
| Harvey, BH; Nel, A | 1 |
| Alaka, K; Battaglia, J; Lindborg, SR; Meehan, K; Wright, P | 1 |
| Barner, JC; Brown, CM; Gibson, PJ; Johnsrud, MT; Opolka, JL; Rascati, KL | 1 |
| Lindborg, SR; Purdon, SE; Stip, E; Woodward, N | 1 |
| Grottick, AJ; Herberg, LJ; Montgomery, AM | 1 |
| Conley, RR; Kelly, DL; Love, RC; McMahon, RP | 1 |
| Coutureau, E; Di Scala, G; Herbeaux, K; Majchrzak, M; Seillier, A; Thiriet, N; Will, B; Zwiller, J | 1 |
| Alaka, K; Beasley, CM; Lindborg, SR; Taylor, CC | 1 |
| Birkett, M; Breier, A; Lindborg, SR; Meehan, K; Morris, P; Taylor, CC; Wright, P | 1 |
| Becker, T; Kopf, A; Köster, J; Krömker, H; Schulz, A | 1 |
| Green, AI; Gur, RE; Hamer, RM; Kahn, R; Lieberman, JA; McEvoy, J; Perkins, D; Sharma, T; Tohen, M; Tollefson, G; Wei, H; Zipursky, R | 1 |
| Chen, R; Christensen, BK; Daskalakis, ZJ; Fitzgerald, PB; Kapur, S; Zipursky, RB | 1 |
| Khan, MM; Mahadik, SP; Parikh, VV | 1 |
| Lin, DA; Zareba, W | 1 |
| Christensen, BK; Daskalakis, ZJ; Kapur, S; Kiang, M; Remington, G | 1 |
| Beasley, CM; Berg, PH; Carlson, CD; Cavazzoni, PA; Kane, JM; Wei, H | 1 |
| Bugarski-Kirola, D; Chakravorty, S; Duncan, E; Efferen, T; Gonzenbach, S; Harmon, J; Kunzova, A; Negi, S; Peselow, E; Rotrosen, J; Schwartz, M; Stephanides, M; Szilagyi, S | 1 |
| Brunnauer, A; Geiger, E; Laux, G | 1 |
| Agrawal, SM; McCullumsmith, RE; Meador-Woodruff, JH; Stincic, TL | 1 |
| Gibson, CJ; Hamm, RJ; Wilson, MS | 1 |
| Sacchetti, E; Valsecchi, P | 1 |
| Bashford, RA; Hamer, RM; Lieberman, JA; Sheitman, BB; Sikich, L | 1 |
| Hamann, J; Kissling, W; Leucht, S; Rummel, C | 1 |
| Arango, C; Buchanan, RW; Summerfelt, A | 1 |
| Apiquian, R; de la Fuente-Sandoval, C; Fresán, A; Gutiérrez, D; Herrera, K; Lóyzaga, C; Nicolini, H; Ulloa, RE | 1 |
| Andersen, J; Duncan, E; Dunlop, BW; Phillips, LS; Sternberg, M | 1 |
| Breier, A; Bymaster, FP; Dossenbach, M; Gilmore, JA; Golshan, S; Jeste, D; Kaiser, CJ; Kennedy, JS; Kinon, BJ; Maguire, GA; Sanger, T; Tollefson, G | 1 |
| Amano, N; Ushizima, M | 1 |
| Hasui, Y; Ikeda, M; Tanabe, H | 1 |
| Deuticke, C; Hajak, G; Müller, JL; Putzhammer, A; Röder, CH; Winkler, J | 1 |
| Cetin, I; Guner, P; Soygur, H; Sungur, MZ; Ustun, B | 1 |
| Allan, E; Bingham, S; Campbell, EC; Caroff, S; Collins, J; Corwin, J; Davis, L; Douyon, R; Dunn, L; Evans, D; Frecska, E; Grabowski, J; Graeber, D; Herz, L; Kwon, K; Lawson, W; Leslie, D; Liu-Mares, W; Mena, F; Perlick, D; Rosenheck, R; Sheikh, J; Smelson, D; Smith-Gamble, V; Warren, S | 1 |
| Khan, MM; Mahadik, SP; Parikh, V; Terry, AV | 1 |
| Azorin, JM; Baker, RW; Breier, A; Emsley, RA; Evans, AR; Goldberg, JF; Gonzalez-Pinto Arrillaga, AM; Hardy-Bayle, MC; Lawson, WB; Namjoshi, MA; Risser, RC; Tohen, M; Vieta, E; Zhang, F | 1 |
| Tamminga, CA | 1 |
| Alevizos, B | 1 |
| Kabanov, SO; Mosolov, SN | 1 |
| Bergeron, N; Dumont, M; Gottfried, SB; Skrobik, YK | 1 |
| Amann, BL; Grunze, H; Hegerl, U; Juckel, G; Mergl, R; Mulert, C; Pogarell, O | 1 |
| Anziano, R; Cutler, NR; Harrigan, EP; Miceli, JJ; Middle, M; Reeves, KR; Shiovitz, T; Sramek, J; Watsky, E | 1 |
| Ambresin, G; Berney, P; Bryois, C; Schulz, P | 1 |
| Alaka, K; Battaglia, J; Birkett, M; Bitter, I; Breier, A; Chouinard, G; Ferchland-Howe, I; Jones, B; Lindborg, SR; Meehan, K; Morris, PL; Pickard, A; Roth, J; Taylor, CC; Wright, P | 1 |
| Abel, T; Bilker, WB; Gur, RE; Kanes, SJ; Lenox, RH; Liang, Y; Maxwell, CR; Siegel, SJ; Turetsky, BI; Weightman, BD | 1 |
| Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J | 1 |
| Khan, MM; Mahadik, SP; Parikh, V | 1 |
| Bédard, MA; Elie, A; Lévesque, M; Paquet, F; Soucy, JP; Stip, E | 1 |
| Correll, CU; Kane, JM; Leucht, S | 1 |
| Citrome, L; Volavka, J | 1 |
| Amin, M; Shukla, VS | 1 |
| Kunz, M | 1 |
| de Haan, L; van Beveren, N | 2 |
| Grande, C; Hiroi, N; Lee, M; Martin, AB; Moratalla, R; Ortiz, O; Zhu, H | 1 |
| Biggio, G; Cherchi, G; Dazzi, L; Seu, E | 1 |
| Kaplan, GB; Leite-Morris, KA; Turalba, AV | 1 |
| Clark, WS; Glick, I; Green, AI; Hamer, RM; Lieberman, JA; Strakowski, SM; Tohen, MF | 1 |
| Burnet, PW; Harrison, PJ; Hutchinson, LJ; Law, AJ | 1 |
| Blessing, WW | 1 |
| Deutch, AY; Dunnavant, FD; Jarman, T; Wang, HD | 1 |
| Bitter, I; Boland, J; Dossenbach, M; el Mahfoud Kessaci, M; Erol, A; Hodge, A; O'Halloran, RA; Shaheen, MO; Sunbol, MM | 1 |
| Chopde, CT; Hirani, K; Morelli, M; Ugale, RR | 1 |
| Citrome, L; Czobor, P; Kennedy, JL; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Ni, X; Nolan, K; Sheitman, B; Volavka, J | 1 |
| Ahl, J; Kinon, BJ; McMullen, E; Rotelli, MD | 1 |
| de Jonge, E; de Rooij, S | 1 |
| Christensen, BK; Gur, RC; Hamer, RM; Keefe, RS; Lewine, RR; Lieberman, JA; Sanger, TM; Seidman, LJ; Sharma, T; Sitskoorn, MM; Tohen, M; Tollefson, GD; Yurgelun-Todd, DA | 1 |
| Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Nolan, K; Sheitman, B; Volavka, J | 1 |
| Green, A; Gu, H; Gur, R; Kahn, R; Lieberman, J; McEvoy, J; Perkins, D; Sharma, T; Strakowski, S; Tohen, M; Tollefson, G; Zipursky, R | 1 |
| Casado, P; Hinojosa, JA; Iglesias, A; Martín-Loeches, M; Molina, V; Muñoz, F | 1 |
| Conn, PJ; Mallorga, PJ; Pettibone, DJ; Sur, C; Williams, JB | 1 |
| Bryois, Ch; Sahli, Ch | 1 |
| Lima, MS; Soares, BG | 1 |
| Dal-Pizzol, F; Lima, MS; Martins, MR; Moreira, JC; Quevedo, J; Reinke, A | 1 |
| Amann, B; Hegerl, U; Juckel, G; Möller, HJ; Mulert, C; Pogarell, O | 1 |
| Lawrie, S; McIntosh, A; Nadeem, Z | 1 |
| Broll, K; Hess, L; Ibach, B; Perfahl, M; Pfeiff, L; Putzhammer, A | 1 |
| Bobes, J; Cañas, F; Mackell, J; Rejas, J | 1 |
| Hou, Y; Huang, M; Wu, CF; Yang, JY | 1 |
| Ball, MP; Buchanan, RW; Carpenter, WT; Gold, JM; Kirkpatrick, B; McMahon, RP; Weiner, E | 1 |
| Ascher-Svanum, H; Kinon, BJ; Stensland, M; Zhao, Z | 1 |
| Arya, P; Butler, R; Warner, J | 1 |
| Barna, I; Gazdag, G; Iványi, Z; Tolna, J | 1 |
| Kapur, S; Nobrega, JN; Remington, G; Turrone, P | 1 |
| Dorph-Petersen, KA; Lewis, DA; Perel, JM; Pierri, JN; Sampson, AR; Sun, Z | 1 |
| Vieta, E | 1 |
| Charles, C; Green, AI; Gu, H; Gur, RE; Hamer, RM; Kahn, RS; Keefe, RS; Lieberman, JA; McEvoy, J; Perkins, D; Sharma, T; Tohen, M; Tollefson, GD; Zipursky, R | 1 |
| Belgamwar, RB; Fenton, M | 1 |
| Agid, O; Arenovich, T; Jones, B; Kapur, S; Lindborg, S; Zipursky, R | 1 |
| Lawrie, S; McIntosh, A | 1 |
| Budin, R; Fleming, AS; Kapur, S; Li, M | 1 |
| Campbell, EC; Caroff, SN; Cornish, J; Kondrich, J; Mann, SC; O'Brien, C; Sayers, SL | 1 |
| Citrome, L; Czobor, P; Kline, L; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Nolan, KA; Sheitman, B; Volavka, J | 1 |
| Alvarez, E; Bobes, J; Cañas, F; Carrasco, JL; Ciudad, A; Gascón, J; Gibert, J; Gómez, JC; Gutiérrez, M | 1 |
| Delbello, MP; Glick, I; Green, AI; Hamer, RM; Johnson, JL; Lieberman, JA; Patel, JK; Strakowski, SM; Tohen, M | 1 |
| Holcomb, HH; Lahti, AC; Medoff, DR; Tamminga, CA; Weiler, MA | 1 |
| Koga, M; Nakayama, K | 1 |
| Canonico, PL; Colella, L; Dellarole, A; Ferri, S; Ghi, P; Orsetti, M | 1 |
| Deitemeyer, N; Dobner, PR; Egnatashvili, V; Kinkead, B; Murray, T; Nemeroff, CB | 1 |
| Matsui-Sakata, A; Ohtani, H; Sawada, Y | 1 |
| Heiser, P; Krieg, JC; Singh, S; Vedder, H | 1 |
| de Beaurepaire, R; Even, PC; Guesdon, B; Minet-Ringuet, J; Tomé, D | 1 |
| Bersani, G; Clemente, R; Conti, CM; Conti, P; Di Giannantonio, M; Doyle, R; Exton, MS; Gherardelli, S; Grilli, A; Pancheri, P | 1 |
| Howell, LL; Kimmel, HL; Lindsey, KP; Wilcox, KM | 1 |
| Adams, AS; Kanavos, P; Park, S; Ross-Degnan, D; Sabin, J; Soumerai, SB | 1 |
| Dwyer, DS; Lu, XH | 1 |
| Bitter, I; Czobor, P; Dossenbach, M; Volavka, J | 1 |
| Aguilar, J; Arango-Dávila, C; Assunção, S; Caro, O; Dossenbach, M; Landa, E; Leadbetter, J; Silva Ibarra, H | 1 |
| Ansari, MS; Dawant, B; Jayathilake, K; Kessler, RM; Li, R; Meltzer, HY; Riccardi, P | 1 |
| Christensen, BK; Daskalakis, Z; Epstein, I; Furimsky, I; Kapur, S; Roy, P; Sanger, T; Zipursky, RB | 1 |
| Barth, VN; Chernet, E; Li, D; Martin, LJ; Need, AB; Phebus, LA; Rash, KS | 1 |
| Christensen, BK; Hamer, RM; Keefe, RS; Lieberman, JA; Rock, SL; Sanger, TM; Seidman, LJ; Sharma, T; Sitskoorn, MM; Tohen, M; Tollefson, GD; Woolson, S | 1 |
| Barbui, C; Fortino, I; Percudani, M; Petrovich, L; Tansella, M | 1 |
| Altman, C; de Nayer, A; Jones, AM; Larmo, I; Lindenbauer, B; Platz, T; Rittmannsberger, H; Windhager, E | 1 |
| Barak, Y; Plopsky, I; Swartz, M | 1 |
| Baser, O; Engelhart, L; Finkel, S; Greenspan, A; Kozma, C; Long, S; Mahmoud, R | 1 |
| Breier, A; Gold, JM; Keefe, RS; Purdon, SE; Rock, SL; Young, CA | 1 |
| Basu, A; Dukic, V; Meltzer, HY | 1 |
| Balit, CR; Isbister, GK; Kilham, HA | 1 |
| Lousberg, R; Verhey, FR; Verkaaik, M | 1 |
| Ascher-Svanum, H; Kinon, BJ; Stensland, MD; Tollefson, GD | 1 |
| Adell, A; Amargós-Bosch, M; Artigas, F; López-Gil, X | 1 |
| Green, AI; Gu, H; Gur, RE; Kahn, RS; Lieberman, JA; McEvoy, JP; Perkins, DO; Sharma, T; Strakowski, SM; Tohen, MF; Tollefson, GD; Zipursky, RB | 1 |
| Ahl, J; Battaglia, J; Houston, JP; Kaiser, CJ; Meyers, AL | 1 |
| Knecht, G; Naber, D; Veismann, S; Wolf, K | 1 |
| Kaune, M; Losonczy, MF; Smelson, DA; Steinberg, ML; Williams, J; Ziedonis, D | 1 |
| Caleo, S; De Graeve, D; Lecompte, D; Mehnert, A; Miadi-Fargier, H; Mosqueda, GJ; Peuskens, J; Smet, A | 1 |
| Heeg, B; Laux, G; Mehnert, A; van Hout, BA | 1 |
| Berg, PH; Briggs, SD; Cavazzoni, PA; Kane, JM; Kryzhanovskaya, LA; Roddy, TE; Tohen, M | 1 |
| Cohrs, S; Huether, G; Jordan, W; Meier, A; Rodenbeck, A; Röher, C; Rüther, E; Wuttke, W | 1 |
| Mahadik, SP; Pillai, A; Terry, AV | 1 |
| de Bruijn, ER; Hulstijn, W; Ruigt, GS; Sabbe, BG; Verkes, RJ | 1 |
| Deng, C; Huang, XF; Zavitsanou, K | 1 |
| Centorrhino, F; Glick, IB; Green, AI; Hamer, RM; Johnson, JL; Kahn, RS; Keefe, RS; Lieberman, JA; McEvoy, JP; Perkins, DO; Sharma, T; Tohen, M; Weiden, PJ; Zipursky, RB | 1 |
| Akram, A; Anders, M; Araszkiewicz, A; Dossenbach, M; Dyachkova, Y; Khalil, A; McBride, M; Pecenak, J; Pirildar, S; Shakhnovich, T; Treuer, T | 1 |
| Birinyi-Strachan, L; Davey, P; Kongsakon, R; Leelahanaj, T; Price, N | 1 |
| de Beaurepaire, R; Even, PC; Goubern, M; Minet-Ringuet, J; Tomé, D | 1 |
| Mahadik, SP; Parikh, V; Pillai, A; Terry, AV | 1 |
| Bloch, MH; Bracken, MB; Coric, V; Kelmendi, B; Landeros-Weisenberger, A; Leckman, JF | 1 |
| Svensson, TH; Wadenberg, ML; Wiker, C | 1 |
| Edgell, ET; Hackworth, J; Haro, JM; Juarez, R; Shi, L; Tohen, MF; Vieta, E | 1 |
| Doraiswamy, PM; Levine, JG; Szarfman, A; Tonning, JM | 1 |
| Bedi, KS; Bryan-Lluka, LJ; Catts, SV; Catts, VS; Naiker, DV | 1 |
| Canonico, PL; Colella, L; Dellarole, A; Ghi, P; Orsetti, M | 1 |
| Fletcher, PJ; Kapur, S; Li, M | 1 |
| Glick, ID; Hamer, RM; Johnson, J; Keefe, RS; Lieberman, JA; McEvoy, JP; Perkins, D; Sharma, T; Tohen, M | 1 |
| Bark, N; Citrome, L; Cooper, TB; Czobor, P; Krakowski, MI | 1 |
| de Beaurepaire, R; Even, PC; Lacroix, M; Minet-Ringuet, J; Tomé, D | 1 |
| Crespo-Facorro, B; Martínez-García, O; Pardo-García, G; Pelayo-Terán, JM; Pérez-Iglesias, R; Ramírez-Bonilla, M; Vázquez-Barquero, JL | 1 |
| Bi, XL; Guo, T; He, X; Hou, Y; Wu, CF; Yang, JY; Yu, L | 1 |
| DeVane, CL; Donovan, JL; Markowitz, JS; Wang, JS; Zhu, HJ | 1 |
| Decker, S; El-Mallakh, RS; El-Masri, MA; Huff, MO; Levy, RS; Li, XP; Morris, M | 1 |
| Bhattacharya, K; Dasgupta, T; Guha, P; Roy, K; Sanyal, D | 1 |
| Guo, T; Hou, Y; Wu, CF; Yang, JY | 1 |
| Gorobets, LN | 1 |
| Cipriani, A; Geddes, JR; Rendell, JM | 1 |
| Kongsakon, R; Leelahanaj, T; Netrakom, P | 1 |
| Mahadik, SP; Pillai, A | 2 |
| Duggal, HS; Mendhekar, DN | 1 |
| Koopmans, RT; Olde Rikkert, MG; van Iersel, MB; Verhey, FR; Zuidema, SU | 1 |
| Glick, ID; Green, AI; Gur, RE; Hamer, RM; Kahn, RS; Lieberman, JA; McEvoy, JP; Perkins, DO; Rothschild, AJ; Sharma, T; Tohen, MF; Woolson, S; Zipursky, RB | 1 |
| Brea, J; Buceta, M; Cano, E; Caruncho, HJ; Castro, M; Domínguez, E; Dopeso-Reyes, IG; Isabel Cadavid, M; Isabel Loza, M; Padín, JF; Rodríguez, MA; Sotelo, E | 1 |
| Bäuml, J; Davis, JM; Engel, RR; Leucht, S | 1 |
| Arranz, MJ; Carrasco-Marín, E; Crespo-Facorro, B; Leyva-Cobían, F; Mata, I; Pelayo-Terán, JM; Pérez-Iglesias, R; Vázquez-Barquero, JL | 1 |
| Antel, J; Firnges, MA; Gregory, P; Haberhausen, M; Hebebrand, J; Reinders, JH; Remschmidt, H; Theisen, FM | 1 |
| Clouth, J; Haggenmüller, L; Naber, D; Reitberger, U; Schmidt, P | 1 |
| Brnabic, AJ; Buenaventura, R; Chan, B; Chaudhry, HR; Ignacio, JC; Ismail, HC; Khan, IU; Kongsakon, R; Leynes, CR; Lowry, AJ; Raza, SB; Rodriguez, SC; Trinidad-Oñate, P | 1 |
| Hsu, MA; Rasmussen, K; Yang, Y | 1 |
| Dorph-Petersen, KA; Konopaske, GT; Lewis, DA; Pierri, JN; Sampson, AR; Wu, Q | 1 |
| Hulstijn, W; Ruigt, GS; Sabbe, BG; Verkes, RJ; Wezenberg, E | 1 |
| Duncan, GE; Koller, BH; Lieberman, JA; Moy, SS | 1 |
| Crespo-Facorro, B; Llorca, J; Luis Vázquez-Barquero, J; Martínez-García, O; Pérez-Iglesias, R; Ramirez-Bonilla, M | 1 |
| Boshoven, W; Duncan, E; Dunlop, BW; Hamer, RM; Phillips, LS; Woolson, SL | 1 |
| Barbanoj, MJ; Clos, S; Giménez, S; Grasa, E; Morte, A; Romero, S | 1 |
| Hinton, T; Johnston, GA; O'Reilly, JN; Skilbeck, KJ | 2 |
| Carpéné, C; Daviaud, D; de Beaurepaire, R; Even, PC; Minet-Ringuet, J; Prévot, D; Quignard-Boulange, A; Tomé, D; Valet, P; Visentin, V | 1 |
| Hulstijn, W; Morrens, M; Ruigt, GS; Sabbe, BG; Verkes, RJ; Wezenberg, E | 1 |
| Engel, JA; Fejgin, K; Klamer, D; Pålsson, E; Safonov, S; Svensson, L; Wass, C | 1 |
| Hirano, K; Kagawa, Y; Kato, Y; Uchida, S; Yamada, S | 1 |
| Jarskog, LF; Lieberman, JA; Perkins, DO | 1 |
| Dierks, T; Irisawa, S; Isotani, T; Kikuchi, M; Kinoshita, T; Koenig, T; Okugawa, G; Strik, W; Yagyu, T; Yamada, K; Yoshimura, M | 1 |
| Hanna, MM; Moreno, RA; Tavares, SM; Wang, YP | 1 |
| Limosin, F | 1 |
| Abad, MT; Iskander, A; Khan, A; Lindenmayer, JP; Parker, B | 1 |
| Azorin, JM; Baker, RW; Bonett-Perrin, E; Brown, E; Brunner, E; Castillo, JJ; Fahrer, RD; Gattaz, WF; González-Pinto, AM; Mazzotti, G; Rovner, J; Tamayo, JM; Tohen, M; Vieta, E; Zapata, R | 1 |
| Short, MR; Winstead, PS | 1 |
| Britton, AM; Lonergan, E; Luxenberg, J; Wyller, T | 1 |
| Ganguli, R; Keshavan, M; Miewald, J; Strassnig, M | 1 |
| Amitai, N; Markou, A; Semenova, S | 1 |
| Joo, YH; Kim, B; Kim, SJ; Son, JI | 1 |
| Bounthavong, M; Okamoto, MP | 1 |
| Bennett, S; Gronier, B | 1 |
| Alfirevic, Z; Degoricija, V; Vucicevic, Z; Vukicevic-Badouin, D | 1 |
| Boulay, LJ; Bourget, D; Habib, R; Labelle, A; Milin, R; Robertson, S; Tessier, P; Tombaugh, T | 1 |
| Aronowitz, J; Bloom, R; Brand, J; Brickman, AM; Buchsbaum, MS; Goldstein, KE; Hazlett, EA; Haznedar, MM; Heath, D; Newmark, RE; Starson, M | 1 |
| Harrison, BE; Therrien, B | 1 |
| Axelsson, S; Eriksson, AC; Hägg, S; Lindahl, TL; Whiss, PA | 1 |
| Breese, GR; Knapp, DJ; Overstreet, DH | 1 |
| Choe, BM; Conley, RR; Jae, YM; Kelly, DL; Kim, HC; Kim, JG; Kim, SG; Oh, MK; Shim, JC | 1 |
| Amato, L; Davoli, M; Minozzi, S; Pani, PP | 1 |
| Hemrick-Luecke, SK; Hsu, MA; Johnson, BG; Noone, S; Rasmussen, K; Thompson, LK | 1 |
| Braff, DL; Erhart, S; Green, MF; Light, GA; Marder, SR; Mintz, J; Reist, C; Sprock, J; Widmark, C; Wynn, JK | 1 |
| Beach, AJ; Calamaras, MR; DeVane, CL; Donovan, J; Gibson, BB; Knight, BT; Nemeroff, CB; Newport, DJ; Owens, MJ; Stowe, ZN; Viguera, AC; Winn, S | 1 |
| Assis, LC; Barbosa, LM; Grandi, E; Quevedo, J; Rezin, GT; Streck, EL | 1 |
| Deutch, AY; Wang, HD | 1 |
| Brodaty, H; Cumming, R; Forrester, L; Grayson, D; Hollis, J; Touyz, S | 2 |
| Arnt, J; Bang-Andersen, B; Brennum, LT; Christoffersen, CT; Di Matteo, V; Didriksen, M; Esposito, E; Hertel, P; Larsen, AK; Marcus, MM; Pouzet, B; Ramirez, T; Svensson, TH; Søby, KK | 1 |
| Bartlett, MG; Terry, AV; Zhang, G | 1 |
| Deng, C; Han, M; Huang, XF; Newell, K; Zavitsanou, K | 1 |
| Bingham, S; Collins, J; Kaczynski, R; Perlick, DA; Rosenheck, RA | 1 |
| Akkaya, C; Cangur, S; Kirli, S; Sarandol, A | 1 |
| Gardner, MP; Graulich, A; Lamy, C; Liégeois, JF; Moran-Gates, T; Tarazi, FI | 1 |
| Enning, F; Heiser, P; Krieg, JC; Vedder, H | 1 |
| Braff, DL; Erhart, S; Green, MF; Kee, KS; Marder, SR; Mintz, J; Reist, C; Sergi, MJ; Widmark, C | 1 |
| Bogetto, F; Fonzo, V; Montemagni, C; Pandullo, P; Rocca, P; Villari, V | 1 |
| Charles Schulz, S; Findling, RL; Kumra, S; McClellan, JM; Oberstar, JV; Sikich, L; Vinogradov, S | 1 |
| Hassan, M; Islam, S; Kalsekar, ID; Kavookjian, J; Madhavan, SS; Makela, EH; Miller, LA; Rajagopalan, K | 1 |
| Dorph-Petersen, KA; Konopaske, GT; Lewis, DA; Pierri, JN; Sampson, AR; Sweet, RA; Zhang, W | 1 |
| Adams, CE; Alexander, J; Raveendran, NS; Tharyan, P | 1 |
| Barnett, MJ; Perry, PJ; Wehring, H | 1 |
| Huang, XF; Wang, Q | 1 |
| Egashira, N; Fujiwara, M; Ishigami, N; Iwasaki, K; Mishima, K; Oishi, R | 1 |
| Amado, JA; Crespo-Facorro, B; Garcia-Unzueta, MT; Gonzalez-Blanch, C; Martinez-Garcia, O; Perez-Iglesias, R; Ramirez-Bonilla, ML; Vazquez-Barquero, JL | 1 |
| Akhtar, S; Ameen, S; Manjunatha, N; Saddichha, S | 2 |
| Alvarez-Jimenez, M; Amado, JA; Crespo-Facorro, B; Garcia-Unzueta, MT; Martinez-Garcia, O; Pelayo-Teran, JM; Perez-Iglesias, R; Ramirez-Bonilla, ML; Vazquez-Barquero, JL | 1 |
| Kim, NR; Kim, YH; Lee, JG; Park, SW | 1 |
| Di Luca, M; Frasca, A; Fumagalli, F; Gardoni, F; Riva, MA; Zianni, E | 1 |
| Inada, T; Oda, T; Yamamoto, N | 2 |
| Cheng, WJ; Huang, MC; Liu, HC | 1 |
| Dembler, T; Gallinat, J; Heinz, A; Juckel, G; Kahnt, T; Kienast, T; Knutson, B; Koslowski, M; Schlagenhauf, F; Wrase, J | 1 |
| Boggs, DL; Carpenter, WT; Davis, JM; Hu, Q; Kelly, DL; Li, L; McMahon, RP | 1 |
| Kaiser, RM; Ozbolt, LB; Paniagua, MA | 1 |
| Guidetti, P; Kelley, JJ; Melendez-Ferro, M; Perez-Costas, E; Roberts, RC | 1 |
| Akhtar, S; Ameen, S; Saddichha, S | 1 |
| Calabrese, JR; Gajwani, P; Ganocy, SJ; Gao, K; Kemp, DE; Muzina, DJ | 1 |
| Carrasco-Marín, E; Crespo-Facorro, B; Fernandez-Prieto, L; Leyva-Cobián, F; Pelayo-Terán, JM; Pérez-Iglesias, R; Vázquez-Barquero, JL | 1 |
| Berk, M; Dodd, S; Lubman, DI; Ng, F; Tohen, M; Vieta, E; Wang, WV | 1 |
| Aarsland, D; Nygaard, HA; Ruths, S; Straand, J | 1 |
| Busch, R; Kane, JM; Kissling, W; Leucht, S; Shamsi, SA | 1 |
| Brennum, LT; Kreilgaard, M; Olsen, CK | 1 |
| Burne, TH; Deng, C; Han, M; Huang, XF; Newell, KA | 1 |
| Kahn, DA; Pelic, C; Shibley, H | 1 |
| Dal-Pizzol, F; Gomes, KM; Martins, MR; Petronilho, FC; Quevedo, J; Streck, EL | 1 |
| Boter, H; Davidson, M; Dollfus, S; Fleischhacker, WW; Gaebel, W; Galderisi, S; Gheorghe, MD; Grobbee, DE; Hranov, LG; Hummer, M; Kahn, RS; Keet, IP; Libiger, J; Lindefors, N; López-Ibor, JJ; Peuskens, J; Riecher-Rössler, A; Rybakowski, JK; Vergouwe, Y | 1 |
| Danilov, DS; Tiul'pin, IuG | 1 |
| Agoston, T; István, S; Tamás, T; Zoltán, J | 1 |
| Palencia-Herrejón, E; Romera, MA; Silva, JA | 1 |
| Allingham, B; Citrome, L; Jaffe, A; Levine, J; Martello, D | 1 |
| Engedal, K; Selbaek, G | 1 |
| Amado, JA; Berja, A; Carrasco-Marín, E; Crespo-Facorro, B; Garcia-Unzueta, MT; Mata, I; Pelayo-Terán, JM; Perez-Iglesias, R; Vazquez-Barquero, JL | 1 |
| Andreazza, AC; Kapczinski, F; Quevedo, J; Rosa, MI; Stertz, L; Streck, EL; Valvassori, SS | 1 |
| Romeo, F; Rossi, A; Tiradritti, P; Vita, A | 1 |
| Kapur, S; Li, M; Mead, A | 1 |
| Hempel, RJ; Hengeveld, MW; Röder, CH; Tulen, JH; van Beveren, NJ | 1 |
| Frasca, A; Fumagalli, F; Murphy, KJ; Racagni, G; Riva, MA; Ter Horst, J | 1 |
| Amato, D; Borsini, F; Nencini, P; Stasi, MA | 1 |
| Aliaga, M; Assié, MB; Barbara, M; Bardin, L; Carilla-Durand, E; Malfètes, N; Maraval, M; Newman-Tancredi, A | 1 |
| Gagnon, PR | 1 |
| Crabbe, JC; Philibin, SD; Porter, JH; Vunck, SA; Walentiny, DM | 1 |
| Bogeski, M; Gogos, A; van den Buuse, M | 1 |
| Costa, E; Dong, E; Grayson, DR; Guidotti, A; Nelson, M | 1 |
| Endo, S; Hamamura, T; Ishihara, T; Kuroda, S; Miyata, S; Taoka, H; Toma, K | 1 |
| Czobor, P; Krakowski, MI; Nolan, KA | 1 |
| Chetcuti, AF; Duncan, CE; Schofield, PR | 1 |
| Baker, R; Breier, A; Dunayevich, E; Lindborg, S; Seaman, J; Spann, M | 1 |
| Cretaz, E; Diniz, BS; Forlenza, OV | 1 |
| Bartzokis, G; Charles, C; Edwards, N; Geaga, JA; Hamer, RM; Hayashi, KM; Hong, MS; Klunder, AD; Lieberman, JA; Lu, PH; McEvoy, J; Perkins, DO; Thompson, PM; Toga, AW; Tohen, M; Tollefson, GD; Yu, M | 1 |
| Kao, U; Ling, WW; Shoptaw, SJ | 1 |
| Farooq, S; Sherin, A | 1 |
| Crespo-Facorro, B; de Lucas, EM; Gutiérrez, A; Martínez, O; Pelayo-Terán, JM; Pérez-Iglesias, R; Ramírez, M; Rodríguez-Sánchez, JM; Roiz-Santiáñez, R; Tordesillas-Gutiérrez, D; Vázquez-Barquero, JL | 1 |
| Frasca, A; Fumagalli, F; Racagni, G; Riva, MA | 1 |
| Kumar, M; Mishra, AK; Mishra, P; Misra, A; Pathak, K | 1 |
| Amado, JA; Berja, A; Crespo-Facorro, B; Garcia-Unzueta, MT; Martinez-Garcia, O; Mata, I; Pelayo-Teran, JM; Perez-Iglesias, R; Vazquez-Barquero, JL | 1 |
| Bogo, MR; Bonan, CD; Dias, RD; Oliveira, Rda L; Rico, EP; Seibt, KJ | 2 |
| Anders, M; Dossenbach, M; Irimia, V; Kotler, M; Logozar-Perkovic, D; Lowry, AJ; Pecenak, J; Peciukaitiene, D; Smulevich, AB; Szulc, A; Treuer, T; West, TM | 1 |
| Alvarez-Jiménez, M; Crespo-Facorro, B; González-Blanch, C; Martínez-García, O; Pelayo-Terán, JM; Pérez-Iglesias, R; Rodríguez-Sánchez, JM; Vázquez-Barquero, JL | 1 |
| San, L | 1 |
| Albert, A; De Graeve, D; Gillain, B; Peuskens, J; Van Vleymen, B | 1 |
| Castle, DJ; Isik, T; Karagianis, J; Kim, CY; Melamed, Y; Omar, AN; Pidrman, V; Rosales, JI; Sarosi, A; Treuer, T; Udristoiu, T | 1 |
| Futamura, T; Maeda, K; Marunaka, Y; Mitsumoto, Y; Sugino, H | 1 |
| Danilov, DS | 1 |
| Ivanets, NN; Kinkul'kina, MA | 1 |
| Kao, U; Ling, W; Shoptaw, SJ | 1 |
| Deng, C; Han, M; Huang, XF | 1 |
| Citrome, L; Czobor, P; Krakowski, M | 1 |
| Clement, HW; Dobschütz, E; Heiser, P; Hoinkes, A; Hopt, UT; Krieg, JC; Schmidt, AJ; Schulz, E; Sommer, O | 1 |
| He, W; Li, M; Mead, A | 1 |
| Li, M; Mead, A | 1 |
| Carlström, EL; Jazin, E; Jiang, L; Saetre, P | 1 |
| Ayesa, R; Crespo-Facorro, B; Martínez-Garcia, O; Mata, I; Pérez-Iglesias, R; Ramirez-Bonilla, M; Rodríguez-Sánchez, JM; Vázquez-Barquero, JL | 1 |
| Bahn, S; Benzel, IM; Chan, MK; Cilia, J; Guest, PC; Hill, MD; Jones, DN; Levin, Y; Lockstone, HE; Ma, D; Maycox, PR; Pietsch, SR; Robbins, MJ; Umrania, Y | 1 |
| Auclair, AL; Barret-Grévoz, C; Barreto, M; Depoortère, R; Kleven, MS; Newman-Tancredi, A | 1 |
| Goldberg, TE; Gomar, JJ | 1 |
| Duncan, EJ; Dunlop, BW; Hamer, RM; Woolson, SL | 1 |
| Husso, M; Kuikka, JT; Tiihonen, J; Tuppurainen, H; Viinamäki, H | 2 |
| Bourguignon, JJ; Carnicella, S; Mongeot, A; Oberling, P | 1 |
| Akkaya, C; Alptekin, K; Brook, S; Danaci, AE; El Tallawy, H; Hafez, J; Karayal, ON; Lowe, W; Tzebelikos, E; Ucok, A | 1 |
| de Beaurepaire, R; Even, PC; Fromentin, G; Hermier, D; Huneau, JF; Tomé, D; Victoriano, M | 1 |
| Alexander, J; Allen, MH; Huf, G; Raveendran, NS | 1 |
| Csernansky, JG; Deberdt, W; Keefe, RS; Kollack-Walker, S; Lipkovich, IA; Sabbe, B | 1 |
| DiPaula, BA; Freeman, DJ; Love, RC | 1 |
| Farias, MR; Grohs, GE; Lindner, LM; Marasciulo, AC | 1 |
| Cropsey, KL; Holcomb, HH; Lahti, AC; Tamminga, CA; Weiler, MA | 1 |
| Dietrich-Muszalska, A; Olas, B; Rabe-Jabłońska, J | 1 |
| Glazebrook, J; Grayson, B; Kirk, SL; Neill, JC; Reynolds, GP | 1 |
| Hewer, W; Kauder, E; Vierling, P | 1 |
| Gaszner, P | 1 |
| Bundzikova, J; Kiss, A; Mikkelsen, JD; Pirnik, Z | 1 |
| Deng, C; du Bois, TM; Han, M; Huang, XF | 1 |
| Adams, CE; Coutinho, ES; Huf, G | 1 |
| Carroll, C; Frost, DO; Kolb, B; Page, SC | 1 |
| de Leeuw van Weenen, JE; Frölich, M; Pijl, H; Roelfsema, F; Romijn, JA; Vidarsdottir, S | 1 |
| Assunção-Talbott, S; Barnes, TR; Buckley, P; Correll, CU; Eudicone, J; Kane, JM; McQuade, R; Pikalov, A; Sachs, G; Tran, QV | 1 |
| Bymaster, F; Duman, RS; Girgenti, MJ; Newton, SS; Nisenbaum, LK; Terwilliger, R | 1 |
| Shafti, SS; Shahveisi, B | 1 |
| Ahangari, G; Ahmadkhaniha, HR; Asadi, SM; Hossein-nezhad, A; Pooyafard, F; Shariati, GR | 1 |
| Burns, T; Derks, EM; Fleischhacker, WW; Gaebel, W; Kahn, RS; Riesbeck, M; Rössler, W; von Wilmsdorff, M | 1 |
| Holdridge, KC; Houston, JP; Saunders, W; Sorsaburu, S | 1 |
| Kastania, A; Katsafouros, K; Laskos, E; Lykouras, L; Michalopoulou, PG; Papadopoulou, A; Rizos, EN; Vasilopoulos, D | 1 |
| Dietrich-Muszalska, A; Kontek, B; Nowak, P; Rabe-Jablonska, J | 1 |
| Cicale, M; de Bartolomeis, A; Fiore, G; Iasevoli, F; Muscettola, G | 1 |
| Benedetti, AM; Frazee, LA; Leung, JG; Myers, N | 1 |
| Arakawa, R; Ito, H; Maeda, J; Okubo, Y; Okumura, M; Suhara, T; Takahashi, H; Takano, A; Takano, H | 1 |
| Ishida, S; Ogata, T; Yokoyama, H | 1 |
| Graff-Guerrero, A; Kapur, S; McCormick, PN; Nobrega, JN; Raymond, R; Wilson, AA | 1 |
| Danna, CL; Elmer, GI | 1 |
| Buyukoglan, H; Kaya, MG; Ulusoy, HB; Yagmur, F | 1 |
| Kenchaiah, BK; Kumar, S; Tharyan, P | 1 |
| Chiu, NY; Hsu, WY; Huang, SS; Lee, BS | 1 |
| Dysken, MW; Lederle, FA; Rector, TS; Rossom, RC | 1 |
| Albaugh, VL; Breazeale, S; Elich, TD; Ilkayeva, O; Joyal, JL; Lang, CH; Lynch, CJ; Maresca, KP; Vary, TC; Wenner, BR | 1 |
| Czobor, P; Krakowski, MI | 3 |
| Ciobica, A; Dobrin, I; Padurariu, M; Stefanescu, C | 1 |
| de Beaurepaire, R; Guerre-Millo, M; Hermier, D; Huneau, JF; Mathé, V; Naour, N; Quignard-Boulangé, A; Tomé, D; Victoriano, M | 1 |
| Hu, G; Li, M; Sun, T; Zhang, C | 1 |
| Kimoto, S; Kishimoto, T; Makinodan, M; Okuda, H; Tatsumi, K; Toritsuka, M; Wanaka, A; Yamauchi, T | 1 |
| Beyer, J; Drummer, OH; Gerostamoulos, D; Saar, E | 1 |
| Eggan, SM; Lewis, DA; Volk, DW | 1 |
| Agid, O; Arenovich, T; Chen, L; Kapur, S; Kinon, BJ; Marques, TR; Muthén, B; Sajeev, G | 1 |
| Calcagno, E; Carli, M; Invernizzi, RW; Mainini, E; Mainolfi, P | 1 |
| Akechi, T; Furukawa, TA; Leucht, S; Wagenpfeil, S | 1 |
| Caseiro, O; Crespo-Facorro, B; Martínez-Garcia, O; Mata, I; Pardo, G; Pelayo-Terán, JM; Pérez-Iglesias, R; Ramirez-Bonilla, M; Vázquez-Barquero, JL | 1 |
| Ascher-Svanum, H; Case, M; Conley, R; Kane, J; Kinon, BJ; Kollack-Walker, S; Lieberman, J; McEvoy, J; Stauffer, VL | 1 |
| Fuller, G; Hughes, L | 1 |
| Bak, M; de Haan, L; Delespaul, PA; Lardinois, M; Lataster, J; Lataster, T; Myin-Germeys, I; Thewissen, V; van Os, J | 1 |
| Kim, LW; Kim, YH; Lee, BJ; Lee, CH; Lee, JG; Park, SW; Shin, BS | 1 |
| Caseiro, O; Crespo-Facorro, B; Martínez-Garcia, O; Mata, I; Pardo-Garcia, G; Pelayo-Terán, JM; Pérez-Iglesias, R; Ramirez-Bonilla, M; Vázquez-Barquero, JL | 1 |
| Dodig, T; Glavina, G; Glavina, T; Mrass, D; Pranić, S; Uglešić, B | 1 |
| Dietrich-Muszalska, A; Kontek, B; Rabe-Jabłońska, J | 1 |
| Di Cosimo, D; Girardi, N; Kotzalidis, GD; Lazanio, S; Manfredi, G; Savoja, V; Talamo, A; Tatarelli, R; Vento, A | 1 |
| Cole-Strauss, A; Jandacek, R; Lipton, JW; McNamara, RK; Rider, T; Tso, P | 1 |
| Baldaçara, L; Cordeiro, DC; Jackoswski, AP; Sanches, M | 1 |
| Czobor, P; Krakowski, M | 1 |
| Barbato, A; D'Avanzo, B; Parabiaghi, A; Tettamanti, M | 2 |
| Feifel, D; MacDonald, K; Vilke, GM; Wilson, MP | 1 |
| Anand, KS; Bajaj, BK; Jhanjee, A | 1 |
| Ferreira, AS; Gattaz, WF; Raposo, NR | 1 |
| Crespo-Facorro, B; Martínez-Garcia, O; Mata, I; Ortiz, V; Pelayo-Terán, JM; Pérez-Iglesias, R; Valdizan, E; Vazquez-Barquero, JL | 1 |
| Farrell, MS; Kroeze, WK; Roth, BL; Yadav, PN | 1 |
| Eberhard, J; Fors, BM; Hansen, K; Lindström, E; Sapin, C | 1 |
| Guglielmo, BJ; Meier, CR; Meyer-Massetti, C; Rätz Bravo, AE; Vaerini, S | 1 |
| Lewis, DA; Radchenkova, PV; Sengupta, EJ; Volk, DW; Walker, EM | 1 |
| Bitter, I; Czobor, P; Derks, EM; Fleischhacker, WW; Kahn, RS; Libiger, J; Volavka, J | 1 |
| Kimoto, S; Kishimoto, T; Makinodan, M; Nakamura, Y; Okuda, A; Okuda, H; Tatsumi, K; Toritsuka, M; Wanaka, A; Yamauchi, T | 1 |
| Andreotti, S; Gattaz, WF; Lima, FB; Passos-Bueno, MR; Sertié, AL; Sertié, RA; Suzuki, AM | 1 |
| Faludi, G; Fejes, L; Inczédy-Farkas, G; Kassai-Farkas, A; Lazáry, J; Makkos, Z | 1 |
| Cho, HY; Fang, ZH; Kim, YH; Lee, BJ; Lee, CH; Lee, JG; Park, SW; Phuong, VT; Seo, MK | 1 |
| Constant, E; Jacques, D; Manceaux, P; Reynaert, C; Zdanowicz, N | 1 |
| Chakrabarti, S; Grover, S; Kumar, V | 1 |
| Andrade, C; Bambole, V; Bang, A; Shah, N; Sonavane, S | 1 |
| Bak, M; Marcelis, M; van Os, J | 1 |
| Jardemark, K; Malmerfelt, A; Marcus, MM; Shahid, M; Svensson, TH | 1 |
| Chan, HY; Chen, CH; Chen, JJ; Gau, SS; Hwu, HG | 1 |
| Higuchi, T; Kanba, S; Katagiri, H; Takahashi, M; Takita, Y; Tohen, M | 1 |
| Bonan, CD; da Luz Oliveira, R; Rosemberg, DB; Savio, LE; Scherer, EB; Schmitz, F; Seibt, KJ; Wyse, AT | 1 |
| Li, M; Zhang, C | 1 |
| Dudova, I; Hrdlicka, M; Urbanek, T; Zedkova, I | 1 |
| Blow, FC; Chiang, C; Cunningham, F; Kales, HC; Kim, HM; Schneider, LS; Seyfried, LS; Valenstein, M; Zivin, K | 1 |
| Czernikiewicz, A; Kucharska-Pietura, K; Mortimer, A; Tylec, A | 2 |
| Chrisphonte, P; Ostroff, RB; Rosenheck, RA | 1 |
| Chang, CH; Kao Yang, YH; Lai, EC; Lin, CY; Lin, SJ | 1 |
| Umeda, K | 1 |
| Atack, J; Cik, M; De Bruyn, M; Hendrickx, H; Langlois, X; Lavreysen, H; Macdonald, G; Megens, A; Peeters, L; te Riele, P; Vermeire, J; Wouters, R | 1 |
| Becker, O; Cobb, P; Feifel, D; Galangue, B; MacDonald, K; Minassian, A; Perez, R; Tallian, K; Vilke, GM; Wilson, M | 1 |
| Kinon, BJ; Kollack-Walker, S; Liu-Seifert, H; Stauffer, V | 1 |
| Bradaia, A; Bruns, A; Buchy, D; Chaboz, S; Galley, G; Groebke Zbinden, K; Hoener, MC; Kilduff, TS; Metzler, V; Morairty, SR; Moreau, JL; Mory, R; Norcross, RD; Pouzet, B; Revel, FG; Risterucci, C; Tuerck, D; Wallace, TL; Wettstein, JG | 1 |
| Detke, HC; Witte, MM; Zhao, F | 1 |
| Bitter, I; Bucci, P; Fleischhacker, WW; Galderisi, S; Kahn, RS; Libiger, J; Mucci, A | 1 |
| Li, M; Swalve, N | 1 |
| Castelli, A; Colombo, R; Corona, A; Giannotti, C; Minari, C; Praga, F; Raimondi, F | 1 |
| Citrome, L | 1 |
| Ayesa-Arriola, R; Crespo-Facorro, B; Gutiérrez, A; Ortíz-García de la Foz, V; Roiz-Santiáñez, R; Tabarés-Seisdedos, R; Tordesillas-Gutiérrez, D; Vázquez-Barquero, JL | 1 |
| Li, M; Sparkman, NL | 1 |
| Aguglia, E; Dipasquale, S; Minutolo, G; Petralia, A | 1 |
| Bédard, AM; Lévesque, D; Maheux, J; Samaha, AN | 1 |
| Capapey, J; Colom, F; Goikolea, JM; Grande, I; Sanchez-Moreno, J; Torres, I; Undurraga, J; Valentí, M; Vieta, E | 1 |
| Amado, JA; Crespo-Facorro, B; Garcia-Unzueta, MT; Martínez-García, O; Mata, I; Pérez-Iglesias, R; Valdizán, EM; Vázquez-Barquero, JL | 1 |
| Gerig, G; Gouttard, S; Lieberman, JA; Maltbie, E; McClure, RK; Shi, X; Styner, M; Zhu, H | 1 |
| Malcolm, P; Pereira, A; Sundram, S; Zhang, B | 1 |
| Crespo-Facorro, B; Díaz, I; Mata, I; Pelayo-Terán, JM; Pérez-Iglesias, R; Suárez-Pinilla, P; Tabarés-Seisdedos, R; Vázquez-Barquero, JL | 1 |
| Anacker, C; Cattaneo, A; Dazzan, P; Kapur, S; Modo, M; Mondelli, V; Natesan, S; Pariante, CM; Vernon, AC | 1 |
| Bienroth, M; Curtis, V; Debenham, M; George, M; Gonzalez, D; Jones, S; Pitsi, D | 1 |
| Carroll, BT; Crosby, D; Peterson, J | 1 |
| Cheung, C; Chua, SE; Collier, DA; Deng, W; Gong, Q; Huang, C; Jiang, L; Li, M; Li, T; Ma, X; McAlonan, GM; Sham, PC; Wang, Q; Wang, Y | 1 |
| Aldana-Bernier, L; Bhojani, S; Pawelzik, T; Sikder, M | 1 |
| Ayesa-Arriola, R; Crespo-Facorro, B; Martínez-García, O; Pérez-Iglesias, R; Rodríguez-Sánchez, JM; Roiz-Santiáñez, R; Sánchez-Moreno, J; Tabarés-Seisdedos, R; Vázquez-Barquero, JL | 1 |
| Crespo-Facorro, B; de León, J; Diaz, FJ; Pelayo-Terán, JM; Pérez-Iglesias, R; Suárez-Pinilla, P; Tabarés-Seisdedos, R | 1 |
| Golla, H; Perrar, KM; Voltz, R | 1 |
| Kirk Morton, N; Zubek, D | 1 |
| Lewis, DA; Siegel, BI; Verrico, CD; Volk, DW | 1 |
| Beck, A; Gillies, D; Rathbone, J; Sampson, S | 1 |
| Carey, RJ; Carrera, MP; de Fátima Dos Santos Sampaio, M; de Mello Bastos, JM; Dias, FR | 1 |
| Adilijiang, A; Fang, F; He, J; Huang, Q; Kong, L; Li, XM; Liu, Y; Tan, Q; Wang, J; Xu, H; Zhang, D; Zhang, H; Zhang, Y; Zhang, Z | 1 |
| Choi, SH; Choi, WJ; Kim, JJ; Park, JY; Park, KM; Seok, JH; Yoon, HJ | 1 |
| Amado, JA; Crespo-Facorro, B; Garcia-Unzueta, MT; Martínez-García, O; Pardo-Garcia, G; Pérez-Iglesias, R; Tabares-Seisdedos, R | 1 |
| Jayarajan, P; Nirogi, R; Shinde, A | 1 |
| Chege, W; Cooper, JD; Crum, WR; Kapur, S; Lerch, JP; Modo, M; Natesan, S; Vernon, AC; Williams, SC | 1 |
| Edelson, JR; Lewis, DA; Sengupta, EJ; Siegel, BI; Volk, DW | 1 |
| Bø, CN; Einarson, TR; Hemels, ME; Jensen, R; Piwko, C; Pudas, H; Vicente, C; Zilbershtein, R | 1 |
| Citrome, L; Czobor, P; Van Dorn, RA; Volavka, J | 1 |
| Abderhalden, C; Horn, H; Maier, N; Moggi, F; Moskvitin, K; Müller, TJ; Strik, W; Walther, S | 1 |
| Gen, K; Suzuki, H; Takahashi, Y | 1 |
| Leucht, S; Zhao, J | 1 |
| Ablordeppey, SY; Bricker, B; Sampson, D | 1 |
| Kozumplik, O; Mihaljevic-Peles, A; Muck-Seler, D; Nedic Erjavec, G; Nikolac Perkovic, M; Pivac, N; Sagud, M; Uzun, S; Zivkovic, M | 1 |
| Bahramzi, M; Campillo, A; Minassian, A; Vilke, GM; Wilson, MP | 1 |
| Eleméry, M; Faludi, G; Kovács, G; Szegő, A | 1 |
| Doufik, J; Ghanmi, J; Khalili, L; Otheman, Y; Ouanass, A | 1 |
| Chan, HY; Chen, CK; Chen, JJ; Chen, YS; Chou, SY; Ree, SC; Su, LW | 1 |
| Aguglia, E; Bianchini, O; Cannavò, D; De Ronchi, D; Nespeca, C; Porcelli, S; Serretti, A; Trappoli, A | 1 |
| Dawood, A; Kaufman, KR; Newman, NB | 1 |
| Li, M; Liu, X; Sun, T | 1 |
| Chen, KP; Lung, FW; Yang, MC | 1 |
| Davoodi, N; Langlois, X; te Riele, P | 1 |
| Case, M; Chen, J; Chen, L; Gupta, S; Jeste, D; Kinon, BJ; Kollack-Walker, S; Stauffer, V | 1 |
| Boettger, S; Breitbart, W; Jenewein, J | 1 |
| Fang, Y; Xu, L; Zhang, C | 1 |
| Castle, DJ; Slott Jensen, JK | 1 |
| Aiello, R; Citraro, R; De Sarro, G; Leo, A; Pugliese, M; Russo, E | 1 |
| Goya, S; Kai, T; Kanemura, S; Kashiwagi, Y; Maeda, I; Matsuda, Y; Nakajima, S; Okamoto, Y; Taira, T; Takei, K; Tanimukai, H; Tokoro, A; Tokuyama, M; Tsujimoto, H; Tsujio, I; Watanabe, M | 1 |
| Deng, C; Han, M; Hu, CH; Huang, XF; Pan, B | 1 |
| Brown, JB; Kadoyama, K; Kimura, G; Miki, I; Nakamura, T; Nisiguchi, K; Okuno, Y; Sakaeda, T | 1 |
| Berardi, MA; Caraceni, A; Caruso, R; Grassi, L; Mitchell, AJ; Nanni, MG; Riba, M | 1 |
| Habata, Y; Imaichi, S; Komatsu, H; Maruyama, M; Mori, M; Sakuma, K | 1 |
| Praharaj, SK; Sarkhel, S; Singh, N | 1 |
| Chiang, C; Kales, HC; Kavanagh, J; Kim, HM; Maust, DT; Schneider, LS; Seyfried, LS | 1 |
| Choi, NK; Lee, J; Lee, SH; Park, BJ; Park, MJ; Seong, JM; Shin, JY | 1 |
| Chen, HH; Chen, YH; Hsieh, MH; Huang, CL; Huang, GH; Hwang, TJ; Hwu, HG | 1 |
| Bédard, AM; El Hage, C; Samaha, AN | 1 |
| Pałasz, A; Rojczyk, E; Wiaderkiewicz, R | 2 |
| Babigumira, JB; Lubinga, SJ; Mutamba, BB; Nganizi, A | 1 |
| Arion, D; Corradi, JP; Datta, D; Lewis, DA | 1 |
| DiPaula, BA; Feldman, S; Kelly, DL; Love, RC; McMahon, RP; Miller, J; Morris, AA; Raley, H; Wehring, H | 1 |
| Andrews, JL; Engel, M; Fernandez-Enright, F; Huang, XF; Lum, JS; Matosin, N; Newell, KA | 1 |
| Bogo, MR; Bonan, CD; Oliveira, Rda L; Seibt, KJ; Senger, MR | 1 |
| Iwata, N; Kishi, T; Matsunaga, S | 1 |
| Cho, HY; Kim, YH; Lee, BJ; Lee, CH; Lee, JG; Park, SW; Seo, MK; You, YS | 1 |
| Cooper, JD; Cotel, MC; Kapur, S; Lenartowicz, EM; Modo, MM; Natesan, S; Vernon, AC; Williams, SC | 1 |
| Catapano, F; Fabrazzo, M; Maj, M; Monteleone, AM; Monteleone, P; Perris, F; Prisco, V; Steardo, L; Tortorella, A | 1 |
| Bogus, K; Krzystanek, E; Krzystanek, M; Pałasz, A; Wiaderkiewicz, R; Worthington, JJ | 1 |
| McCollum, LA; McCullumsmith, RE; Roberts, RC | 1 |
| Kashiwase, Y; Matoba, M; Miyano, K; Nishimura, H; Ohe, Y; Shiraishi, S; Suzuki, M; Tagami, K; Uezono, Y; Yokoyama, A | 1 |
| Hammarlund-Udenaes, M; Jansson, B; König, F; Loryan, I; Melander, E; Payan, M; Svensson, M | 1 |
| Dold, M; Gianatsi, M; Helfer, B; Leucht, S; Nikolakopoulou, A; Salanti, G; Samara, MT | 1 |
| Antczak, A; Górski, P; Karbownik, MS; Kowalczyk, E; Pietras, T; Szemraj, J; Wieteska, Ł | 1 |
| Edelson, JR; Lewis, DA; Volk, DW | 1 |
| Baymeeva, NV; Burminskiy, DS; Miroshnichenko, II; Morozova, MA; Platova, AI; Potanin, SS | 1 |
| Amato, L; Indave, BI; Minozzi, S; Pani, PP | 1 |
| Cordes, J; Gründer, G; Heinze, M; Mühlbauer, B; Rüther, E; Schulz, C; Timm, J | 1 |
| Caton, M; Newman, WJ; Scangos, KW | 1 |
| Hudson, MR; Jones, NC; O'Brien, TJ; Rind, G | 1 |
| Bereza, BG; Einarson, TR; Goswami, P; Maia-Lopes, S; Van Impe, K | 1 |
| Anglin, RE; Mazurek, MF; Rasmussen, SA; Rosebush, PI | 1 |
| Barbosa, DS; Bonifácio, KL; Brinholi, FF; Casagrande, R; Farias, CC; Higachi, L; Moreira, EG | 1 |
| Park, JI | 1 |
| Bogus, K; Filipczyk, Ł; Krzystanek, M; Pałasz, A; Rojczyk, E; Wiaderkiewicz, A; Wiaderkiewicz, R; Worthington, J | 1 |
| Cotel, MC; Crum, WR; Danckaers, F; Huysmans, T; Kapur, S; Modo, MM; Natesan, S; Sijbers, J; Vernon, AC; Williams, SC | 1 |
| Faissner, A; Geissler, M; Gottschling, C; Juckel, G; Springer, G; Wolf, R | 1 |
| Alphs, L; Correll, CU; Kim, E; Mao, L; Starr, HL | 1 |
| Khushu, A; Powney, MJ | 1 |
| Khokhar, MA; Rathbone, J | 1 |
| Avagliano, C; Buonaguro, EF; de Bartolomeis, A; Eramo, A; Iasevoli, F; Latte, G; Marmo, F; Tomasetti, C | 1 |
| Ding, X; Hu, G; Li, M; Li, X; Shu, Q; Wu, R | 1 |
| Banerjee, M; Nair, C; Nair, IV; Saradalekshmi, KR; Swathy, B | 2 |
| Altamura, AC; Buoli, M; Caldiroli, A; Esposito, CM; Godio, M; Serati, M | 1 |
| Onaolapo, AY; Onaolapo, OJ; Paul, TB | 1 |
| Crespo-Facorro, B; Gomez-Arnau, J; Juncal-Ruiz, M; Martinez-Garcia, O; Neergaard, KD; Ortiz-Garcia de la Foz, V; Ramirez-Bonilla, M; Suarez-Pinilla, P; Tabares-Seisdedos, R | 1 |
| Ademakinwa, OQ; Olalekan, TO; Onaolapo, AY; Onaolapo, OJ | 1 |
| De Vos, C; Decuypere, F; Denee, TR; Geerts, P; Lamotte, M; Malfait, B; Mulder, CL; Sermon, J | 1 |
| Delis, F; Leonard, KE; Rosko, L; Shroff, A; Thanos, PK | 1 |
| Baretic, M; Kuzman, MR; Osvatic, MM; Vuk, A | 1 |
| Bereza, BG; Denee, TR; Dries, PJT; Einarson, TR; Tedouri, F; Van Impe, K | 1 |
| Mock, CK; Teslyar, P; Thom, RP | 1 |
| Cao, D; Kang, B; Meng, Y; Ning, H; Wang, H; Xie, S | 1 |
| Chikama, K; Kajitani, K; Nakabeppu, Y; Tsukamoto, T; Uchimura, N; Yamada, H | 1 |
| Dzyubenko, E; Faissner, A; Juckel, G | 1 |
| Mazurek, MF; Rasmussen, SA; Rosebush, PI | 1 |
| Bertolino, A; Dukart, J; Hawkins, PCT; Mazibuko, N; Mehta, MA; Merlo-Pich, E; Risterucci, C; Sambataro, F; Silber-Baumann, H; Vernon, AC; Walsh, E; Wood, TC; Zelaya, FO | 1 |
| Ershov, EE; Grunina, MN; Krupitsky, EM; Nasyrova, RF; Sosin, DN; Sosina, КА; Taraskina, AE; Zabotina, AM | 1 |
| Jajawi, S; Jayaram, MB; Ostinelli, EG; Sayal, K; Spyridi, S | 1 |
| Zun, LS | 1 |
| Capuani, C; Corsi, M; Harada, A; Kimura, H; Suzuki, H; Suzuki, K; Ugolini, A | 1 |
| Chen, X; Fan, Q; Song, Y; Tang, J; Xue, X; Yu, X | 1 |
| Sakamoto, S; Sato, K; Takaki, M; Yamada, N; Yoshimura, B | 1 |
| Rosini, JM; Whyte, CJ | 1 |
| Ershov, EE; Grunina, MN; Krupitsky, EM; Nasyrova, RF; Sosin, DN; Sosina, KA; Taraskina, AE; Zabotina, AM | 1 |
| Calevro, A; Cotel, MC; Modo, M; Mondelli, V; Natesan, S; Vernon, AC | 1 |
| Cole, JB; Klein, LR; Martel, ML | 1 |
| Cole, JB; Collins, JD; Driver, BE; Fagerstrom, E; Hessel, M; Horton, GB; Klein, LR; Martel, ML; Miner, JR; Satpathy, R | 1 |
| Bell, C; Burry, L; Fergusson, DA; Hutton, B; Luxenberg, JS; Mehta, S; Perreault, MM; Rose, L; Siddiqi, N | 1 |
| Dickert, NW; Sugarman, J | 2 |
| Hanprasertpong, N; Koonrungsesomboon, N; Na Takuathung, M; Teekachunhatean, S | 1 |
| Jasińska-Stroschein, M; Jóźwiak-Bębenista, M; Kowalczyk, E | 1 |
| Huh, L; Lee, JG; Lee, JH; Lee, Y; Mansur, RB; McIntyre, RS; Park, SC; Park, SW; Seo, MK | 1 |
| Hardman, MI; Sprung, J; Weingarten, TN | 1 |
| Aguirre, C; Erezuma, I; Garcia, M; Hernandez, R; Lertxundi, U; Medrano, J | 1 |
| Bertolino, A; Dipasquale, O; Dukart, J; Hawkins, PCT; Mehta, MA; Pergola, G; Rizzo, G; Sambataro, F; Selvaggi, P; Turkheimer, F; Veronese, M; Williams, SCR; Zelaya, F | 1 |
| Bak, E; Bak, M; Bervoets, C; Bienkowski, P; De Fruyt, J; Dom, G; Drukker, M; Fiorillo, A; Frydecka, D; Misiak, B; Preuss, WU; Samochowiec, A; Samochowiec, J; Sampogna, G; Weltens, I | 1 |
| Cole, JB; Driver, BE; Horton, G; Klein, LR; Martel, ML; Scharber, S | 1 |
| Nordstrom, K; Wilson, M; Zeller, S | 1 |
| Cole, JB; Driver, BE; Klein, LR; Martel, ML; Miner, JR | 2 |
| Bogus, K; Krzystanek, M; Pałasz, A; Suszka-Świtek, A; Wiaderkiewicz, R; Worthington, JJ | 1 |
| Acharya, B; Dulal, S; Neupane, P; Paudel, BD; Poudyal, BS; Shah, A; Shilpakar, R; Wood, LA | 1 |
| April, MD; De Lorenzo, RA; Schauer, SG; Wheeler, AR | 1 |
| Janas-Kozik, M; Krysta, K; Krzystanek, M; Martyniak, E; Rybakowski, J | 1 |
| Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S | 1 |
| Ayesa-Arriola, R; Crespo-Facorro, B; Gómez-Revuelta, M; Juncal-Ruiz, M; Pelayo-Terán, JM; Romero-Jiménez, R; Setién Suero, E; Suárez-Pinilla, P; Vázquez-Bourgon, J | 1 |
| Beeker, A; Beekman, ATF; Berkhof, J; Boddaert, MSA; Neefjes, ECW; Teunissen, SCC; van der Vorst, MJDL; Verdegaal, BATT; Verheul, HMW; Wilschut, JA; Zuurmond, WWA | 1 |
| Wang, C; Zhou, J; Zong, C | 1 |
| Chandrasekaran, S; Dhandapani, VR; Iyer, S; Mohan, G; Mohan, M; Pattabiraman, R; Paul, V; Ramachandran, P; Rangaswamy, T; Singh, SP | 1 |
| Avagliano, C; Barone, A; Buonaguro, EF; de Bartolomeis, A; Eramo, A; Iasevoli, F; Vellucci, L | 1 |
| Babinska, Z; Hammer, T; Horska, K; Karpisek, M; Kotolova, H; Micale, V; Prochazka, J; Ruda-Kucerova, J; Stark, T | 1 |
| Gropp, C; Jaworowski, S; Malka, M; Weiser, M | 1 |
| Bienertova-Vasku, J; Horska, K; Hruska, P; Kucera, J; Kuruczova, D; Micale, V; Ruda-Kucerova, J | 1 |
| D Mahale, S; Gajbhiye, RK; Mahajan, NN; Nachane, HB; Shinde, S; Subramanyam, AA | 1 |
| Cepaityte, D; Egberts, T; Kouvelas, D; Leucht, S; Papazisis, G; Siafis, S | 1 |
| Chen, A; Cloutier, A; Copeli, F; Metzger, E; Osser, DN | 1 |
| Likhitsathian, S; Maneeton, B; Maneeton, N; Oon-Arom, A; Srisurapanont, M; Suradom, C; Suttajit, S | 1 |
| Abdallah, GT; Eche, IJ; Eche, IM; Hsu, D; Knoph, KN; Patel, P; Wang, M; Wong, A; Yankama, TT | 1 |
| Czobor, P; Krakowski, M; Tural, U | 1 |
| Barbui, C; Bertolini, F; Bovo, C; Correll, CU; Del Giovane, C; Gastaldon, C; Nosé, M; Ogheri, F; Ostuzzi, G; Papola, D; Purgato, M; Tedeschi, F; Turrini, G | 1 |
| Bighelli, I; Davis, JM; Deste, G; Leucht, S; Paris, G; Schneider-Thoma, J; Siafis, S; Vita, A; Zhu, Y | 1 |
| Faay, MDM; Sommer, IE | 1 |
| Bakırdere, S; Chormey, DS; Dalgıç Bozyiğit, G; Fırat Ayyıldız, M; Onkal Engin, G | 1 |
| Arranz, B; Arrojo, M; Becoña, E; Bernardo, M; Castells, X; Cunill, R; Flórez, G; Fonseca, F; Garriga, M; Goikolea, JM; González-Pinto, A; López, A; Sáiz, PA; San, L; Tirado-Muñoz, J; Torrens, M; Zorrilla, I | 1 |
| Rose, MQ; Santos, CD | 1 |
| Bakker, IM; Kamphuis, J; Schoevers, RA; Smith-Apeldoorn, SY; Touw, DJ; Veraart, JKE; Visser, BAE | 1 |
| Hirakawa, T; Kimura, H; Kurimoto, E; Yamada, R | 1 |
| Hatano, M; Ikuta, T; Iwata, N; Kishi, T; Matsuda, Y; Nomura, I; Okuya, M; Sakuma, K | 1 |
| Baldwin, DS | 1 |
| Bloemhof-Bris, E; Shelef, A; Sinai, O; Stryjer, R; Weizman, S | 1 |
| Davis, JM; Hamza, T; Leucht, S; Salanti, G; Schneider-Thoma, J; Siafis, S; Wu, H | 1 |
| Chan, EW; Haendler, M; Knapp, MRJ; Lao, KSJ; Lau, H; Li, X; Tsui, SH; Yan, VKC; Yap, CYL | 1 |
| Abrantes, A; Ancalade, N; Basiri, ML; Giusti-Rodriguez, P; Hultman, R; Sekle, S; Stuber, GD; Sullivan, PF | 1 |
| Chong, PH; Kan, AD; Koh, YH; Lin, K; Lyu, XJ; Yeo, ZZ | 1 |
| Hamilton, J; Richardson, B; Thanos, P; Waldman, L | 1 |
| Osser, DN; Stetson, SR | 1 |
| Byeon, SJ; Chung, SJ; Oh, S | 1 |
| Osman, E; Yıldız, M | 1 |
| Arango, C; Leucht, S; Lopez-Morinigo, JD | 1 |
| Cao, D; Hong, Y; Huang, W; Wang, L; Wei, H; Xu, J; Zhang, J | 1 |
| Boesen, MS; Ladefoged, MR; Marloth, PV | 1 |
| Chen, Q; Deng, W; Du, X; Hao, Q; Hu, X; Li, C; Li, K; Li, L; Li, T; Li, X; Lu, T; Lv, L; Ma, X; Ren, H; Tan, L; Tan, Q; Tang, Y; Wang, C; Wang, L; Wang, Q; Wang, Y; Wu, Y; Yan, H; Yang, F; Yang, G; Yang, J; Yu, H; Yue, W; Zhang, D; Zhang, F; Zhang, G; Zhang, H; Zhang, Y; Zhao, L | 1 |
| Chen, Q; Coid, J; Deng, W; Guo, W; Li, K; Li, L; Li, T; Lu, T; Lv, L; Ma, X; Tan, L; Tan, Q; Tao, S; Wang, C; Wang, L; Wang, Q; Wei, W; Yan, H; Yang, F; Yang, G; Yang, J; Yue, W; Zhang, D; Zhang, F; Zhang, H; Zhang, Y; Zhao, L | 1 |
| Carvalho, AF; Hsu, CW; Hsu, TW; Liang, CS; Thompson, T; Tsai, TC; Tseng, PT; Yu, CL | 1 |
| Havas, L; Lőke, J; Maglóczky, Z; Papp, P; Szocsics, P | 1 |
| Anczewska, M; Balicki, M; Droździkowska, A; Gorczyca, P; Janus, J; Paciorek, S; Plisko, R; Zięba, M | 1 |
| Bateman, BT; Ely, EW; Inouye, SK; Jones, RN; Kim, DH; Lee, SB; Levin, R; Marcantonio, ER; Metzger, E; Pandharipande, PP; Park, CM; Pisani, MA | 1 |
| Baldessarini, RJ; Gardner, DM; McAdam, MK; Murphy, AL | 1 |
99 review(s) available for haloperidol and olanzapine
| Article | Year |
|---|---|
Selective optimization of side activities: another way for drug discovery.
Topics: Animals; Biological Availability; Combinatorial Chemistry Techniques; Databases, Factual; Drug Design; Humans; Patents as Topic; Pharmaceutical Preparations; Structure-Activity Relationship | 2004 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Efficacy of olanzapine: an overview of pivotal clinical trials.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Haloperidol; Humans; Male; Multicenter Studies as Topic; Olanzapine; Pirenzepine; Placebos; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 1997 |
Safety of olanzapine.
Topics: Acute Disease; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Blood Pressure; Clinical Trials as Topic; Cross-Over Studies; Dizziness; Double-Blind Method; Dystonia; Haloperidol; Heart Rate; Humans; Liver; Olanzapine; Parkinson Disease, Secondary; Pirenzepine; Placebos; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Sleep; Transaminases; Treatment Outcome; Weight Gain | 1997 |
Dosing the antipsychotic medication olanzapine.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Prolactin; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology | 1997 |
Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Cost-Benefit Analysis; Data Collection; Double-Blind Method; Drug Costs; Economics, Pharmaceutical; Haloperidol; Health Care Costs; Humans; Olanzapine; Patient Selection; Pirenzepine; Research Design; Schizophrenia; Treatment Outcome | 1997 |
The relationship of pharmacology to side effects.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloperidol; Humans; Olanzapine; Parkinson Disease, Secondary; Pirenzepine; Receptors, Neurotransmitter; Seizures; Sleep; Weight Gain | 1997 |
Emergency treatment of acute psychosis.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Decision Trees; Drug Administration Schedule; Emergency Services, Psychiatric; Emergency Treatment; Haloperidol; History, 20th Century; Humans; Lorazepam; Olanzapine; Pirenzepine; Psychotic Disorders; Risperidone | 1998 |
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Dibenzothiazepines; Double-Blind Method; Haloperidol; Humans; Imidazoles; Indoles; Olanzapine; Pirenzepine; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 1999 |
Cognitive deficit in schizophrenia and its neurochemical basis.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Glutamic Acid; Haloperidol; Humans; N-Methylaspartate; Olanzapine; Pirenzepine; Risperidone; Schizophrenia; Schizophrenic Psychology | 1999 |
D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET.
Topics: Amoxapine; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Dopamine Antagonists; Haloperidol; Humans; In Vitro Techniques; Loxapine; Olanzapine; Pirenzepine; Quetiapine Fumarate; Receptors, Dopamine; Receptors, Serotonin; Risperidone; Schizophrenia; Serotonin Antagonists; Tomography, Emission-Computed | 1999 |
[Clinical efficacy of olanzapine].
Topics: Antipsychotic Agents; Benzodiazepines; Binding Sites; Clinical Trials as Topic; Clozapine; Dopamine D2 Receptor Antagonists; Haloperidol; Humans; Olanzapine; Pirenzepine; Risperidone; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Serotonin | 1999 |
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Haloperidol; Humans; Incidence; Molindone; Olanzapine; Pirenzepine; Prospective Studies; Risk Factors; Risperidone; Schizophrenia; Substance Withdrawal Syndrome; Survival Analysis | 2000 |
The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Cross-Over Studies; Dose-Response Relationship, Drug; Haloperidol; Humans; Olanzapine; Pirenzepine; Prolactin; Risperidone; Schizophrenia | 2000 |
Rationale and guidelines for the inpatient treatment of acute psychosis.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Administration Schedule; Drug Therapy, Combination; Haloperidol; Hospitalization; Hostility; Humans; Olanzapine; Pirenzepine; Practice Guidelines as Topic; Psychomotor Agitation; Psychotic Disorders; Risperidone; Treatment Outcome | 2000 |
Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; Dopamine Antagonists; Drug Monitoring; Haloperidol; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Receptors, Dopamine D2; Receptors, Dopamine D4; Risperidone; Schizophrenia; Schizophrenic Psychology; Serotonin Antagonists; Sulpiride; Thiazoles; Treatment Outcome | 2001 |
[Atypical neuroleptics: new approaches to drug therapy of schizophrenic disorders].
Topics: Aged; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Controlled Clinical Trials as Topic; Dibenzothiazepines; Dibenzothiepins; Haloperidol; Humans; Imidazoles; Indoles; Multicenter Studies as Topic; Olanzapine; Piperazines; Pirenzepine; Placebos; Quetiapine Fumarate; Risperidone; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Sulpiride; Thiazoles | 2000 |
Olanzapine: an updated review of its use in the management of schizophrenia.
Topics: Adolescent; Aged; Animals; Antipsychotic Agents; Benzodiazepines; Child; Child, Preschool; Cognition Disorders; Cost-Benefit Analysis; Cytochrome P-450 Enzyme System; Depression; Drug Interactions; Haloperidol; Humans; Olanzapine; Pirenzepine; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Serotonin; Risperidone; Schizophrenia | 2001 |
Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.
Topics: Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Dopamine D2 Receptor Antagonists; Haloperidol; Humans; Olanzapine; Pirenzepine; Psychotic Disorders; Receptors, Dopamine D2; Receptors, Dopamine D4; Receptors, Serotonin; Risperidone; Schizophrenia; Terminology as Topic; Tomography, Emission-Computed | 2001 |
Weight change and atypical antipsychotic treatment in patients with schizophrenia.
Topics: Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Dose-Response Relationship, Drug; Follow-Up Studies; Haloperidol; Health Behavior; Humans; Obesity; Olanzapine; Pirenzepine; Risperidone; Schizophrenia; Weight Gain | 2001 |
Effects of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants.
Topics: Abnormalities, Drug-Induced; Acetates; Adult; Amines; Antimanic Agents; Benzodiazepines; Breast Feeding; Carbamazepine; Cyclohexanecarboxylic Acids; Female; Fetus; Gabapentin; gamma-Aminobutyric Acid; Haloperidol; Humans; Infant, Newborn; Lithium; Mood Disorders; Olanzapine; Pirenzepine; Placenta; Pregnancy; Risk Factors; Valproic Acid | 2001 |
Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Drug Therapy, Combination; Haloperidol; Humans; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Treatment Outcome | 2001 |
The role of novel antipsychotics in bipolar disorders.
Topics: Acute Disease; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Haloperidol; Humans; Lithium; Olanzapine; Pirenzepine; Randomized Controlled Trials as Topic; Risperidone | 2002 |
Recent developments in pharmacotherapy for the acutely psychotic patient.
Topics: Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Injections, Intramuscular; Olanzapine; Piperazines; Pirenzepine; Psychomotor Agitation; Psychotic Disorders; Thiazoles | 2002 |
Safety in treating bipolar disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Dyskinesias; Haloperidol; Humans; Hyperglycemia; Hyperprolactinemia; Olanzapine; Pirenzepine; Quetiapine Fumarate; Risperidone; Thioridazine; Weight Gain | 2003 |
Chlorpromazine equivalent doses for the newer atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Therapeutic Equivalency; Thiazoles | 2003 |
[Life threatening neuroleptic malignant syndrome due to olanzapine].
Topics: Antipsychotic Agents; Benzodiazepines; Critical Care; Electroconvulsive Therapy; Female; Haloperidol; Humans; Middle Aged; Neuroleptic Malignant Syndrome; Olanzapine; Pirenzepine; Psychotic Disorders; Recurrence | 2003 |
Antipsychotic drugs and QT interval prolongation.
Topics: Age Factors; Algorithms; Antipsychotic Agents; Benzodiazepines; Death, Sudden, Cardiac; Dopamine Antagonists; Drug Labeling; Haloperidol; Humans; Long QT Syndrome; Olanzapine; Pirenzepine; Sex Factors; Thioridazine; Torsades de Pointes | 2003 |
An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine.
Topics: Acute Disease; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cholinergic Antagonists; Clozapine; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Placebos; Randomized Controlled Trials as Topic; Retrospective Studies; Risperidone; Schizophrenia | 2003 |
New generation antipsychotics for first episode schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Olanzapine; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 2003 |
[Brain tumor].
Topics: Antipsychotic Agents; Benzodiazepines; Brain Neoplasms; Haloperidol; Humans; Hydrocephalus; Immunoglobulins, Intravenous; Intracranial Hypertension; Mental Disorders; Olanzapine; Pirenzepine; Seizures | 2003 |
[Porphyria].
Topics: 5-Aminolevulinate Synthetase; Analgesics, Opioid; Antipsychotic Agents; Arginine; Benzodiazepines; Ferrochelatase; Haloperidol; Heme; Humans; Hydroxymethylbilane Synthase; Olanzapine; Pirenzepine; Plasma Exchange; Porphyria, Acute Intermittent; Prognosis | 2003 |
[The appearance of metabolic syndrome in treatment with atypical antipsychotics].
Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Clinical Trials as Topic; Clozapine; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dibenzothiazepines; Female; Glucose; Haloperidol; Humans; Intellectual Disability; Male; Mental Disorders; Metabolic Syndrome; Middle Aged; Olanzapine; Quetiapine Fumarate; Retrospective Studies; Risk Factors; Risperidone; Schizophrenia; Sex Factors; Time Factors; Weight Gain | 2003 |
Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Benzodiazepines; Child; Dibenzothiazepines; Double-Blind Method; Dyskinesia, Drug-Induced; Haloperidol; Humans; Middle Aged; Neurologic Examination; Olanzapine; Piperazines; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risk; Sulpiride; Thiazoles | 2004 |
[Psychotropics and weight gain].
Topics: Adolescent; Adult; Amisulpride; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Child; Clozapine; Dibenzothiazepines; Double-Blind Method; Female; Fructose; Haloperidol; Humans; Imidazoles; Indoles; Male; Obesity; Olanzapine; Piperazines; Placebos; Psychotropic Drugs; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Socioeconomic Factors; Sulpiride; Thiazoles; Time Factors; Topiramate; Valproic Acid; Weight Gain | 2004 |
Schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Cognitive Behavioral Therapy; Dibenzothiepins; Haloperidol; Humans; Olanzapine; Patient Compliance; Perazine; Pimozide; Risperidone; Schizophrenia; Sulpiride | 2003 |
Dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Cognition; Dementia; Donepezil; Galantamine; Ginkgo biloba; Haloperidol; Humans; Indans; Memantine; Olanzapine; Phenylcarbamates; Physostigmine; Phytotherapy; Piperidines; Risperidone; Rivastigmine; Selegiline; Tacrine; Vitamin E | 2004 |
The treatment of mixed states and the risk of switching to depression.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Electroconvulsive Therapy; Haloperidol; Health Education; Humans; Lithium Carbonate; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Thiazoles | 2005 |
Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Injections, Intramuscular; Lorazepam; Olanzapine; Psychotic Disorders; Randomized Controlled Trials as Topic | 2005 |
Schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Haloperidol; Humans; Olanzapine; Patient Compliance; Perazine; Pimozide; Risperidone; Schizophrenia; Sulpiride | 2004 |
Estimating transitions between symptom severity states over time in schizophrenia: a Bayesian meta-analytic approach.
Topics: Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Computer Simulation; Decision Making; Haloperidol; Humans; Markov Chains; Models, Psychological; Monte Carlo Method; Olanzapine; Risperidone; Schizophrenia | 2006 |
Antipsychotic poisoning in young children: a systematic review.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Child, Preschool; Chlorpromazine; Clozapine; Dibenzothiazepines; Haloperidol; Humans; Infant; Infant, Newborn; Olanzapine; Pimozide; Piperazines; Poisoning; Quetiapine Fumarate; Quinolones; Risperidone | 2005 |
Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Bipolar Disorder; Brief Psychiatric Rating Scale; Cholinergic Antagonists; Databases, Bibliographic; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Humans; Incidence; Male; Olanzapine; Randomized Controlled Trials as Topic; Schizophrenia | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive Disorder; Dibenzothiazepines; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Haloperidol; Humans; Middle Aged; Obsessive-Compulsive Disorder; Olanzapine; Patient Dropouts; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Selective Serotonin Reuptake Inhibitors; Tic Disorders; Treatment Outcome | 2006 |
Haloperidol alone or in combination for acute mania.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Carbamazepine; Dibenzothiazepines; Drug Therapy, Combination; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Sulpiride; Valproic Acid | 2006 |
[Efficacy and adverse reactions of antipsychotics for neuropsychiatric symptoms in dementia: a systematic review].
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Dementia; Haloperidol; Humans; Olanzapine; Psychotic Disorders; Risperidone; Treatment Outcome | 2006 |
[The use of atypical antipsychotics in the long-term care of schizophrenia].
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Cognition Disorders; Drug Tolerance; Dyskinesia, Drug-Induced; Haloperidol; Humans; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia; Sulpiride; Time Factors | 2006 |
Delirium dilemma.
Topics: Antioxidants; Antipsychotic Agents; Benzodiazepines; Delirium; Haloperidol; Hospitalization; Humans; Incidence; Melatonin; Olanzapine; Risk Factors | 2007 |
Antipsychotics for delirium.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delirium; Female; Haloperidol; Humans; Male; Olanzapine; Randomized Controlled Trials as Topic; Risperidone | 2007 |
Antipsychotic medications for cocaine dependence.
Topics: Antipsychotic Agents; Benzodiazepines; Cocaine-Related Disorders; Haloperidol; Humans; Olanzapine; Randomized Controlled Trials as Topic; Risperidone | 2007 |
Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Disorders of Excessive Somnolence; Haloperidol; Humans; Olanzapine; Prolactin; Schizophrenia, Childhood; Treatment Outcome; Weight Gain | 2008 |
Atypical antipsychotics for the treatment of delirious elders.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Delirium; Geriatrics; Haloperidol; Humans; Olanzapine; Risk Factors; Risperidone | 2008 |
A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Double-Blind Method; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Research Design; Risperidone; Schizophrenia; Sleep Stages; Thiazoles; Treatment Outcome | 2008 |
Going up in smoke: tobacco smoking is associated with worse treatment outcomes in mania.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Comorbidity; Double-Blind Method; Female; Haloperidol; Humans; Least-Squares Analysis; Male; Meta-Analysis as Topic; Olanzapine; Placebos; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Severity of Illness Index; Smoking; Survival Analysis; Treatment Outcome; Valproic Acid | 2008 |
[Delusion in the critical patient].
Topics: Antipsychotic Agents; Benzodiazepines; Critical Illness; Delusions; Diagnostic and Statistical Manual of Mental Disorders; Haloperidol; Humans; Olanzapine; Propofol; Risk Factors; Risperidone; Severity of Illness Index; Surveys and Questionnaires | 2008 |
Treatment of delirium in supportive and palliative care.
Topics: Antipsychotic Agents; Benzodiazepines; Delirium; Dopamine Antagonists; Haloperidol; Humans; Olanzapine; Palliative Care; Prognosis; Risperidone; Serotonin Antagonists; Severity of Illness Index; Time Factors | 2008 |
[The use of antipsychotics in patients with dementia].
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cerebrovascular Disorders; Dementia; Dementia, Vascular; Dibenzothiazepines; Double-Blind Method; Evidence-Based Medicine; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Treatment Outcome | 2008 |
Treatment for amphetamine psychosis.
Topics: Amphetamine-Related Disorders; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Olanzapine; Psychoses, Substance-Induced | 2008 |
Interventions for psychotic symptoms concomitant with epilepsy.
Topics: Antipsychotic Agents; Benzodiazepines; Epilepsy; Haloperidol; Humans; Olanzapine; Psychotic Disorders | 2008 |
[Clinical and therapeutic aspects of agitation].
Topics: Acute Disease; Aggression; Antipsychotic Agents; Benzodiazepines; Controlled Clinical Trials as Topic; Haloperidol; Humans; Injections, Intramuscular; Irritable Mood; Olanzapine; Psychiatric Status Rating Scales; Psychomotor Agitation; Schizophrenia; Schizophrenic Language; Schizophrenic Psychology; Treatment Outcome; Verbal Behavior | 2007 |
Treatment for amphetamine psychosis.
Topics: Amphetamine-Related Disorders; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Olanzapine; Psychoses, Substance-Induced | 2009 |
Haloperidol plus promethazine for psychosis-induced aggression.
Topics: Aggression; Benzodiazepines; Drug Therapy, Combination; Haloperidol; Humans; Lorazepam; Midazolam; Olanzapine; Promethazine; Psychomotor Agitation; Psychotic Disorders; Randomized Controlled Trials as Topic | 2009 |
[Haloperidol plus promethazine for agitated patients--a systematic review].
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Haloperidol; Humans; Lorazepam; Midazolam; Olanzapine; Promethazine; Psychomotor Agitation; Randomized Controlled Trials as Topic | 2009 |
Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Haloperidol; Humans; Hypnotics and Sedatives; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2010 |
Relative indices of treatment effect may be constant across different definitions of response in schizophrenia trials.
Topics: Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Male; Olanzapine; Predictive Value of Tests; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Schizophrenia; Sensitivity and Specificity; Treatment Outcome | 2011 |
Management of marked liver enzyme increase during olanzapine treatment: a case report and review of the literature.
Topics: Age Factors; Antipsychotic Agents; Benzodiazepines; Chemical and Drug Induced Liver Injury; Clozapine; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Liver; Middle Aged; Olanzapine; Perazine; Risk Factors; Risperidone; Transaminases | 2011 |
[Rapid tranquillisation; review of the literature and recommendations].
Topics: Aggression; Benzodiazepines; Conscious Sedation; Drug Therapy, Combination; Haloperidol; Humans; Hypnotics and Sedatives; Lorazepam; Midazolam; Olanzapine; Practice Guidelines as Topic; Promethazine; Psychotic Disorders; Time Factors; Treatment Outcome | 2011 |
[Antipsychotics].
Topics: Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Drug Discovery; Drug Interactions; Haloperidol; History, 20th Century; History, 21st Century; Humans; Olanzapine | 2011 |
Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol.
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Depression; Depressive Disorder; Dibenzothiazepines; Double-Blind Method; Drug Industry; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Research Support as Topic; Risperidone; Thiazoles | 2013 |
[Pharmacological treatment of delirium in palliative care patients. A systematic literature review].
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Delirium; Evidence-Based Medicine; Haloperidol; Humans; Hypnotics and Sedatives; Lorazepam; Olanzapine; Palliative Care; Piperazines; Quinolones; Risk Factors | 2013 |
Benzodiazepines for psychosis-induced aggression or agitation.
Topics: Acute Disease; Aggression; Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Emergency Treatment; Haloperidol; Humans; Lorazepam; Olanzapine; Psychomotor Agitation; Psychotic Disorders; Randomized Controlled Trials as Topic | 2013 |
Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program.
Topics: Antipsychotic Agents; Benzodiazepines; Dibenzocycloheptenes; Haloperidol; Heterocyclic Compounds, 4 or More Rings; Humans; Olanzapine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Remission Induction; Risperidone; Schizophrenia; Sensitivity and Specificity; Treatment Outcome | 2014 |
Capgras delusion with violent behavior in Alzheimer dementia: case analysis with literature review.
Topics: Aged; Aggression; Alzheimer Disease; Amitriptyline; Anticonvulsants; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Capgras Syndrome; Chlordiazepoxide; Fructose; Haloperidol; Humans; Hypnotics and Sedatives; Male; Olanzapine; Potentially Inappropriate Medication List; Renal Insufficiency, Chronic; Topiramate; Violence | 2014 |
Management of delirium in palliative care: a review.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cholinesterase Inhibitors; Delirium; Disease Management; Haloperidol; Health Personnel; Humans; Olanzapine; Palliative Care; Quetiapine Fumarate; Risperidone | 2015 |
Intramuscular olanzapine for agitated patients: A systematic review and meta-analysis of randomized controlled trials.
Topics: Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Olanzapine; Psychomotor Agitation; Randomized Controlled Trials as Topic | 2015 |
Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.
Topics: Adult; Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Clozapine; Double-Blind Method; Drug Resistance; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Patient Acceptance of Health Care; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Single-Blind Method; Treatment Outcome | 2016 |
Antipsychotic medications for cocaine dependence.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cocaine-Related Disorders; Haloperidol; Humans; Lamotrigine; Olanzapine; Patient Dropouts; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Reserpine; Risperidone; Triazines | 2016 |
Haloperidol for long-term aggression in psychosis.
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Administration Schedule; Haloperidol; Humans; Middle Aged; Olanzapine; Psychotic Disorders; Randomized Controlled Trials as Topic; Schizophrenia | 2016 |
Droperidol for psychosis-induced aggression or agitation.
Topics: Acute Disease; Aggression; Antipsychotic Agents; Benzodiazepines; Droperidol; Haloperidol; Humans; Midazolam; Olanzapine; Psychomotor Agitation; Psychotic Disorders; Randomized Controlled Trials as Topic | 2016 |
Diabetic ketoacidosis associated with antipsychotic drugs: case reports and a review of literature.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Clozapine; Diabetic Ketoacidosis; Drug Therapy, Combination; Female; Haloperidol; Humans; Insulin; Male; Middle Aged; Olanzapine; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Young Adult | 2017 |
Delirium in hospitalized patients: Risks and benefits of antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Delirium; Haloperidol; Hospitalization; Humans; Olanzapine; Quetiapine Fumarate; Risperidone | 2017 |
Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation).
Topics: Aggression; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Injections, Intramuscular; Olanzapine; Psychomotor Agitation; Randomized Controlled Trials as Topic; Tranquilizing Agents | 2018 |
Evidence-Based Review of Pharmacotherapy for Acute Agitation. Part 1: Onset of Efficacy.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Drug Therapy; Evidence-Based Practice; Haloperidol; Humans; Injections, Intramuscular; Olanzapine; Psychomotor Agitation | 2018 |
Antipsychotics for treatment of delirium in hospitalised non-ICU patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delirium; Female; Haloperidol; Hospitalization; Humans; Male; Olanzapine; Placebo Effect; Randomized Controlled Trials as Topic; Risperidone | 2018 |
Impact of CYP1A2 genetic polymorphisms on pharmacokinetics of antipsychotic drugs: a systematic review and meta-analysis.
Topics: Adult; Alleles; Antipsychotic Agents; Clozapine; Cytochrome P-450 CYP1A2; Ethnicity; Female; Genotype; Haloperidol; Humans; Male; Middle Aged; Mutation; Olanzapine; Polymorphism, Genetic | 2019 |
Acute phenibut withdrawal: A comprehensive literature review and illustrative case report.
Topics: Akathisia, Drug-Induced; Baclofen; Cyproheptadine; Dexmedetomidine; Diphenhydramine; GABA-A Receptor Antagonists; GABA-B Receptor Agonists; gamma-Aminobutyric Acid; Haloperidol; Humans; Lorazepam; Male; Melatonin; Neuroleptic Malignant Syndrome; Olanzapine; Receptors, GABA; Substance Withdrawal Syndrome; Substance-Related Disorders; Young Adult | 2019 |
The pharmacological management of agitated and aggressive behaviour: A systematic review and meta-analysis.
Topics: Aggression; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Haloperidol; Humans; Hypnotics and Sedatives; Lorazepam; Midazolam; Olanzapine; Promethazine; Psychomotor Agitation; Psychotic Disorders; Treatment Outcome | 2019 |
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Topics: Acute Disease; Administration, Oral; Antipsychotic Agents; Aripiprazole; Clozapine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Haloperidol; Humans; Imidazoles; Indoles; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Thiophenes | 2020 |
The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An update on management of behavioral and psychological symptoms in dementia.
Topics: Academic Medical Centers; Aged; Algorithms; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Citalopram; Dementia; Electroconvulsive Therapy; Haloperidol; Humans; Olanzapine; Psychopharmacology; Risperidone | 2021 |
Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Methamphetamine; Network Meta-Analysis; Olanzapine; Patient Dropouts; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia | 2021 |
Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis.
Topics: Antipsychotic Agents; Aripiprazole; Clopenthixol; Delayed-Action Preparations; Flupenthixol; Fluphenazine; Haloperidol; Humans; Injections, Intramuscular; Network Meta-Analysis; Olanzapine; Paliperidone Palmitate; Patient Acceptance of Health Care; Phenothiazines; Psychotic Disorders; Risperidone; Schizophrenia; Secondary Prevention | 2021 |
Short-acting intramuscular second-generation antipsychotic drugs for acutely agitated patients with schizophrenia spectrum disorders. A systematic review and network meta-analysis.
Topics: Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Injections, Intramuscular; Network Meta-Analysis; Olanzapine; Psychomotor Agitation; Schizophrenia | 2021 |
Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review.
Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Depression; Drug Interactions; Female; Haloperidol; Humans; Ketamine; Lithium; Male; Olanzapine; Psychotropic Drugs; Risperidone; Schizophrenia; Treatment Outcome | 2021 |
Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Carbamazepine; Female; Haloperidol; Humans; Lithium; Male; Mania; Network Meta-Analysis; Olanzapine; Paliperidone Palmitate; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Tamoxifen; Valproic Acid | 2022 |
Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials.
Topics: Adult; Antipsychotic Agents; Haloperidol; Humans; Olanzapine; Randomized Controlled Trials as Topic; Weight Gain | 2022 |
Psychopharmacology of agitation in acute psychotic and manic episodes.
Topics: Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Haloperidol; Humans; Lorazepam; Mania; Olanzapine; Promethazine; Psychomotor Agitation; Psychopharmacology; Psychotic Disorders | 2022 |
Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Haloperidol; Humans; Lurasidone Hydrochloride; Molindone; Olanzapine; Paliperidone Palmitate; Quality of Life; Quetiapine Fumarate; Risperidone; Schizophrenia; Systematic Reviews as Topic | 2022 |
A cumulative Bayesian network meta-analysis on the comparative efficacy of pharmacotherapies for mania over the last 40 years.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Carbamazepine; Dibenzocycloheptenes; Haloperidol; Humans; Lithium; Mania; Network Meta-Analysis; Olanzapine; Paliperidone Palmitate; Pharmaceutical Preparations; Piperazines; Quetiapine Fumarate; Risperidone; Tamoxifen; Thiazoles; Valproic Acid | 2022 |
Comparison of antipsychotic dose equivalents for acute bipolar mania and schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Haloperidol; Humans; Mania; Olanzapine; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 2023 |
212 trial(s) available for haloperidol and olanzapine
| Article | Year |
|---|---|
Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Schizophrenia | 1996 |
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive Disorder; Double-Blind Method; Europe; Female; Haloperidol; Humans; Male; North America; Olanzapine; Patient Dropouts; Pirenzepine; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 1997 |
Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Haloperidol; Hospitalization; Humans; Male; Middle Aged; Models, Statistical; Neurotransmitter Agents; Olanzapine; Pirenzepine; Placebos; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 1997 |
Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Schizophrenia | 1997 |
Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Method; Drug Administration Schedule; Drug Tolerance; Female; Haloperidol; Humans; Incidence; Male; Olanzapine; Patient Compliance; Patient Dropouts; Pirenzepine; Schizophrenia; Treatment Outcome | 1997 |
Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Cost-Benefit Analysis; Data Collection; Double-Blind Method; Drug Costs; Economics, Pharmaceutical; Haloperidol; Health Care Costs; Humans; Olanzapine; Patient Selection; Pirenzepine; Research Design; Schizophrenia; Treatment Outcome | 1997 |
Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Incidence; Male; Olanzapine; Pirenzepine; Placebos; Psychotic Disorders; Schizophrenia; Severity of Illness Index; Treatment Outcome | 1997 |
The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Cross-Sectional Studies; Dopamine Antagonists; Double-Blind Method; Female; Haloperidol; Humans; Hyperprolactinemia; Longitudinal Studies; Male; Olanzapine; Pirenzepine; Schizophrenia; Sex Distribution; Time Factors | 1997 |
Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Quality of Life; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 1998 |
Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Comorbidity; Depressive Disorder; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Prospective Studies; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Treatment Outcome | 1998 |
The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology | 1998 |
A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.
Topics: Adult; Antipsychotic Agents; Anxiety; Benzodiazepines; Depression; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology | 1998 |
Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
Topics: Adult; Akathisia, Drug-Induced; Analysis of Variance; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatric Rating Scale; Chlorpromazine; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Headache; Humans; Male; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Sleep Stages; Treatment Outcome; Xerostomia | 1998 |
Olanzapine versus haloperidol treatment in first-episode psychosis.
Topics: Age of Onset; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatric Rating Scale; Double-Blind Method; Haloperidol; Humans; Olanzapine; Pirenzepine; Prospective Studies; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Time Factors; Treatment Outcome | 1999 |
In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzamides; Benzodiazepines; Clozapine; Contrast Media; Corpus Striatum; Female; Haloperidol; Humans; Iodine Radioisotopes; Male; Middle Aged; Olanzapine; Pirenzepine; Pyrrolidines; Receptors, Dopamine D2; Schizophrenia; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 1999 |
Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia.
Topics: Adult; Akathisia, Drug-Induced; Analysis of Variance; Antipsychotic Agents; Behavioral Symptoms; Benzodiazepines; Chi-Square Distribution; Double-Blind Method; Drug Resistance; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Prospective Studies; Schizophrenia; Treatment Outcome | 1999 |
Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy?
Topics: Antipsychotic Agents; Anxiety; Benzodiazepines; Brief Psychiatric Rating Scale; Depression; Double-Blind Method; Haloperidol; Humans; Olanzapine; Pirenzepine; Schizophrenia; Schizophrenic Psychology | 1999 |
Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Prospective Studies; Psychotic Disorders; Treatment Outcome | 1999 |
Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.
Topics: Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Dyskinesia, Drug-Induced; Haloperidol; Humans; Olanzapine; Pirenzepine; Risk Factors; Schizophrenia; Survival Analysis | 1999 |
Novel antipsychotics: comparison of weight gain liabilities.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Haloperidol; Humans; Imidazoles; Indoles; Male; Obesity; Olanzapine; Pirenzepine; Placebos; Retrospective Studies; Risperidone; Schizophrenia; Weight Gain | 1999 |
Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol.
Topics: Activities of Daily Living; Adult; Antipsychotic Agents; Benzodiazepines; Cost of Illness; Cost-Benefit Analysis; Discriminant Analysis; Factor Analysis, Statistical; Female; Haloperidol; Health Status Indicators; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Psychometrics; Reproducibility of Results; Schizophrenia; Surveys and Questionnaires; Treatment Outcome | 1999 |
A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cannabis; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Psychoses, Substance-Induced | 1999 |
Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Europe; Female; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Quality of Life; Schizophrenia | 1999 |
A comparison of the effects of olanzapine, haloperidol and placebo on cognitive and psychomotor functions in healthy elderly volunteers.
Topics: Aged; Aged, 80 and over; Aging; Antipsychotic Agents; Attention; Benzodiazepines; Cognition; Cross-Over Studies; Double-Blind Method; Female; Haloperidol; Humans; Male; Mental Recall; Middle Aged; Neuropsychological Tests; Olanzapine; Pirenzepine; Psychomotor Performance; Reaction Time | 1999 |
Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Double-Blind Method; Drug Costs; Female; Haloperidol; Health Care Costs; Health Status; Hospitalization; Humans; Male; Olanzapine; Personality Inventory; Pirenzepine; Psychiatric Status Rating Scales; Schizophrenia | 1999 |
Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Haloperidol; Humans; Olanzapine; Pirenzepine; Schizophrenia; Treatment Outcome; United States | 1999 |
The impact of schizophrenic patient functionality on service utilization and cost. Based on a presentation by Sandra L. Tunis, PhD.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Haloperidol; Hospital Costs; Humans; Olanzapine; Pirenzepine; Quality of Life; Schizophrenia; Treatment Outcome; United States | 1999 |
Elevated prolactin in pediatric patients on typical and atypical antipsychotics.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Child; Clozapine; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Prolactin; Sex Factors | 1999 |
Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Motor Skills; Neuropsychological Tests; Olanzapine; Pirenzepine; Psychomotor Performance; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2000 |
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Haloperidol; Humans; Incidence; Molindone; Olanzapine; Pirenzepine; Prospective Studies; Risk Factors; Risperidone; Schizophrenia; Substance Withdrawal Syndrome; Survival Analysis | 2000 |
Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample.
Topics: Activities of Daily Living; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Hospitalization; Humans; Male; Middle Aged; Occupations; Olanzapine; Pirenzepine; Schizophrenia; Social Behavior; Treatment Outcome | 2000 |
Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Prospective Studies; Psychiatric Status Rating Scales; Psychomotor Agitation; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2001 |
The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms.
Topics: Acute Disease; Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Hospitalization; Humans; Injections, Intramuscular; Male; Olanzapine; Pirenzepine; Psychomotor Agitation; Schizophrenia; Schizophrenic Psychology; Single-Blind Method; Treatment Outcome | 2001 |
Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Female; Haloperidol; Hospitalization; Humans; Male; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2001 |
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Cholesterol; Diastole; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Humans; Longitudinal Studies; Male; Olanzapine; Pirenzepine; Psychotic Disorders; Retrospective Studies; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Weight Gain | 2001 |
Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.
Topics: Acute Disease; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antipsychotic Agents; Arrhythmias, Cardiac; Benzodiazepines; Electrocardiography; Female; Haloperidol; Humans; Incidence; Long QT Syndrome; Male; Middle Aged; Olanzapine; Pirenzepine; Placebos; Risperidone; Schizophrenia | 2001 |
Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
Topics: Adult; Age Factors; Antipsychotic Agents; Appetite; Benzodiazepines; Body Mass Index; Body Weight; Brief Psychiatric Rating Scale; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Racial Groups; Retrospective Studies; Risk Factors; Risperidone; Schizophrenia; Sex Factors; Treatment Outcome; Weight Gain | 2001 |
Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Prolactin; Schizophrenia | 2001 |
Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Olanzapine; Pirenzepine; Placebos; Psychiatric Status Rating Scales; Psychomotor Agitation; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2001 |
Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Patient Compliance; Pirenzepine; Schizophrenia; Severity of Illness Index; Treatment Outcome | 2001 |
Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Latin America; Male; Middle Aged; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Schizophrenia; Treatment Outcome | 2001 |
Olanzapine versus haloperidol in children with autistic disorder: an open pilot study.
Topics: Antipsychotic Agents; Autistic Disorder; Benzodiazepines; Child; Child Development Disorders, Pervasive; Child, Preschool; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Olanzapine; Pilot Projects; Pirenzepine; Treatment Outcome | 2001 |
Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Benzamides; Benzodiazepines; Contrast Media; Corpus Striatum; Double-Blind Method; Female; Frontal Lobe; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Prospective Studies; Pyrrolidines; Receptors, Dopamine D2; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 2001 |
The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cognition; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Memory; Middle Aged; Neuropsychological Tests; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology | 2001 |
Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Double-Blind Method; Emotions; Female; Haloperidol; Hostility; Humans; Linear Models; Male; Olanzapine; Pirenzepine; Prospective Studies; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Statistics, Nonparametric; Survival Analysis | 2001 |
Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dopamine Antagonists; Dose-Response Relationship, Drug; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Pituitary Gland; Prolactin; Receptors, Dopamine D2; Risperidone; Schizophrenia; Sulpiride | 2001 |
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Patient Admission; Pirenzepine; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2002 |
Olanzapine versus haloperidol in schizoaffective disorder, bipolar type.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Psychotic Disorders; Severity of Illness Index; Treatment Outcome | 2001 |
Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Recurrence; Risperidone; Schizophrenia; Substance Withdrawal Syndrome; Survival Analysis; Time Factors; Treatment Outcome; Treatment Refusal | 2002 |
A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Middle Aged; Olanzapine; Pirenzepine; Placebos; Psychiatric Status Rating Scales; Psychomotor Agitation; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2002 |
Sex differences in clinical response to olanzapine compared with haloperidol.
Topics: Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Female; Follow-Up Studies; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Schizophrenia; Schizophrenic Psychology; Sex Factors; Treatment Outcome | 2002 |
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Double-Blind Method; Female; Haloperidol; Humans; Male; Neuropsychological Tests; Olanzapine; Pirenzepine; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2002 |
Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Eating; Energy Intake; Energy Metabolism; Haloperidol; Hospitalization; Humans; Male; Obesity; Olanzapine; Physical Exertion; Pilot Projects; Pirenzepine; Schizophrenia; Weight Gain | 2002 |
Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Quality of Life; Treatment Outcome; Work | 2002 |
Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Incidence; Japan; Male; Middle Aged; Olanzapine; Pirenzepine; Schizophrenia; Statistics, Nonparametric | 2002 |
Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Bone Density; Clopenthixol; Clozapine; Female; Fluphenazine; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Risperidone; Schizophrenia | 2002 |
Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Retrospective Studies; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2002 |
Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Prospective Studies; Psychiatric Status Rating Scales; Safety; Schizophrenia; Treatment Outcome | 2003 |
Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Diagnosis, Differential; Female; Haloperidol; Humans; Incidence; Male; Middle Aged; Odds Ratio; Olanzapine; Pirenzepine; Prevalence; Psychiatric Status Rating Scales; Retrospective Studies; Schizophrenia | 2003 |
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; Clozapine; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Hospitalization; Humans; Hypercholesterolemia; Hyperglycemia; Male; Middle Aged; Olanzapine; Pirenzepine; Prospective Studies; Psychotic Disorders; Risperidone; Schizophrenia; Weight Gain | 2003 |
Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Corpus Striatum; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Haloperidol; Humans; Iodobenzenes; Male; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2003 |
Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Depression; Dopamine Antagonists; Dyskinesia, Drug-Induced; Fatigue; Female; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Risperidone; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Treatment Outcome | 2003 |
Calming versus sedative effects of intramuscular olanzapine in agitated patients.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dementia; Double-Blind Method; Drug Administration Schedule; Haloperidol; Humans; Hypnotics and Sedatives; Injections, Intramuscular; Lorazepam; Olanzapine; Pirenzepine; Psychomotor Agitation; Retrospective Studies; Schizophrenia; Treatment Outcome | 2003 |
Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Double-Blind Method; Female; Haloperidol; Humans; Learning; Male; Middle Aged; Neuropsychological Tests; Olanzapine; Outpatients; Pirenzepine; Risperidone; Schizophrenia; Time Factors | 2003 |
Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dementia; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Haloperidol; Humans; Injections, Intramuscular; Long QT Syndrome; Olanzapine; Psychomotor Agitation; Schizophrenia | 2003 |
A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Olanzapine; Pirenzepine; Schizophrenia | 2003 |
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Severity of Illness Index; Treatment Outcome | 2003 |
Effect of antipsychotics on cortical inhibition using transcranial magnetic stimulation.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Electromyography; Female; Half-Life; Haloperidol; Humans; Male; Middle Aged; Olanzapine | 2003 |
Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Haloperidol; Humans; Middle Aged; Motor Activity; Muscle Rigidity; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales | 2003 |
A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Olanzapine; Pilot Projects; Pirenzepine; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Time Factors; Treatment Outcome | 2004 |
Olanzapine effects on auditory sensory gating in schizophrenia.
Topics: Acoustic Stimulation; Adolescent; Adult; Antipsychotic Agents; Auditory Perception; Benzodiazepines; Evoked Potentials, Auditory; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Reflex, Startle; Schizophrenia | 2003 |
Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Mexico; Neurologic Examination; Olanzapine; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2003 |
Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Dose-Response Relationship, Drug; Double-Blind Method; Haloperidol; Humans; Middle Aged; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Schizophrenia; Treatment Outcome | 2003 |
Schizophrenia and Parkinson's disease lead to equal motor-related changes in cortical and subcortical brain activation: an fMRI fingertapping study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Dopamine; Female; Fingers; Functional Laterality; Haloperidol; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Movement; Olanzapine; Parkinson Disease; Pirenzepine; Psychiatric Status Rating Scales; Psychomotor Performance; Putamen; Schizophrenia; Schizophrenic Psychology; Thalamus | 2003 |
Optimal treatment project for schizophrenia: results from a randomized, controlled, longitudinal study.
Topics: Adaptation, Psychological; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Case Management; Cognitive Behavioral Therapy; Community Mental Health Services; Female; Haloperidol; Humans; Longitudinal Studies; Male; Middle Aged; Olanzapine; Patient Care Team; Pirenzepine; Quality Assurance, Health Care; Schizophrenia | 2003 |
Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Benztropine; Double-Blind Method; Female; Haloperidol; Health Care Costs; Health Services; Humans; Male; Middle Aged; Muscarinic Antagonists; Neuropsychological Tests; Olanzapine; Pirenzepine; Quality of Life; Schizophrenia; Treatment Outcome; United States | 2003 |
A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Personality Inventory; Pirenzepine; Psychiatric Status Rating Scales; Treatment Outcome | 2003 |
Olanzapine vs haloperidol: treating delirium in a critical care setting.
Topics: Adult; Aged; Analysis of Variance; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Delirium; Haloperidol; Humans; Infusions, Parenteral; Intensive Care Units; Middle Aged; Olanzapine; Prospective Studies | 2004 |
A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition.
Topics: Adolescent; Adult; Antipsychotic Agents; Aryl Hydrocarbon Hydroxylases; Benzodiazepines; Biotransformation; Clozapine; Dibenzothiazepines; Electrocardiography; Female; Haloperidol; Heart Conduction System; Humans; Long QT Syndrome; Male; Middle Aged; Olanzapine; Quetiapine Fumarate; Risperidone; Thioridazine | 2004 |
Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment.
Topics: Acute Disease; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatric Rating Scale; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Olanzapine; Schizophrenia; Severity of Illness Index; Time Factors; Treatment Outcome | 2003 |
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Prolactin; Risperidone; Schizophrenia; Sexual Dysfunction, Physiological | 2004 |
Comparison between olanzapine and haloperidol on procedural learning and the relationship with striatal D2 receptor occupancy in schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzamides; Benzodiazepines; Case-Control Studies; Corpus Striatum; Female; Functional Laterality; Haloperidol; Humans; Learning; Male; Olanzapine; Psychiatric Status Rating Scales; Pyrrolidines; Radiopharmaceuticals; Receptors, Dopamine D2; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 2004 |
First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol.
Topics: Adolescent; Adult; Benzodiazepines; Comorbidity; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Substance-Related Disorders | 2004 |
Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Factor Analysis, Statistical; Female; Haloperidol; Humans; Male; Olanzapine; Prospective Studies; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2004 |
Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia.
Topics: Acute Disease; Administration, Oral; Adult; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Emergency Services, Psychiatric; Emergency Treatment; Female; Haloperidol; Humans; Lorazepam; Male; Olanzapine; Prospective Studies; Psychomotor Agitation; Schizophrenia; Severity of Illness Index; Treatment Outcome | 2004 |
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cognition Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Humans; Male; Neuropsychological Tests; Olanzapine; Principal Component Analysis; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2004 |
Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Haloperidol; Humans; Olanzapine; Psychiatric Status Rating Scales; Psychometrics; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology | 2004 |
Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Prognosis; Psychiatric Status Rating Scales; Psychotic Disorders; Remission Induction; Schizophrenia; Treatment Outcome | 2004 |
Long-term olanzapine treatment and p300 parameters in schizophrenia.
Topics: Adult; Antipsychotic Agents; Auditory Perception; Benzodiazepines; Electroencephalography; Event-Related Potentials, P300; Female; Haloperidol; Humans; Longitudinal Studies; Male; Olanzapine; Schizophrenia; Schizophrenic Psychology | 2004 |
[Alterations of gait parameters under external cueing in schizophrenic patients: a switch study].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Exercise Test; Female; Flupenthixol; Fluphenazine; Gait; Haloperidol; Humans; Male; Middle Aged; Muscle Rigidity; Olanzapine; Schizophrenia | 2004 |
Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Dyskinesia, Drug-Induced; Follow-Up Studies; Haloperidol; Hospitalization; Humans; Mental Disorders; Models, Econometric; Olanzapine; Outpatients; Patient Compliance; Piperazines; Psychiatric Status Rating Scales; Retrospective Studies; Risperidone; Sensitivity and Specificity; Spain; Survival Analysis; Thiazoles; Treatment Outcome; Weight Gain | 2004 |
Olanzapine treatment of residual positive and negative symptoms.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Weight; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Obesity; Olanzapine; Prospective Studies; Psychiatric Status Rating Scales; Retrospective Studies; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2005 |
Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Male; Obesity; Olanzapine; Outcome Assessment, Health Care; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Sex Factors; Treatment Outcome; Weight Gain | 2005 |
Antipsychotic drug effects on brain morphology in first-episode psychosis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain; Caudate Nucleus; Cognition Disorders; Female; Haloperidol; Humans; Magnetic Resonance Imaging; Male; Neuropsychological Tests; Olanzapine; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2005 |
Evidence for onset of antipsychotic effects within the first 24 hours of treatment.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Dopamine Antagonists; Double-Blind Method; Factor Analysis, Statistical; Haloperidol; Humans; Injections, Intramuscular; Middle Aged; Olanzapine; Placebos; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome | 2005 |
Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Behavior, Addictive; Benzodiazepines; Cocaine-Related Disorders; Comorbidity; Depressive Disorder; Female; Haloperidol; Hospitals, Veterans; Humans; Male; Middle Aged; Olanzapine; Philadelphia; Research Design; Schizophrenia; Schizophrenic Psychology; Substance Abuse Detection | 2005 |
Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Haloperidol; Humans; Nursing Assessment; Olanzapine; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2005 |
Safety and effectiveness of olanzapine in monotherapy: a multivariate analysis of a naturalistic study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Demography; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Olanzapine; Prospective Studies; Risk; Schizophrenia; Severity of Illness Index; Treatment Outcome | 2005 |
Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Haloperidol; Humans; Male; Olanzapine; Pain; Pain Measurement; Psychotic Disorders; Quality of Life; Time Factors | 2005 |
Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO).
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Cohort Studies; Dibenzothiazepines; Female; Haloperidol; Hostility; Humans; Male; Olanzapine; Outpatients; Prospective Studies; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2005 |
Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Cross-Cultural Comparison; Dibenzothiazepines; Drug Therapy, Combination; Female; Follow-Up Studies; Haloperidol; Humans; International Classification of Diseases; Male; Olanzapine; Patient Compliance; Prospective Studies; Psychiatric Status Rating Scales; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome | 2005 |
Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzamides; Benzodiazepines; Brain Chemistry; Corpus Striatum; Dopamine Antagonists; Female; Haloperidol; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Olanzapine; Positron-Emission Tomography; Pyrimidinones; Pyrrolidines; Radiopharmaceuticals; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D3; Schizophrenia; Serotonin Antagonists | 2005 |
Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Corpus Striatum; Dose-Response Relationship, Drug; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Positron-Emission Tomography; Psychotic Disorders; Raclopride; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2005 |
Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Haloperidol; Humans; Male; Neuropsychological Tests; Olanzapine; Principal Component Analysis; Psychotic Disorders; Statistics, Nonparametric | 2006 |
Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Quetiapine Fumarate; Risperidone; Schizophrenia; Time Factors; Treatment Outcome | 2005 |
Assessing cardiovascular risks of olanzapine treatment: a 6-month study versus haloperidol in schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cardiovascular Diseases; Female; Haloperidol; Humans; Male; Medical Records; Olanzapine; Risk Assessment; Schizophrenia | 2005 |
One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Attention; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Reaction Time; Risperidone; Schizophrenia; Treatment Outcome | 2006 |
Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial.
Topics: Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Haloperidol; Humans; Olanzapine; Psychomotor Agitation | 2006 |
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Cholesterol; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Patient Dropouts; Schizophrenia; Time Factors; Treatment Outcome; Weight Gain | 2005 |
The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report.
Topics: Adult; Antipsychotic Agents; Behavior, Addictive; Benzodiazepines; Cocaine-Related Disorders; Cues; Double-Blind Method; Haloperidol; Humans; Olanzapine; Pilot Projects; Psychiatric Status Rating Scales; Schizophrenia | 2006 |
The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects.
Topics: Adrenocorticotropic Hormone; Adult; Antipsychotic Agents; Benzodiazepines; Cross-Over Studies; Dibenzothiazepines; Double-Blind Method; Haloperidol; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Olanzapine; Pituitary-Adrenal System; Prolactin; Quetiapine Fumarate | 2006 |
Effects of antipsychotic and antidepressant drugs on action monitoring in healthy volunteers.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Brain Mapping; Contingent Negative Variation; Double-Blind Method; Electroencephalography; Female; Haloperidol; Humans; Linear Models; Male; Monitoring, Physiologic; Olanzapine; Paroxetine; Reaction Time | 2006 |
Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Haloperidol; Health Surveys; Humans; Male; Odds Ratio; Olanzapine; Outpatients; Prevalence; Prospective Studies; Quetiapine Fumarate; Risperidone; Schizophrenia; Sexual Dysfunction, Physiological; Time; Treatment Outcome | 2006 |
Open-label olanzapine treatment in bipolar I disorder: clinical and work functional outcomes.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Efficiency; Female; Haloperidol; Health Status; Humans; Male; Middle Aged; Olanzapine; Surveys and Questionnaires; Treatment Outcome; Work | 2006 |
Insight in first-episode psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Attitude to Health; Benzodiazepines; Brain; Cognition Disorders; Depressive Disorder, Major; Double-Blind Method; Female; Haloperidol; Humans; Male; Neuropsychological Tests; Olanzapine; Psychotic Disorders; Surveys and Questionnaires; Treatment Refusal | 2006 |
Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Treatment Outcome; Violence | 2006 |
Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Comorbidity; Female; Haloperidol; Humans; Longitudinal Studies; Male; Middle Aged; Olanzapine; Prognosis; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Schizotypal Personality Disorder; Socioeconomic Factors; Spain; Treatment Outcome | 2007 |
Olanzapine-induced obesity and diabetes in Indian patients: a prospective trial comparing olanzapine with typical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus; Female; Haloperidol; Humans; Hyperglycemia; India; Male; Obesity; Olanzapine; Prospective Studies; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Time Factors; Trifluoperazine | 2005 |
A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis.
Topics: Adult; Amphetamine-Related Disorders; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Psychoses, Substance-Induced; Treatment Outcome | 2005 |
Olanzapine and haloperidol in first episode psychosis: two-year data.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Follow-Up Studies; Haloperidol; Humans; International Cooperation; Male; Neuropsychological Tests; Olanzapine; Psychiatric Status Rating Scales; Psychotic Disorders; Treatment Outcome | 2006 |
Asian outpatients with schizophrenia: a double-blind randomized comparison of quality of life and clinical outcomes for patients treated with olanzapine or haloperidol.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Asian People; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Quality of Life; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2006 |
The role of sedation tests in identifying sedative drug effects in healthy volunteers and their power to dissociate sedative-related impairments from memory dysfunctions.
Topics: Adult; Affect; Antipsychotic Agents; Arousal; Benzodiazepines; Choice Behavior; Cross-Over Studies; Double-Blind Method; Female; Haloperidol; Histamine H1 Antagonists; Humans; Hypnotics and Sedatives; Lorazepam; Male; Memory; Memory Disorders; Mianserin; Mirtazapine; Olanzapine; Psychological Tests; Psychomotor Performance; Reaction Time; Reference Values; Saccades; Surveys and Questionnaires; Verbal Learning | 2007 |
A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Female; Haloperidol; Humans; Longitudinal Studies; Male; Middle Aged; Olanzapine; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Treatment Outcome | 2006 |
Effects of olanzapine, risperidone and haloperidol on sleep after a single oral morning dose in healthy volunteers.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Electroencephalography; Female; Haloperidol; Humans; Male; Olanzapine; Polysomnography; Reference Values; Risperidone; Sleep; Sleep, REM; Time Factors; Wakefulness | 2007 |
Psychomotor and memory effects of haloperidol, olanzapine, and paroxetine in healthy subjects after short-term administration.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Humans; Male; Memory; Olanzapine; Paroxetine; Psychomotor Performance; Reference Values | 2007 |
A pharmaco-EEG study on antipsychotic drugs in healthy volunteers.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Cross-Over Studies; Dibenzothiazepines; Electroencephalography; Fourier Analysis; Haloperidol; Humans; Indoles; Isoindoles; Male; Olanzapine; Quetiapine Fumarate; Reference Values; Risperidone; Single-Blind Method; Thiazoles; Time Factors | 2007 |
A double-blind comparison of the effect of the antipsychotics haloperidol and olanzapine on sleep in mania.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Brief Psychiatric Rating Scale; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Polysomnography; Sleep; Treatment Outcome | 2007 |
A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
Topics: Adult; Affect; Antipsychotic Agents; Attention; Benzodiazepines; Cognition; Cognition Disorders; Communication; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Motivation; Olanzapine; Schizophrenia; Social Behavior; Treatment Outcome | 2007 |
Outcomes for Latin American versus White patients suffering from acute mania in a randomized, double-blind trial comparing olanzapine and haloperidol.
Topics: Acute Disease; Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Cholesterol; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Fasting; Female; Haloperidol; Hispanic or Latino; Hospitalization; Humans; Male; Middle Aged; Olanzapine; Remission Induction; Time Factors; Treatment Outcome; Weight Gain; White People | 2007 |
Dissociating medication effects from learning and practice effects in a neurocognitive study of schizophrenia: Olanzapine versus haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Male; Mental Processes; Middle Aged; Neuropsychological Tests; Olanzapine; Schizophrenia | 2007 |
Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial.
Topics: Acoustic Stimulation; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Electromyography; Female; Habituation, Psychophysiologic; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Psychotic Disorders; Reflex, Startle; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2007 |
Association of symptomatology and cognitive deficits to functional capacity in schizophrenia.
Topics: Activities of Daily Living; Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Employment; Female; Follow-Up Studies; Haloperidol; Humans; Male; Middle Aged; Neuropsychological Tests; Olanzapine; Psychiatric Status Rating Scales; Psychotic Disorders; Quality of Life; Schizophrenia; Schizophrenic Psychology; Social Adjustment; Veterans | 2008 |
Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aggression; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatric Rating Scale; Dibenzothiazepines; Emergency Services, Psychiatric; Female; Haloperidol; Hostility; Humans; Italy; Male; Middle Aged; Olanzapine; Prospective Studies; Psychomotor Agitation; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2008 |
Rapid tranquillisation in psychiatric emergency settings in India: pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Combinations; Emergency Services, Psychiatric; Haloperidol; Humans; India; Injections, Intramuscular; Mental Disorders; Olanzapine; Promethazine; Psychomotor Agitation; Treatment Outcome; Violence | 2007 |
A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.
Topics: Adolescent; Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cohort Studies; Diabetes Mellitus, Type 2; Diagnostic and Statistical Manual of Mental Disorders; Dyslipidemias; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Prevalence; Prospective Studies; Psychotic Disorders; Risperidone; Severity of Illness Index; Weight Gain | 2007 |
Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study.
Topics: Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Haloperidol; Humans; India; Male; Obesity; Olanzapine; Prevalence; Prospective Studies; Risperidone; Schizophrenia; Time Factors | 2007 |
Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Chronic Disease; Cohort Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Haloperidol; Humans; Long-Term Care; Male; Middle Aged; Olanzapine; Risperidone; Spain; Treatment Outcome; Weight Gain | 2008 |
Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Prognosis; Prospective Studies; Risperidone; Schizophrenia; Weight Gain | 2008 |
Interleukin-12 plasma levels in drug-naïve patients with a first episode of psychosis: effects of antipsychotic drugs.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Demography; Diagnostic and Statistical Manual of Mental Disorders; Female; Haloperidol; Haplotypes; Humans; Interleukin-12; Male; Olanzapine; Psychotic Disorders; Risperidone; Time Factors | 2008 |
Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study--the Bergen District Nursing Home Study (BEDNURS).
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Dementia; Double-Blind Method; Female; Haloperidol; Humans; Long-Term Care; Male; Neuropsychological Tests; Norway; Nursing Homes; Olanzapine; Risperidone; Withholding Treatment | 2008 |
Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucose Intolerance; Haloperidol; Humans; Male; Olanzapine; Prospective Studies; Schizophrenia | 2008 |
Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Follow-Up Studies; Haloperidol; Humans; International Cooperation; Logistic Models; Olanzapine; Predictive Value of Tests; Psychiatric Status Rating Scales; ROC Curve; Schizophrenia; Sensitivity and Specificity; Treatment Outcome | 2008 |
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Haloperidol; Humans; Linear Models; Male; Olanzapine; Patient Compliance; Piperazines; Proportional Hazards Models; Quetiapine Fumarate; Schizophrenia; Sulpiride; Thiazoles; Treatment Outcome | 2008 |
Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment.
Topics: Adiponectin; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Composition; Body Mass Index; Dose-Response Relationship, Drug; Energy Metabolism; Female; Ghrelin; Haloperidol; Humans; Insulin; Leptin; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase; Olanzapine; Prospective Studies; Psychotic Disorders; Resistin; Risperidone; Schizophrenia; Weight Gain | 2008 |
Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients.
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Violence | 2008 |
Bayesian adaptive non-inferiority with safety assessment: retrospective case study to highlight potential benefits and limitations of the approach.
Topics: Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Dystonia; Haloperidol; Humans; Monte Carlo Method; Olanzapine; Psychiatric Status Rating Scales; Psychotic Disorders; Research Design; Retrospective Studies; Sample Size; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Treatment Outcome | 2009 |
Time-lapse mapping of cortical changes in schizophrenia with different treatments.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain; Brain Mapping; Disease Progression; Female; Haloperidol; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Male; Olanzapine; Schizophrenia; Young Adult | 2009 |
Effect of antipsychotic drugs on brain morphometry. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Brain; Double-Blind Method; Female; Follow-Up Studies; Haloperidol; Humans; Magnetic Resonance Imaging; Male; Mental Disorders; Olanzapine; Psychiatric Status Rating Scales; Risperidone; Young Adult | 2008 |
Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Follow-Up Studies; Haloperidol; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Olanzapine; Prospective Studies; Risk Factors; Risperidone; Schizophrenia; Spain; Triglycerides; Weight Gain; Young Adult | 2009 |
Lack of association between clinical and cognitive change in first-episode psychosis: the first 6 weeks of treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Female; Haloperidol; Humans; Male; Middle Aged; Neuropsychological Tests; Olanzapine; Psychiatric Status Rating Scales; Psychometrics; Psychotic Disorders; Risperidone; Schizophrenia; Statistics as Topic; Young Adult | 2008 |
Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol.
Topics: Adult; Aggression; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Clozapine; Double-Blind Method; Ethnicity; Female; Haloperidol; Humans; Inpatients; Lipid Metabolism; Male; Middle Aged; Olanzapine; Prospective Studies; Schizophrenia; Weight Gain; Young Adult | 2009 |
Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Cognition Disorders; Female; Follow-Up Studies; Haloperidol; Humans; Male; Neuropsychological Tests; Olanzapine; Perphenazine; Piperazines; Prospective Studies; Psychotic Disorders; Risperidone; Severity of Illness Index; Sulpiride; Thiazoles | 2009 |
Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Thiazoles | 2009 |
Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Female; Follow-Up Studies; Haloperidol; Humans; Male; Neuropsychological Tests; Olanzapine; Psychiatric Status Rating Scales; Psychometrics; Quality of Life; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2009 |
Modulation of limbic circuitry predicts treatment response to antipsychotic medication: a functional imaging study in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain; Cerebrovascular Circulation; Female; Haloperidol; Humans; Limbic System; Magnetic Resonance Imaging; Male; Olanzapine; Psychiatric Status Rating Scales; Radionuclide Imaging; Regional Blood Flow; Schizophrenia; Treatment Outcome | 2009 |
Effects of olanzapine and haloperidol on the metabolic status of healthy men.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Glucose; Glucose Clamp Technique; Haloperidol; Health; Health Status; Humans; Lipid Metabolism; Male; Metabolism; Olanzapine; Oxidation-Reduction; Young Adult | 2010 |
Olanzapine versus haloperidol in the management of borderline personality disorder: a randomized double-blind trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Borderline Personality Disorder; Double-Blind Method; Female; Haloperidol; Humans; Inpatients; Olanzapine; Psychiatric Status Rating Scales; Treatment Outcome | 2010 |
Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST).
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Medication Adherence; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quetiapine Fumarate; ROC Curve; Schizophrenia; Schizophrenic Psychology; Sulpiride; Surveys and Questionnaires; Thiazoles; Treatment Outcome | 2010 |
Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan.
Topics: Acute Disease; Administration, Oral; Adult; Benzodiazepines; Disease Management; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Middle Aged; Olanzapine; Pharmaceutical Solutions; Prospective Studies; Psychiatric Department, Hospital; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Risperidone; Solubility; Tablets; Taiwan; Treatment Outcome | 2010 |
The different trajectories of antipsychotic response: antipsychotics versus placebo.
Topics: Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Double-Blind Method; Haloperidol; Humans; Olanzapine; Placebos; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2011 |
Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Diagnostic and Statistical Manual of Mental Disorders; Female; Follow-Up Studies; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Secondary Prevention; Treatment Outcome; Young Adult | 2011 |
Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Method; Female; Follow-Up Studies; Haloperidol; Humans; International Cooperation; Male; Mental Disorders; Olanzapine; Predictive Value of Tests; Psychiatric Status Rating Scales; Time Factors; Treatment Outcome; Weight Gain; Young Adult | 2011 |
Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Olanzapine; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Severity of Illness Index; Treatment Failure | 2011 |
Blood lactate levels in patients receiving first- or second- generation antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dopamine Antagonists; Drug Monitoring; Haloperidol; Humans; Lactic Acid; Male; Middle Aged; Movement Disorders; Olanzapine; Parkinson Disease, Secondary; Psychiatric Status Rating Scales; Psychotic Disorders; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2011 |
Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone.
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Emergency Services, Psychiatric; Female; Haloperidol; Humans; Hypnotics and Sedatives; Injections, Intramuscular; Male; Midazolam; Olanzapine; Piperazines; Promethazine; Psychomotor Agitation; Psychotic Disorders; Thiazoles; Tranquilizing Agents | 2011 |
Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Cholesterol; Clozapine; Cognition Disorders; Double-Blind Method; Female; Follow-Up Studies; Haloperidol; Humans; Male; Middle Aged; Neuropsychological Tests; Olanzapine; Prospective Studies; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Triglycerides; Young Adult | 2011 |
The GiSAS study: rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatment of schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Italy; Logistic Models; Olanzapine; Patient Selection; Piperazines; Proportional Hazards Models; Quinolones; Research Design; Schizophrenia; Time Factors | 2011 |
Body mass index increase, serum leptin, adiponectin, neuropeptide Y and lipid levels during treatment with olanzapine and haloperidol.
Topics: Adiponectin; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Biomarkers; Body Mass Index; Haloperidol; Humans; Leptin; Lipids; Male; Middle Aged; Neuropeptide Y; Olanzapine; Psychiatric Status Rating Scales; Schizophrenia | 2011 |
Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis.
Topics: Adult; Benzodiazepines; Cohort Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Haloperidol; Humans; Longitudinal Studies; Male; Olanzapine; Prospective Studies; Psychotic Disorders; Risperidone; Time Factors; Treatment Outcome; Young Adult | 2012 |
Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).
Topics: Adult; Aggression; Amisulpride; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Haloperidol; Hostility; Humans; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Schizophrenic Psychology; Sulpiride; Thiazoles; Treatment Outcome | 2011 |
Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Delirium; Drug Administration Schedule; Female; Follow-Up Studies; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Risperidone; Single-Blind Method; Treatment Outcome | 2011 |
Risperidone and olanzapine versus another first generation antipsychotic in patients with schizophrenia inadequately responsive to first generation antipsychotics.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Drug Resistance; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Single-Blind Method; Trifluoperazine | 2012 |
Efficacy and safety of olanzapine in the treatment of Japanese patients with bipolar I disorder in a current manic or mixed episode: a randomized, double-blind, placebo- and haloperidol-controlled study.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Female; Haloperidol; Humans; Japan; Male; Middle Aged; Olanzapine; Young Adult | 2012 |
Executive function predicts response to antiaggression treatment in schizophrenia: a randomized controlled trial.
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Executive Function; Female; Haloperidol; Humans; Male; Olanzapine; Predictive Value of Tests; Psychological Tests; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology | 2012 |
Social cognition and visual perception in schizophrenia inpatients treated with first-and second-generation antipsychotic drugs.
Topics: Adolescent; Adult; Affect; Antipsychotic Agents; Awareness; Benzodiazepines; Case-Control Studies; Clozapine; Cues; Discrimination, Psychological; Emotions; Facial Expression; Female; Haloperidol; Hospitalization; Humans; Linear Models; Male; Middle Aged; Olanzapine; Perphenazine; Psychotic Disorders; Retina; Schizophrenia; Schizophrenic Psychology; Social Behavior; Social Perception; Speech Perception; Theory of Mind; Visual Perception; Young Adult | 2012 |
Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Injections; Male; Middle Aged; Olanzapine; Schizophrenia; Treatment Outcome; Weight Gain | 2012 |
Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Neuropsychological Tests; Olanzapine; Piperazines; Psychomotor Disorders; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Schizophrenic Psychology; Sulpiride; Thiazoles; Treatment Outcome; Young Adult | 2013 |
A reorientation strategy for reducing delirium in the critically ill. Results of an interventional study.
Topics: Acoustic Stimulation; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Critical Care; Critical Illness; Delirium; Female; Haloperidol; Humans; Hypnotics and Sedatives; Internal Medicine; Male; Medical Audit; Midazolam; Middle Aged; Narcotics; Olanzapine; Orientation; Photic Stimulation; Postoperative Complications; Propofol; Proportional Hazards Models; Risk Factors; Surveys and Questionnaires; Wounds and Injuries | 2012 |
Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; Dibenzothiazepines; Disorders of Excessive Somnolence; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Isoindoles; Likelihood Functions; Lurasidone Hydrochloride; Male; Medication Adherence; Nausea; Numbers Needed To Treat; Olanzapine; Psychiatric Status Rating Scales; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Research Design; Schizophrenia; Thiazoles; Treatment Outcome; Triglycerides; Weight Gain | 2012 |
Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Cognition Disorders; Double-Blind Method; Female; Follow-Up Studies; Haloperidol; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Olanzapine; Psychiatric Status Rating Scales; Retrospective Studies; Risperidone; Schizophrenia; Young Adult | 2012 |
Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Biomarkers; Female; Follow-Up Studies; Haloperidol; Humans; Male; Olanzapine; Prolactin; Prospective Studies; Psychotic Disorders; Risperidone; Time Factors; Treatment Outcome; Young Adult | 2012 |
Localized differences in caudate and hippocampal shape are associated with schizophrenia but not antipsychotic type.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Caudate Nucleus; Double-Blind Method; Female; Haloperidol; Hippocampus; Humans; Image Processing, Computer-Assisted; Longitudinal Studies; Magnetic Resonance Imaging; Male; Olanzapine; Organ Size; Schizophrenia | 2013 |
Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Educational Status; Female; Haloperidol; Humans; Logistic Models; Longitudinal Studies; Male; Olanzapine; Prognosis; Psychotic Disorders; Remission Induction; Risk Factors; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Time-to-Treatment; Young Adult | 2013 |
Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Female; Follow-Up Studies; Haloperidol; Humans; Longitudinal Studies; Male; Olanzapine; Prospective Studies; Psychotic Disorders; Risperidone; Schizophrenia; Time Factors; Treatment Outcome; Young Adult | 2013 |
Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Female; Haloperidol; Humans; Male; Marijuana Smoking; Middle Aged; Models, Psychological; Olanzapine; Prognosis; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Sex Factors; Time Factors; Treatment Outcome; Young Adult | 2014 |
Depression and impulsivity as pathways to violence: implications for antiaggressive treatment.
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Depression; Double-Blind Method; Female; Haloperidol; Humans; Impulsive Behavior; Male; Middle Aged; Olanzapine; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Violence; Young Adult | 2014 |
Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Male; Metabolic Diseases; Middle Aged; Olanzapine; Prospective Studies; Psychotic Disorders; Risk Factors; Risperidone; Time Factors; Weight Gain; Young Adult | 2014 |
Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.
Topics: Adult; Aggression; Amisulpride; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Hostility; Humans; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride; Thiazoles | 2014 |
Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Prospective Studies; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Sex Factors; Switzerland; Time Factors; Treatment Outcome; Young Adult | 2014 |
A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia.
Topics: Acute Disease; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Methotrimeprazine; Middle Aged; Olanzapine; Psychiatric Status Rating Scales; Psychomotor Agitation; Schizophrenia; Treatment Outcome | 2014 |
A double-blind, randomized comparison study of efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia and acute agitated behavior.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Middle Aged; Olanzapine; Psychiatric Status Rating Scales; Psychomotor Agitation; Schizophrenia; Taiwan; Treatment Outcome | 2014 |
Incidence of tardive dyskinesia in older adult patients treated with olanzapine or conventional antipsychotics.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Female; Haloperidol; Humans; Incidence; Kaplan-Meier Estimate; Male; Movement Disorders; Olanzapine; Prospective Studies; Psychotic Disorders; Treatment Outcome; United States | 2015 |
Management of depressive symptoms in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dibenzocycloheptenes; Double-Blind Method; Female; Haloperidol; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Olanzapine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Young Adult | 2015 |
Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; Haloperidol; Humans; Injections, Intramuscular; Lorazepam; Male; Middle Aged; Olanzapine; Prospective Studies; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Schizophrenia; Taiwan; Treatment Outcome | 2015 |
Urine testing for antipsychotics: a pilot trial for a method to determine detection levels.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Biological Assay; Chromatography, Liquid; Haloperidol; Humans; Male; Mass Spectrometry; Medication Adherence; Middle Aged; Olanzapine; Pilot Projects; Quetiapine Fumarate; Risperidone | 2015 |
Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Follow-Up Studies; Haloperidol; Humans; Male; Metabolic Syndrome; Middle Aged; Olanzapine; Schizophrenia; Treatment Outcome | 2016 |
Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Delayed-Action Preparations; Female; Haloperidol; Humans; Hyperprolactinemia; Injections, Intramuscular; Male; Middle Aged; Olanzapine; Paliperidone Palmitate; Perphenazine; Proportional Hazards Models; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Failure; Treatment Outcome | 2016 |
Have antipsychotics a different speed of action in the acute treatment of mania? A single-blind comparative study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dibenzocycloheptenes; Female; Haloperidol; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Olanzapine; Single-Blind Method; Time Factors; Treatment Outcome | 2017 |
Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Haloperidol; Humans; Incidence; Male; Olanzapine; Piperazines; Prospective Studies; Psychotic Disorders; Quetiapine Fumarate; Risk Factors; Risperidone; Schizophrenia; Thiazoles; Young Adult | 2017 |
Does early antipsychotic response predict long-term treatment outcome?
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Follow-Up Studies; Haloperidol; Hospitalization; Humans; Male; Mental Disorders; Olanzapine; Prognosis; Psychiatric Status Rating Scales; Regression Analysis; Severity of Illness Index; Time Factors; Treatment Outcome | 2017 |
An investigation of regional cerebral blood flow and tissue structure changes after acute administration of antipsychotics in healthy male volunteers.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain; Brain Mapping; Cerebrovascular Circulation; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Haloperidol; Humans; Magnetic Resonance Imaging; Male; Olanzapine; Risperidone; Young Adult | 2018 |
Potential diagnostic markers of olanzapine efficiency for acute psychosis: a focus on peripheral biogenic amines.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Biomarkers; Dopamine; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Olanzapine; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D4; Treatment Outcome; Young Adult | 2017 |
Olanzapine and haloperidol for the treatment of acute symptoms of mental disorders induced by amphetamine-type stimulants: A randomized controlled trial.
Topics: Adult; Amphetamine; Amphetamine-Related Disorders; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Central Nervous System Stimulants; Female; Haloperidol; Humans; Male; Mental Disorders; Olanzapine; Research Design; Treatment Outcome | 2018 |
Increased cerebral blood flow after single dose of antipsychotics in healthy volunteers depends on dopamine D2 receptor density profiles.
Topics: Adult; Antipsychotic Agents; Benzamides; Brain; Cerebrovascular Circulation; Cross-Over Studies; Dopamine D2 Receptor Antagonists; Double-Blind Method; Fluorine Radioisotopes; Haloperidol; Healthy Volunteers; Humans; Olanzapine; Positron-Emission Tomography; Receptors, Dopamine D2; Risperidone; RNA, Messenger; Spin Labels | 2019 |
Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Haloperidol; Humans; Male; Middle Aged; Nausea; Neoplasms; Olanzapine; Ondansetron; Random Allocation; Treatment Outcome; Vomiting; Young Adult | 2019 |
Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Follow-Up Studies; Haloperidol; Humans; Male; Olanzapine; Outcome Assessment, Health Care; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Young Adult | 2020 |
Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delirium; Haloperidol; Humans; Neoplasms; Olanzapine; Risperidone | 2020 |
The Importance of Conduct Disorder in the Treatment of Violence in Schizophrenia: Efficacy of Clozapine Compared With Olanzapine and Haloperidol.
Topics: Adult; Antipsychotic Agents; Clozapine; Conduct Disorder; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Psychiatric Status Rating Scales; Schizophrenia; Violence | 2021 |
Cost-Effectiveness of Midazolam Versus Haloperidol Versus Olanzapine for the Management of Acute Agitation in the Accident and Emergency Department.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Emergency Service, Hospital; Haloperidol; Humans; Injections, Intramuscular; Midazolam; Olanzapine; Psychomotor Agitation | 2022 |
An open-label clinical trial of oral transmucosal haloperidol and oral transmucosal olanzapine in the treatment of terminal delirium at home.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Olanzapine; Psychomotor Agitation | 2022 |
Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Olanzapine; Quetiapine Fumarate; Risperidone; Schizophrenia; Treatment Outcome | 2023 |
The Role of Total White Blood Cell Count in Antipsychotic Treatment for Patients with Schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Glucose; Haloperidol; Humans; Inflammation; Olanzapine; Perphenazine; Quetiapine Fumarate; Risperidone; Schizophrenia | 2024 |
513 other study(ies) available for haloperidol and olanzapine
| Article | Year |
|---|---|
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.
Topics: Animals; Antipsychotic Agents; Cell Line; Molecular Structure; Rats; Receptors, Serotonin | 1994 |
Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate.
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Binding, Competitive; Cell Line; CHO Cells; Cricetinae; Humans; Male; Molecular Structure; Motor Activity; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Dopamine D4; Receptors, Serotonin; Spiperone; Spiro Compounds; Stereotyped Behavior; Structure-Activity Relationship; Thiazoles; Thiazolidines | 1996 |
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
Topics: Animals; Antipsychotic Agents; Brain; Cells, Cultured; Clozapine; Haloperidol; Humans; Male; Rats; Rats, Wistar; Receptors, Dopamine; Receptors, Serotonin; Risperidone | 1996 |
Iloperidone binding to human and rat dopamine and 5-HT receptors.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; CHO Cells; Cricetinae; Humans; Isoxazoles; Kinetics; Piperidines; Rats; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, Dopamine D4; Receptors, Dopamine D5; Receptors, Serotonin | 1996 |
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
Topics: Animals; Antipsychotic Agents; CHO Cells; Cricetinae; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin Agents; Sulfur Radioisotopes | 1998 |
N-Substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as D(2) antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents.
Topics: Animals; Antipsychotic Agents; Brain; Catalepsy; Dioxanes; Dopamine Antagonists; Drug Evaluation, Preclinical; Humans; In Vitro Techniques; Male; Mice; Motor Activity; Piperidines; Rats; Receptors, Adrenergic, alpha-1; Receptors, Dopamine D2; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Recombinant Proteins; Serotonin Receptor Agonists; Stereoisomerism; Stereotyped Behavior; Structure-Activity Relationship; Swine | 1999 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Catalepsy; Crystallography, X-Ray; Dopamine; Dopamine Antagonists; Homovanillic Acid; In Vitro Techniques; Male; Mice; Microdialysis; Models, Molecular; Molecular Conformation; Molecular Structure; Prolactin; Pyrroles; Radioligand Assay; Rats; Rats, Inbred F344; Rats, Wistar; Receptors, Dopamine D2; Stereoisomerism; Structure-Activity Relationship; Thiazepines | 2002 |
In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.
Topics: Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzodiazepines; Binding, Competitive; Clozapine; Dibenzothiazepines; Dose-Response Relationship, Drug; Humans; Kinetics; Olanzapine; Pirenzepine; Quetiapine Fumarate; Recombinant Proteins; Risperidone | 2002 |
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Discriminant Analysis; Drug Evaluation, Preclinical; Forecasting; Humans; Protein Binding; Receptors, Histamine H1; Statistics, Nonparametric; Weight Gain | 2003 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Benzothiepins; Catalepsy; Cognition Disorders; Dopamine Antagonists; Humans; Male; Mice; Models, Molecular; Motor Activity; Pituitary Gland, Anterior; Prolactin; Pyrroles; Rats; Rats, Inbred F344; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, Serotonin, 5-HT2; Serotonin Antagonists; Structure-Activity Relationship; Thiazepines | 2004 |
Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Benzazepines; Binding Sites; Catalepsy; Catalysis; Cell Line; Crystallography, X-Ray; Dopamine D2 Receptor Antagonists; Drug Design; In Vitro Techniques; Mice; Models, Molecular; Molecular Conformation; Palladium; Pyrroles; Radioligand Assay; Rats; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Serotonin 5-HT2 Receptor Antagonists; Structure-Activity Relationship | 2005 |
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Furans; Heterocyclic Compounds, 4 or More Rings; Humans; In Vitro Techniques; Mice; Psychotropic Drugs; Radioligand Assay; Rats; Stereoisomerism; Structure-Activity Relationship | 2005 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.
Topics: Adenylate Kinase; Animals; Antipsychotic Agents; Enzyme Activation; Hypothalamus; Immunohistochemistry; Mice; Phosphorylation; Receptors, Histamine H1; Weight Gain | 2007 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolactinemia; Indoles; Metabolic Diseases; Phthalimides; Piperazines; Principal Component Analysis; Pyridines; Radioligand Assay; Receptors, Biogenic Amine; Weight Gain | 2007 |
Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.
Topics: Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Cloning, Molecular; Clozapine; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Histamine Release; Humans; Inhibitory Concentration 50; Molecular Structure; Olanzapine; Psychotropic Drugs; Radioligand Assay; Receptors, Adrenergic; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Muscarinic; Receptors, Serotonin; Schizophrenia; Substrate Specificity | 2009 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.
Topics: Animals; Antipsychotic Agents; Apomorphine; Azepines; Butyrophenones; Clozapine; Haloperidol; Lethal Dose 50; Male; Mice; Molecular Structure; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Structure-Activity Relationship | 2008 |
Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Binding Sites; Drug Design; Drug Evaluation, Preclinical; Humans; Ligands; Mice; Models, Molecular; Molecular Structure; Protein Binding; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D3; Structure-Activity Relationship | 2009 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
Topics: Binding Sites; Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Ligands; Models, Molecular; Potassium Channel Blockers; Protein Binding; Protein Conformation | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Binding, Competitive; Cell Line; Corpus Striatum; Dopamine; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Discovery; Drug Evaluation, Preclinical; Humans; Ligands; Male; Models, Chemical; Molecular Structure; Motor Activity; Piperazines; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2 | 2010 |
Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors.
Topics: Animals; Antipsychotic Agents; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Ligands; Mice; Models, Molecular; Piperazines; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D3; Structure-Activity Relationship | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.
Topics: Administration, Oral; Animals; Cyclic GMP; Dose-Response Relationship, Drug; Drug Discovery; Humans; Molecular Structure; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pyridines; Pyrimidines; Rats; Schizophrenia; Structure-Activity Relationship | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.
Topics: Adrenergic Uptake Inhibitors; Animals; Behavior, Animal; Biological Availability; Drug Discovery; Electroshock; Indicators and Reagents; Male; Mental Disorders; Nervous System Diseases; Quinoxalines; Quipazine; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Recombinant Proteins; Schizophrenia; Serotonin Antagonists; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship | 2014 |
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Avoidance Learning; Benzoxazoles; Catalepsy; CHO Cells; Cricetulus; Dementia; Dopamine D2 Receptor Antagonists; HEK293 Cells; Humans; Male; Models, Molecular; Motor Activity; Radioligand Assay; Rats, Wistar; Receptors, Serotonin; Serotonin Antagonists; Structure-Activity Relationship; Sulfonamides | 2014 |
Further evaluation of the tropane analogs of haloperidol.
Topics: Animals; Antipsychotic Agents; Apomorphine; Catalepsy; Dose-Response Relationship, Drug; Haloperidol; Mice; Molecular Structure; Motor Activity; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Structure-Activity Relationship; Tropanes | 2014 |
Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies.
Topics: Amides; Animals; Antipsychotic Agents; Behavior, Animal; Dizocilpine Maleate; Dopamine Antagonists; Drug Evaluation, Preclinical; Female; Kinetics; Ligands; Male; Mice; Prefrontal Cortex; Protein Binding; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D3; Schizophrenia; Serotonin Receptor Agonists; Structure-Activity Relationship | 2014 |
Structure-activity relationships and molecular studies of novel arylpiperazinylalkyl purine-2,4-diones and purine-2,4,8-triones with antidepressant and anxiolytic-like activity.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Binding Sites; Disease Models, Animal; Models, Molecular; Molecular Structure; Piperazine; Piperazines; Purines; Pyrimidinones; Structure-Activity Relationship | 2015 |
Synthesis of novel pyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT
Topics: Animals; Chemistry Techniques, Synthetic; Drug Design; Ligands; Mice; Pyrimidines; Receptor, Serotonin, 5-HT1A; Selective Serotonin Reuptake Inhibitors; Structure-Activity Relationship; Tryptamines | 2019 |
Synthesis of new 5,6,7,8-tetrahydropyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT
Topics: Animals; Cells, Cultured; Crystallography, X-Ray; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Ligands; Male; Mice; Models, Molecular; Molecular Structure; Pyrimidines; Rats; Receptor, Serotonin, 5-HT1A; RNA-Binding Proteins; Structure-Activity Relationship; Tryptamines | 2019 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Drug Repositioning; HEK293 Cells; Host-Pathogen Interactions; Humans; Immunity, Innate; Mass Spectrometry; Molecular Targeted Therapy; Pandemics; Pneumonia, Viral; Protein Binding; Protein Biosynthesis; Protein Domains; Protein Interaction Mapping; Protein Interaction Maps; Receptors, sigma; SARS-CoV-2; SKP Cullin F-Box Protein Ligases; Vero Cells; Viral Proteins | 2020 |
Olanzapine, an atypical antipsychotic, increases rates of punished responding in pigeons.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Chlordiazepoxide; Clozapine; Columbidae; Conditioning, Operant; Dose-Response Relationship, Drug; Haloperidol; Isoxazoles; Male; Olanzapine; Piperidines; Pirenzepine; Punishment; Risperidone | 1995 |
Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.
Topics: Adult; Antipsychotic Agents; Benzamides; Benzodiazepines; Corpus Striatum; Haloperidol; Humans; Middle Aged; Olanzapine; Pirenzepine; Pyrrolidines; Receptors, Dopamine D2; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 1996 |
Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice.
Topics: Animals; Benzodiazepines; Clozapine; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Haloperidol; Male; Mice; Motor Activity; Olanzapine; Phencyclidine; Pirenzepine; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Receptors, Serotonin, 5-HT3; Serotonin Antagonists | 1997 |
BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; CHO Cells; Clozapine; Corpus Striatum; COS Cells; Cricetinae; Dibenzothiazepines; Dopamine; Female; Guinea Pigs; Haloperidol; Indoles; Kidney; Male; Microdialysis; Neuroblastoma; Nucleus Accumbens; Olanzapine; Piperazines; Pirenzepine; Prefrontal Cortex; Pyridines; Quetiapine Fumarate; Radioligand Assay; Rats; Rats, Sprague-Dawley; Risperidone; Tritium; Tumor Cells, Cultured | 1997 |
Olanzapine on trial.
Topics: Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Haloperidol; Humans; Olanzapine; Pirenzepine; Research Design; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 1998 |
Clinical predictors of acute response with olanzapine in psychotic mood disorders.
Topics: Adolescent; Adult; Affective Disorders, Psychotic; Age Factors; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Controlled Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Retrospective Studies; Sex Factors; Treatment Outcome | 1998 |
Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Dopamine; Haloperidol; Male; Microdialysis; Neostriatum; Norepinephrine; Nucleus Accumbens; Olanzapine; Pirenzepine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley | 1998 |
Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Fluorobenzenes; Haloperidol; Male; Nucleus Accumbens; Olanzapine; Piperidines; Pirenzepine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Serotonin; Serotonin Antagonists; Time Factors | 1998 |
Conventional psychotropic-induced tremor extinguished by olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Fluphenazine; Haloperidol; Humans; Male; Mental Disorders; Olanzapine; Pirenzepine; Tremor | 1998 |
Olanzapine for primary negative symptoms.
Topics: Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Controlled Clinical Trials as Topic; Double-Blind Method; Haloperidol; Humans; Olanzapine; Pirenzepine; Research Design; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 1998 |
Olanzapine for the treatment of tardive dyskinesia.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Biperiden; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Olanzapine; Pirenzepine; Schizophrenia; Substance Withdrawal Syndrome | 1998 |
Olanzapine-induced Fos expression in the rat forebrain; cross-tolerance with haloperidol and clozapine.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Corticosterone; Drug Tolerance; Haloperidol; Male; Olanzapine; Pirenzepine; Prosencephalon; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Time Factors | 1998 |
Atypical antipsychotic drugs selectively increase neurotensin efflux in dopamine terminal regions.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Corpus Striatum; Haloperidol; Infusion Pumps; Male; Microdialysis; Neurotensin; Nucleus Accumbens; Olanzapine; Pirenzepine; Rats; Rats, Sprague-Dawley; RNA, Messenger | 1998 |
Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared to haloperidol.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Haloperidol; Imidazoles; Indoles; Male; Mastication; Olanzapine; Pirenzepine; Rats; Rats, Sprague-Dawley | 1998 |
Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Life Tables; Male; Olanzapine; Pirenzepine; Psychotic Disorders; Randomized Controlled Trials as Topic; Recurrence; Schizophrenia; Survival Analysis; Treatment Outcome | 1998 |
Some, but not all, antipsychotic drugs potentiate a low level of prepulse inhibition shown by rats of the Wistar strain.
Topics: Adrenergic alpha-Antagonists; Animals; Antipsychotic Agents; Behavior, Animal; Benzazepines; Benzodiazepines; Clozapine; Haloperidol; Imidazoles; Indoles; Injections, Intraperitoneal; Male; Neural Inhibition; Olanzapine; Pirenzepine; Prazosin; Rats; Rats, Wistar; Reflex, Startle; Remoxipride; Risperidone; Ritanserin; Serotonin Antagonists | 1997 |
Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Dopamine; Dopamine Agonists; Extracellular Space; Haloperidol; Male; Norepinephrine; Olanzapine; Piperazines; Pirenzepine; Prefrontal Cortex; Rats; Rats, Wistar; Reference Values; Risperidone; Tetrahydronaphthalenes; Thiazoles | 1998 |
Atypical neuroleptics enhance histamine turnover in brain via 5-Hydroxytryptamine2A receptor blockade.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Catalepsy; Clozapine; Drug Interactions; Haloperidol; Histamine; Histamine Antagonists; Imidazoles; Male; Methylhistamines; Mice; Olanzapine; Pirenzepine; Receptor, Serotonin, 5-HT2A; Receptors, Histamine H3; Receptors, Serotonin; Serotonin Antagonists | 1999 |
Body weight and leptin plasma levels during treatment with antipsychotic drugs.
Topics: Adipose Tissue; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Clozapine; Haloperidol; Hospitalization; Humans; Leptin; Mental Disorders; Olanzapine; Pirenzepine; Proteins; Weight Gain | 1999 |
[Neuroleptic malignant syndrome: case report with recurrence associated with the use of olanzapine].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome; Olanzapine; Pirenzepine; Recurrence | 1998 |
Complicated delirium in a cancer patient successfully treated with olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Olanzapine; Pirenzepine; Psychoses, Substance-Induced | 1999 |
A cost-effectiveness clinical decision analysis model for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cost-Benefit Analysis; Decision Support Systems, Clinical; Haloperidol; Humans; Markov Chains; Olanzapine; Pirenzepine; Quality-Adjusted Life Years; Risperidone; Schizophrenia; Treatment Outcome; United States | 1998 |
Atypical antipsychotics and formulary decisions.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Drug Costs; Efficiency; Formularies as Topic; Haloperidol; Humans; Managed Care Programs; Olanzapine; Pirenzepine; Quality of Life; Schizophrenia; United States | 1998 |
Interaction between olanzapine and haloperidol.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Drug Interactions; Haloperidol; Humans; Male; Olanzapine; Parkinson Disease, Secondary; Pirenzepine | 1999 |
Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo.
Topics: 3T3 Cells; Animals; Antipsychotic Agents; Benzodiazepines; Cell Line; Clozapine; Dendrites; Fluorobenzenes; Haloperidol; Mianserin; Mice; Olanzapine; Piperidines; Pirenzepine; Prefrontal Cortex; Pyramidal Cells; Rats; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Recombinant Proteins; Risperidone; Ritanserin; Serotonin Antagonists; Transfection | 1999 |
Seizure associated with olanzapine.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Drug Interactions; Female; Haloperidol; Humans; Olanzapine; Phenytoin; Pirenzepine; Seizures | 1999 |
Stimulation of dopamine release in the bed nucleus of stria terminalis. A trait of atypical antipsychotics?
Topics: Amygdala; Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Dopamine; Haloperidol; Indoles; Male; Olanzapine; Pirenzepine; Pyridines; Raclopride; Rats; Rats, Sprague-Dawley; Risperidone; Salicylamides; Thalamus | 1999 |
Effects of acute and chronic administration of olanzapine in comparison to clozapine and haloperidol on extracellular recordings of substantia nigra reticulata neurons in the rat brain.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Haloperidol; Male; Neurons; Olanzapine; Pirenzepine; Rats; Rats, Wistar; Substantia Nigra | 1999 |
Differential effects of treatment with typical and atypical antipsychotic drugs on adenylyl cyclase and G proteins.
Topics: Adenylyl Cyclases; Animals; Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Corpus Striatum; GTP-Binding Proteins; Guanosine 5'-O-(3-Thiotriphosphate); Haloperidol; Male; Mice; Olanzapine; Pirenzepine | 1999 |
Effects of atypical antipsychotic drugs vs. haloperidol on expression of heat shock protein in the discrete brain regions of phencyclidine-treated rats.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Corpus Striatum; Gene Expression Regulation; Gyrus Cinguli; Haloperidol; HSP70 Heat-Shock Proteins; Male; Nucleus Accumbens; Olanzapine; Phencyclidine; Pirenzepine; Prefrontal Cortex; Rats; Rats, Wistar; Risperidone; RNA, Messenger | 1999 |
A comparison of the acute effects of zotepine and other antipsychotics on rat cortical dopamine release, in vivo.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Dibenzothiepins; Dopamine; Fluoxetine; Frontal Lobe; Haloperidol; Male; Microdialysis; Olanzapine; Pirenzepine; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, Serotonin | 2000 |
Olanzapine. Keep an eye on this neuroleptic.
Topics: Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clinical Trials as Topic; Dopamine Antagonists; Double-Blind Method; Haloperidol; Humans; Olanzapine; Pirenzepine; Risperidone; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists | 2000 |
Effect of atypical antipsychotics on phencyclidine-induced expression of arc in rat brain.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Cytoskeletal Proteins; Gene Expression; Haloperidol; Male; Nerve Tissue Proteins; Olanzapine; Phencyclidine; Pirenzepine; Rats; Rats, Wistar; Risperidone; RNA, Messenger; Tissue Distribution | 2000 |
Effects of antipsychotic drugs on metabolite ratios in rat brain in vivo.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aspartic Acid; Benzodiazepines; Brain; Choline; Clozapine; Creatine; Haloperidol; Magnetic Resonance Spectroscopy; Male; Olanzapine; Pirenzepine; Rats; Rats, Sprague-Dawley | 2000 |
The discriminative stimulus properties of the atypical antipsychotic olanzapine in rats.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Discrimination Learning; Generalization, Psychological; Haloperidol; Male; Olanzapine; Pirenzepine; Raclopride; Rats; Rats, Sprague-Dawley; Risperidone; Ritanserin; Scopolamine | 2000 |
Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex.
Topics: Action Potentials; Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Dopamine; Haloperidol; Male; Neurons; Olanzapine; Pirenzepine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Ventral Tegmental Area | 2000 |
Olanzapine and tardive dyskinesia.
Topics: Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Haloperidol; Humans; Olanzapine; Pirenzepine; Psychotic Disorders | 1999 |
Effects of antipsychotic drugs on neurotoxicity, expression of fos-like protein and c-fos mRNA in the retrosplenial cortex after administration of dizocilpine.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Dizocilpine Maleate; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Haloperidol; Immunohistochemistry; In Situ Hybridization; Limbic System; Nervous System; Olanzapine; Pirenzepine; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Risperidone; RNA, Messenger | 2000 |
Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Drug Utilization; Female; Haloperidol; Humans; Male; Olanzapine; Pharmacoepidemiology; Pirenzepine; Practice Patterns, Physicians'; Prospective Studies; Risperidone; Schizophrenia | 2000 |
Restoration of latent inhibition by olanzapine but not haloperidol in entorhinal cortex-lesioned rats.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Entorhinal Cortex; Haloperidol; Inhibition, Psychological; Male; Olanzapine; Pirenzepine; Rats; Rats, Long-Evans; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2000 |
5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Chromatography, High Pressure Liquid; Clozapine; Corpus Striatum; Dopamine; Haloperidol; Male; Microdialysis; Olanzapine; Piperazines; Pirenzepine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Sensitivity and Specificity; Synaptic Transmission; Thiazoles; Time Factors | 2000 |
Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Costs and Cost Analysis; Haloperidol; Health Care Costs; Humans; Markov Chains; Models, Economic; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; United Kingdom | 2000 |
Subchronic treatment with either clozapine, olanzapine or haloperidol produces a hyposensitive response of the rat cortical cells to N-methyl-D-aspartate.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Synergism; Electrophysiology; Excitatory Amino Acid Agonists; Haloperidol; In Vitro Techniques; Male; N-Methylaspartate; Olanzapine; Pharmaceutical Vehicles; Pirenzepine; Prefrontal Cortex; Pyramidal Cells; Rats; Rats, Sprague-Dawley; Time Factors | 2000 |
Effect of chronic olanzapine treatment on striatal synaptic organization.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Haloperidol; Male; Neostriatum; Olanzapine; Pirenzepine; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Synapses | 2001 |
Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study.
Topics: Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Haloperidol; Humans; Olanzapine; Pirenzepine; Risperidone | 2000 |
Neuroleptic therapy influences basal ganglia activation: a functional magnetic resonance imaging study comparing controls to haloperidol- and olanzapine-treated inpatients.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Benzodiazepines; Brain; Haloperidol; Hospitalization; Humans; Magnetic Resonance Imaging; Male; Olanzapine; Pirenzepine; Schizophrenia | 2000 |
Drug review "surprises" reader.
Topics: Aged; Alanine Transaminase; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Drug Interactions; Dyskinesia, Drug-Induced; Haloperidol; Humans; Liver; Middle Aged; Multicenter Studies as Topic; Olanzapine; Pirenzepine; Prolactin; Risk Factors; Safety; Schizophrenia | 2000 |
Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal ganglia-thalamocortical neural pathways.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Corpus Striatum; Down-Regulation; Haloperidol; Imidazoles; Indoles; Male; Neurotransmitter Agents; Olanzapine; Pirenzepine; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Thalamus; Up-Regulation | 2001 |
Reversal of rabbit syndrome with olanzapine.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Female; Haloperidol; Humans; Mouth Diseases; Olanzapine; Pirenzepine; Schizophrenia; Stereotypic Movement Disorder; Syndrome; Treatment Outcome | 2000 |
Repeated episodes of hypothermia in a subject treated with haloperidol, levomepromazine, olanzapine, and thioridazine.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Hypothermia; Methotrimeprazine; Olanzapine; Pirenzepine; Thioridazine | 2001 |
The economic consequences of a drug-drug interaction.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Depression; Drug Interactions; Female; Fluoxetine; Haloperidol; Health Care Costs; Humans; Olanzapine; Parkinson Disease; Pirenzepine; Selegiline; Trihexyphenidyl | 2001 |
Neuroleptic malignant syndrome after addition of haloperidol to atypical antipsychotic.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Emergency Service, Hospital; Female; Haloperidol; Humans; Neuroleptic Malignant Syndrome; Olanzapine; Pirenzepine; Schizophrenia | 2001 |
Atypical antipsychotic drugs: how much better are they?
Topics: Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Haloperidol; Humans; Olanzapine; Pirenzepine | 2001 |
Dopamine receptor responsivity in schizophrenic patients in a drug-free state and after treatment with olanzapine.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Dopamine D2 Receptor Antagonists; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Prolactin; Receptors, Dopamine D2; Schizophrenia | 2001 |
Olanzapine in the treatment of tardive dyskinesia: a report of 2 cases.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Risperidone; Treatment Outcome | 2001 |
Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Binding Sites; Binding, Competitive; Cell Line; Clozapine; Dibenzothiazepines; Dopamine Antagonists; Haloperidol; Humans; Neurons; Norepinephrine; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Rats; Receptors, Adrenergic, alpha; Receptors, Dopamine; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Risperidone; Serotonin; Serotonin Antagonists; Thiazoles | 2001 |
Atypical neuroleptic drugs downregulate dopamine sensitivity in rat cortical and striatal astrocytes.
Topics: Adrenergic beta-Antagonists; Animals; Animals, Newborn; Antipsychotic Agents; Astrocytes; Benzodiazepines; Calcium; Calcium Signaling; Cells, Cultured; Cerebral Cortex; Clozapine; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Down-Regulation; Haloperidol; Intracellular Fluid; Neostriatum; Olanzapine; Pirenzepine; Rats; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D4; Risperidone; Serotonin Antagonists; Sulpiride | 2001 |
Extended treatment with typical and atypical antipsychotic drugs differential effects on the densities of dopamine D2-like and GABAA receptors in rat striatum.
Topics: Animals; Antipsychotic Agents; Benzamides; Benzazepines; Benzodiazepines; Chlorpromazine; Clozapine; Corpus Striatum; Dose-Response Relationship, Drug; Haloperidol; Male; Muscimol; Olanzapine; Pirenzepine; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, GABA-A | 2001 |
Effects of acute versus chronic treatment with typical or atypical antipsychotics on d-amphetamine-induced sensorimotor gating deficits in rats.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Benzodiazepines; Central Nervous System Stimulants; Dextroamphetamine; Haloperidol; Hyperkinesis; Imidazoles; Indoles; Male; Olanzapine; Pirenzepine; Rats; Rats, Wistar; Receptors, Dopamine; Reflex, Startle; Time Factors | 2001 |
Increased responsiveness of dopamine to atypical, but not typical antipsychotics in the medial prefrontal cortex of rats reared in isolation.
Topics: Amino Acids; Animals; Antipsychotic Agents; Benzodiazepines; Chromatography, High Pressure Liquid; Clozapine; Dopamine; Excitatory Amino Acids; Haloperidol; Indicators and Reagents; Male; Microdialysis; Olanzapine; Pirenzepine; Prefrontal Cortex; Rats; Reflex, Startle; Social Isolation | 2001 |
Global index of safety (GIS): a new instrument to assess drug safety.
Topics: Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Benzodiazepines; Consumer Product Safety; Drug Monitoring; Haloperidol; Humans; Olanzapine; Pharmacoepidemiology; Pirenzepine; Risperidone; Schizophrenia | 2001 |
Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine.
Topics: Animals; Benzodiazepines; Binding, Competitive; Clozapine; Dibenzothiazepines; Dose-Response Relationship, Drug; Guanosine 5'-O-(3-Thiotriphosphate); Guinea Pigs; Haloperidol; HeLa Cells; Humans; Ileum; In Vitro Techniques; Indoles; Lysergic Acid; Muscle Contraction; Olanzapine; Ondansetron; Pirenzepine; Quetiapine Fumarate; Receptors, Serotonin; Receptors, Serotonin, 5-HT3; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Sulfur Radioisotopes; Tritium; Tropisetron | 2001 |
[Heart rate variability in schizophrenic patients treated with antipsychotic agents].
Topics: Adult; Antipsychotic Agents; Arrhythmias, Cardiac; Benzodiazepines; Clozapine; Female; Haloperidol; Heart Rate; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Schizophrenia | 2001 |
Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine.
Topics: Adolescent; Adult; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cohort Studies; Drug Interactions; Female; Haloperidol; Humans; Male; Middle Aged; Netherlands; Olanzapine; Pirenzepine; Risk Factors; Risperidone | 2001 |
Acute administration of antipsychotics modulates Homer striatal gene expression differentially.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Carrier Proteins; Caudate Nucleus; Corpus Striatum; Disks Large Homolog 4 Protein; Enkephalins; Frontal Lobe; Haloperidol; Homer Scaffolding Proteins; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Nerve Tissue Proteins; Neuronal Plasticity; Neuropeptides; Nucleus Accumbens; Olanzapine; Parietal Lobe; Pirenzepine; Prefrontal Cortex; Putamen; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; RNA, Messenger | 2002 |
Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study).
Topics: Adult; Antipsychotic Agents; Attitude to Health; Basal Ganglia Diseases; Benzodiazepines; Female; Haloperidol; Humans; Incidence; Male; Olanzapine; Patient Compliance; Prospective Studies; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2001 |
Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum.
Topics: Acetylcholine; Acetylcholinesterase; Animals; Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Cholinesterase Inhibitors; Clozapine; Corpus Striatum; Haloperidol; Male; Nucleus Accumbens; Olanzapine; Oxotremorine; Piperazines; Pirenzepine; Rats; Rats, Sprague-Dawley; Risperidone; Scopolamine; Sulpiride; Thiazoles; Thioridazine | 2002 |
Effects of antipsychotic drugs on operant responding after acute and repeated administration.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Conditioning, Operant; Dibenzothiazepines; Dose-Response Relationship, Drug; Haloperidol; Imidazoles; Indoles; Male; Olanzapine; Pirenzepine; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; Remoxipride; Risperidone; Thioridazine; Time Factors | 2002 |
Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Male; Mental Disorders; Olanzapine; Pirenzepine; Prospective Studies; Risperidone; Weight Gain | 2002 |
Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat.
Topics: Acetylcholine; Adrenergic alpha-Antagonists; Animals; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Dialysis Solutions; Dopamine Antagonists; Extracellular Space; Haloperidol; Hippocampus; Injections, Intraperitoneal; Injections, Subcutaneous; Male; Microdialysis; Olanzapine; Piperazines; Pirenzepine; Rats; Rats, Wistar; Risperidone; Serotonin Antagonists; Thiazoles; Thioridazine | 2002 |
Subcortical overactivation in untreated schizophrenic patients: a functional magnetic resonance image finger-tapping study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Benzodiazepines; Brain; Brain Mapping; Female; Fingers; Haloperidol; Hospitalization; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Motor Activity; Olanzapine; Pirenzepine; Schizophrenia; Schizophrenic Psychology | 2002 |
Motor-induced brain activation in cortical, subcortical and cerebellar regions in schizophrenic inpatients. A whole brain fMRI fingertapping study.
Topics: Adult; Basal Ganglia; Benzodiazepines; Cerebellum; Cerebral Cortex; Female; Haloperidol; Humans; Linear Models; Magnetic Resonance Imaging; Male; Motor Skills; Olanzapine; Pirenzepine; Schizophrenia | 2002 |
Phencyclidine supersensitivity in rats with neonatal dopamine loss.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Animals, Newborn; Antipsychotic Agents; Benzazepines; Benzodiazepines; Corpus Striatum; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Amino Acid Antagonists; Female; Haloperidol; Ketamine; Male; Motor Activity; Olanzapine; Oxidopamine; Phencyclidine; Pirenzepine; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate; Sex Factors | 2002 |
Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Disease Models, Animal; Haloperidol; Hippocampus; Male; Olanzapine; Pirenzepine; Rats; Rats, Sprague-Dawley; Reflex, Startle; Reserpine; Schizophrenia | 2002 |
Prolactin responses to acute clomipramine and haloperidol of male schizophrenic patients in a drug-free state and after treatment with clozapine or with olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clomipramine; Clozapine; Haloperidol; Humans; Hypothalamo-Hypophyseal System; Male; Middle Aged; Olanzapine; Pirenzepine; Prolactin; Psychiatric Status Rating Scales; Receptors, Dopamine D2; Receptors, Serotonin; Schizophrenia; Treatment Outcome | 2002 |
Atypical neuroleptics stimulate neurogenesis in adult rat brain.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Brain Chemistry; Cell Differentiation; Haloperidol; Immunohistochemistry; Male; Olanzapine; Pirenzepine; Rats; Rats, Wistar; Risperidone | 2002 |
Effect of prenatal administration of haloperidol, risperidone, quetiapine and olanzapine on spatial learning and retention in adult rats.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Dibenzothiazepines; Drinking; Female; Haloperidol; Learning; Male; Olanzapine; Pirenzepine; Pregnancy; Prenatal Exposure Delayed Effects; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Retention, Psychology; Risperidone; Spatial Behavior | 2002 |
Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Child; Clozapine; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Prolactin; Psychotic Disorders; Schizophrenia | 2002 |
ECT treatment of malignant catatonia/NMS in an adolescent: a useful lesson in delayed diagnosis and treatment.
Topics: Adolescent; Benzodiazepines; Brain; Catatonia; Diagnosis, Differential; Diagnostic Imaging; Electroconvulsive Therapy; Electroencephalography; Female; Haloperidol; Humans; Neuroleptic Malignant Syndrome; Neurologic Examination; Neuropsychological Tests; Olanzapine; Pirenzepine; Treatment Outcome | 2002 |
[Improvement of tardive dyskinesia after treatment with olanzapine].
Topics: Affective Disorders, Psychotic; Aged; Benzodiazepines; Depressive Disorder, Major; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Neurologic Examination; Olanzapine; Paroxetine; Patient Admission; Pirenzepine | 2002 |
Decreased density of [3H]TCP binding following antipsychotic drug withdrawal in rats.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Chlorpromazine; Clozapine; Haloperidol; Ion Channels; Male; Olanzapine; Phencyclidine; Pirenzepine; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Substance Withdrawal Syndrome | 2002 |
Weight gain associated with atypical antipsychotics.
Topics: Adolescent; Benzodiazepines; Child; Dopamine Antagonists; Female; Haloperidol; Humans; Male; Obesity; Olanzapine; Pirenzepine; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Weight Gain | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clozapine; Diabetes Mellitus, Type 2; Dibenzothiazepines; Female; Haloperidol; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Olanzapine; Pirenzepine; Psychotic Disorders; Quetiapine Fumarate; Retrospective Studies; Risk Factors; Risperidone; Triglycerides; Weight Gain | 2002 |
Comparable dopamine 2 receptor occupancy.
Topics: Benzodiazepines; Cognition Disorders; Dopamine Antagonists; Haloperidol; Humans; Olanzapine; Pirenzepine; Risperidone; Schizophrenia; Selective Serotonin Reuptake Inhibitors | 2002 |
Glucose intolerance with atypical antipsychotics.
Topics: Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Chlorpromazine; Clozapine; Diabetes Mellitus; Glucose Intolerance; Haloperidol; Humans; Hyperglycemia; Olanzapine; Pirenzepine; Risk Factors; Risperidone; World Health Organization | 2002 |
Differential effects of chronic haloperidol and olanzapine exposure on brain cholinergic markers and spatial learning in rats.
Topics: Animals; Benzodiazepines; Brain; Choline O-Acetyltransferase; Cholinergic Fibers; Drug Administration Schedule; Escape Reaction; Haloperidol; Male; Maze Learning; Mental Recall; Microscopy, Fluorescence; Olanzapine; Orientation; Pirenzepine; Rats; Rats, Wistar; Reaction Time; Receptors, Cholinergic | 2002 |
Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Benzodiazepines; Brain-Derived Neurotrophic Factor; Clozapine; Dopamine Agents; Dose-Response Relationship, Drug; Gene Expression; Haloperidol; Hippocampus; In Situ Hybridization; Levodopa; Male; Olanzapine; Pirenzepine; Rats; Rats, Wistar; RNA, Messenger | 2003 |
Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents.
Topics: Adrenalectomy; Animals; Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Clozapine; Corticosterone; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; Gonadal Steroid Hormones; Haloperidol; Male; Olanzapine; Pirenzepine; Pregnanolone; Progesterone; Radioimmunoassay; Rats; Rats, Sprague-Dawley; Risperidone | 2003 |
Insight in persons with schizophrenia: effects of switching from conventional neuroleptics to atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Cognition Disorders; Female; Haloperidol; Humans; Male; Olanzapine; Patient Compliance; Pirenzepine; Risperidone; Schizophrenia; Severity of Illness Index; Treatment Outcome | 2002 |
Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Diagnostic and Statistical Manual of Mental Disorders; Dibenzothiazepines; Female; Haloperidol; Humans; Leptin; Male; Olanzapine; Pirenzepine; Quetiapine Fumarate; Schizophrenia; Triglycerides; Weight Gain | 2003 |
alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brimonidine Tartrate; Chlorpromazine; CHO Cells; Clozapine; Cricetinae; Cyclic AMP; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Gene Expression; Haloperidol; Humans; Isoxazoles; Norepinephrine; Olanzapine; Piperazines; Piperidines; Pirenzepine; Quetiapine Fumarate; Quinolones; Quinoxalines; Receptors, Adrenergic, alpha-2; Receptors, Dopamine D2; Risperidone; Thiazoles; Transfection; Yohimbine | 2003 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Humans; Olanzapine; Pirenzepine; Psychotic Disorders; Research Design; Risperidone; Schizophrenia; Treatment Outcome | 2003 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Haloperidol; Humans; Olanzapine; Pirenzepine; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Risperidone; Schizophrenia; Treatment Outcome | 2003 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Humans; Olanzapine; Pirenzepine; Research Design; Research Support as Topic; Risperidone; Schizophrenia; Treatment Outcome | 2003 |
Chronic administration of haloperidol and olanzapine attenuates ketamine-induced brain metabolic activation.
Topics: Analgesics; Animals; Antipsychotic Agents; Autoradiography; Benzodiazepines; Brain; Clozapine; Deoxyglucose; Drug Interactions; Haloperidol; Ketamine; Olanzapine; Pirenzepine; Rats; Rats, Sprague-Dawley | 2003 |
Olanzapine and clozapine but not haloperidol reverse subchronic phencyclidine-induced functional hyperactivity of N-methyl-D-aspartate receptors in pyramidal cells of the rat medial prefrontal cortex.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Excitatory Amino Acid Agonists; Haloperidol; Male; Membrane Potentials; N-Methylaspartate; Olanzapine; Patch-Clamp Techniques; Phencyclidine; Pirenzepine; Prefrontal Cortex; Pyramidal Cells; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Schizophrenia | 2003 |
Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Estrogens; Female; Haloperidol; Humans; Hyperprolactinemia; Male; Olanzapine; Pirenzepine; Prolactin; Risk Factors; Risperidone; Schizophrenia; Sex Characteristics | 2003 |
Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Drinking Behavior; Eating; Fat Emulsions, Intravenous; Feeding Behavior; Haloperidol; Male; Movement; Olanzapine; Pirenzepine; Rats; Time Factors; Tongue | 2003 |
Successful therapy of tardive dyskinesia in a 71-year-old woman with a combination of tetrabenazine, olanzapine and tiapride.
Topics: Aged; Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Olanzapine; Pirenzepine; Tetrabenazine; Tiapamil Hydrochloride; Treatment Outcome | 2003 |
Role of ethnicity in predicting antipsychotic medication adherence.
Topics: Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Ethnicity; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Patient Compliance; Pirenzepine; Risperidone; Schizophrenia | 2003 |
Cells in midline thalamus, central amygdala, and nucleus accumbens responding specifically to antipsychotic drugs.
Topics: Amygdala; Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Diphenhydramine; Haloperidol; Immunohistochemistry; Injections, Intraperitoneal; Lorazepam; Male; Midline Thalamic Nuclei; Nucleus Accumbens; Olanzapine; Pirenzepine; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley | 2003 |
Comparison of the effects of antipsychotics on a delayed radial maze task in the rat.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Dose-Response Relationship, Drug; Food Deprivation; Haloperidol; Male; Maze Learning; Memory; Olanzapine; Piperazines; Pirenzepine; Rats; Rats, Sprague-Dawley; Risperidone; Thiazoles | 2003 |
Effect of antipsychotic drugs on brain-derived neurotrophic factor expression under reduced N-methyl-D-aspartate receptor activity.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Brain-Derived Neurotrophic Factor; Dizocilpine Maleate; Dose-Response Relationship, Drug; Down-Regulation; Excitatory Amino Acid Antagonists; Glutamic Acid; Haloperidol; Male; Neuronal Plasticity; Olanzapine; Pirenzepine; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Schizophrenia; Synaptic Transmission | 2003 |
Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Body Weight; Diet; Disease Models, Animal; Dose-Response Relationship, Drug; Drinking; Eating; Female; Food Preferences; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Rats; Rats, Wistar; Sex Characteristics; Weight Gain | 2003 |
Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Cross-Sectional Studies; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Spain; Weight Gain | 2003 |
A comparison of drug effects in latent inhibition and the forced swim test differentiates between the typical antipsychotic haloperidol, the atypical antipsychotics clozapine and olanzapine, and the antidepressants imipramine and paroxetine.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Clozapine; Conditioning, Psychological; Haloperidol; Imipramine; Inhibition, Psychological; Male; Models, Animal; Olanzapine; Paroxetine; Pirenzepine; Rats; Rats, Wistar; Swimming | 2003 |
Haloperidol-induced dyskinesia is associated with striatal NO synthase suppression: reversal with olanzapine.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Corpus Striatum; Cyclic GMP; Dyskinesia, Drug-Induced; Haloperidol; Male; Mastication; Nitric Oxide; Nitric Oxide Synthase; Olanzapine; Pirenzepine; Rats; Rats, Sprague-Dawley | 2003 |
Ethnic differences in use of antipsychotic medication among Texas medicaid clients with schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Black or African American; Drug Utilization; Female; Haloperidol; Hispanic or Latino; Humans; Logistic Models; Male; Medicaid; Middle Aged; Olanzapine; Pirenzepine; Schizophrenia; Texas; White People | 2003 |
Alpha2-adrenoceptor antagonism is neither sufficient nor necessary for the distinctive action of atypical neuroleptics on intracranial self-stimulation in the rat.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Clonidine; Haloperidol; Idazoxan; Male; Motivation; Olanzapine; Pirenzepine; Rats; Receptors, Adrenergic, alpha-2; Self Stimulation | 2003 |
Rehospitalization risk with second-generation and depot antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Data Collection; Delayed-Action Preparations; Female; Fluphenazine; Haloperidol; Humans; Male; Olanzapine; Patient Readmission; Pirenzepine; Risperidone; Schizophrenia; Secondary Prevention; Time Factors; Treatment Outcome | 2003 |
Bilateral lesions of the entorhinal cortex differentially modify haloperidol- and olanzapine-induced c-fos mRNA expression in the rat forebrain.
Topics: Animals; Benzodiazepines; Entorhinal Cortex; Gene Expression Regulation; Genes, fos; Haloperidol; Male; Olanzapine; Pirenzepine; Prosencephalon; Rats; Rats, Long-Evans; RNA, Messenger | 2003 |
Antipsychotic drugs differentially modulate apolipoprotein D in rat brain.
Topics: Animals; Antipsychotic Agents; Apolipoproteins; Apolipoproteins D; Benzodiazepines; Brain; Haloperidol; Male; Neuronal Plasticity; Neurons; Olanzapine; Pirenzepine; Rats; Rats, Wistar; Risperidone | 2003 |
Prepulse inhibition of acoustic startle in subjects with schizophrenia treated with olanzapine or haloperidol.
Topics: Acoustic Stimulation; Adult; Analysis of Variance; Antipsychotic Agents; Arousal; Attention; Benzodiazepines; Blinking; Electromyography; Habituation, Psychophysiologic; Haloperidol; Humans; Male; Middle Aged; Neural Inhibition; Olanzapine; Psychiatric Status Rating Scales; Reaction Time; Reflex, Startle; Schizophrenia; Schizophrenic Psychology | 2003 |
[Neuroleptics and cognition].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Middle Aged; Neuropsychological Tests; Olanzapine; Pirenzepine; Product Surveillance, Postmarketing; Risperidone; Schizophrenia; Schizophrenic Psychology | 2003 |
Differential effects of antipsychotics on haloperidol-induced vacuous chewing movements and subcortical gene expression in the rat.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Dyskinesia, Drug-Induced; Gene Expression; Haloperidol; In Situ Hybridization; Injections, Intramuscular; Male; Mastication; Olanzapine; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, N-Methyl-D-Aspartate; RNA, Messenger | 2003 |
Haloperidol, but not olanzapine, impairs cognitive performance after traumatic brain injury in rats.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Benzodiazepines; Brain Injuries; Cognition Disorders; Dopamine Antagonists; Dose-Response Relationship, Drug; Haloperidol; Injections, Intraperitoneal; Male; Maze Learning; Olanzapine; Pirenzepine; Rats; Rats, Sprague-Dawley; Swimming | 2003 |
Quetiapine, clozapine, and olanzapine in the treatment of tardive dyskinesia induced by first-generation antipsychotics: a 124-week case report.
Topics: Amphetamine-Related Disorders; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Olanzapine; Quetiapine Fumarate; Schizophrenia, Paranoid | 2003 |
[Fast control of manic or mixed episodes. Atypical neuroleptics for bipolar patients].
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Dopamine Antagonists; Drug Therapy, Combination; Haloperidol; Humans; Isotopes; Lithium; Olanzapine; Pirenzepine; Selective Serotonin Reuptake Inhibitors; Time Factors; Valproic Acid | 2003 |
Disturbed glucose metabolism among patients taking olanzapine and typical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Cohort Studies; Depressive Disorder; Diabetes Mellitus; Female; Fluphenazine; Glucose; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Perphenazine; Retrospective Studies | 2003 |
Modulation of nerve growth factor and choline acetyltransferase expression in rat hippocampus after chronic exposure to haloperidol, risperidone, and olanzapine.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Benzodiazepines; Choline O-Acetyltransferase; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Haloperidol; Hippocampus; Immunohistochemistry; Male; Nerve Growth Factor; Olanzapine; Rats; Rats, Wistar; Risperidone; Septum of Brain | 2004 |
Similarities and differences among antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Haloperidol; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2003 |
Dependence and chronic psychosis with D-nor-pseudoephedrine.
Topics: Antipsychotic Agents; Appetite; Appetite Depressants; Benzodiazepines; Central Nervous System Stimulants; Delusions; Depressive Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ephedrine; Euphoria; Female; Hallucinations; Haloperidol; Humans; Long-Term Care; Mazindol; Middle Aged; Olanzapine; Psychoses, Substance-Induced; Recurrence; Substance Withdrawal Syndrome; Substance-Related Disorders; Thioridazine | 2003 |
EEG abnormalities associated with antipsychotics: a comparison of quetiapine, olanzapine, haloperidol and healthy subjects.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Dose-Response Relationship, Drug; Electroencephalography; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Quetiapine Fumarate; Retrospective Studies; Seizures; Sex Factors | 2003 |
Olanzapine excretion into breast milk: a case report.
Topics: Adult; Benzodiazepines; Breast Feeding; Chromatography, Gas; Drug Therapy, Combination; Female; Haloperidol; Humans; Infant, Newborn; Lactation; Methotrimeprazine; Milk, Human; Olanzapine; Psychotic Disorders; Puerperal Disorders | 2004 |
Effects of chronic olanzapine and haloperidol differ on the mouse N1 auditory evoked potential.
Topics: Acoustic Stimulation; Analysis of Variance; Animals; Benzodiazepines; Dopamine Antagonists; Dose-Response Relationship, Drug; Electroencephalography; Evoked Potentials, Auditory; Haloperidol; Mice; Mice, Inbred C57BL; Olanzapine; Selective Serotonin Reuptake Inhibitors; Time Factors | 2004 |
Olanzapine counteracts reduction of brain-derived neurotrophic factor and TrkB receptors in rat hippocampus produced by haloperidol.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain-Derived Neurotrophic Factor; Haloperidol; Hippocampus; Immunohistochemistry; Male; Olanzapine; Rats; Rats, Wistar; Receptor, trkB | 2004 |
Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Black or African American; Drug Utilization; Haloperidol; Hispanic or Latino; Humans; Logistic Models; Medicaid; Middle Aged; Minority Groups; Multivariate Analysis; Olanzapine; Practice Patterns, Physicians'; Retrospective Studies; Risperidone; Schizophrenia; Texas; United States; White People | 2004 |
Olanzapine vs haloperidol for treatment of schizophrenia.
Topics: Akathisia, Drug-Induced; Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Benztropine; Haloperidol; Humans; Olanzapine; Schizophrenia; Selection Bias | 2004 |
Olanzapine vs haloperidol for treatment of schizophrenia.
Topics: Akathisia, Drug-Induced; Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Benztropine; Haloperidol; Humans; Olanzapine; Schizophrenia | 2004 |
Olanzapine vs haloperidol for treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Endocrine System; Haloperidol; Humans; Olanzapine; Quality of Life; Schizophrenia | 2004 |
Olanzapine vs haloperidol for treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Drug Resistance; Haloperidol; Humans; Olanzapine; Quality of Life; Schizophrenia | 2004 |
Olanzapine vs haloperidol for treatment of schizophrenia.
Topics: Akathisia, Drug-Induced; Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Benztropine; Cognition; Haloperidol; Humans; Olanzapine; Receptors, Dopamine D2; Schizophrenia | 2004 |
Chronic treatment with atypical neuroleptics induces striosomal FosB/DeltaFosB expression in rats.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Caudate Nucleus; Clozapine; Drug Administration Schedule; Haloperidol; Male; Movement Disorders; Neural Pathways; Nucleus Accumbens; Olanzapine; Peptide Fragments; Proto-Oncogene Proteins c-fos; Putamen; Rats; Rats, Wistar; Tissue Distribution; Transcription Factors | 2004 |
Inhibition of stress-induced dopamine output in the rat prefrontal cortex by chronic treatment with olanzapine.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Dopamine; Down-Regulation; Drug Administration Schedule; Electroshock; Haloperidol; Male; Neurons; Olanzapine; Prefrontal Cortex; Random Allocation; Rats; Rats, Sprague-Dawley; Stress, Psychological | 2004 |
Antipsychotics regulate cyclic AMP-dependent protein kinase and phosphorylated cyclic AMP response element-binding protein in striatal and cortical brain regions in mice.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Corpus Striatum; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Down-Regulation; Haloperidol; Male; Mice; Nucleus Accumbens; Olanzapine; Phosphorylation; Signal Transduction | 2004 |
Antipsychotics increase microtubule-associated protein 2 mRNA but not spinophilin mRNA in rat hippocampus and cortex.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Chlorpromazine; Clozapine; Gene Expression Regulation; Haloperidol; Hippocampus; In Situ Hybridization; Male; Microfilament Proteins; Microtubule-Associated Proteins; Nerve Tissue Proteins; Neurites; Olanzapine; Rats; Rats, Sprague-Dawley; Risperidone; RNA, Messenger; Tissue Distribution | 2004 |
Clozapine and olanzapine, but not haloperidol, reverse cold-induced and lipopolysaccharide-induced cutaneous vasoconstriction.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Body Temperature; Clozapine; Cold Temperature; Dose-Response Relationship, Drug; Ear, External; Haloperidol; Laser-Doppler Flowmetry; Lipopolysaccharides; Olanzapine; Rabbits; Regional Blood Flow; Skin; Vasoconstriction | 2004 |
Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Benzodiazepines; Bromodeoxyuridine; Cell Count; Cell Division; Corpus Striatum; Dentate Gyrus; Haloperidol; Immunohistochemistry; Male; Neurons; Olanzapine; Phosphopyruvate Hydratase; Prosencephalon; Rats; Rats, Sprague-Dawley | 2004 |
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Diagnostic and Statistical Manual of Mental Disorders; Dibenzothiazepines; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Hyperprolactinemia; International Classification of Diseases; Male; Observation; Olanzapine; Prospective Studies; Quetiapine Fumarate; Risperidone; Schizophrenia; Severity of Illness Index; Sexual Dysfunction, Physiological; Surveys and Questionnaires; Weight Gain | 2004 |
Role of neuroactive steroid allopregnanolone in antipsychotic-like action of olanzapine in rodents.
Topics: Animals; Antipsychotic Agents; Apomorphine; Avoidance Learning; Behavior, Animal; Benzodiazepines; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Interactions; GABA Antagonists; GABA-A Receptor Antagonists; gamma-Aminobutyric Acid; Haloperidol; Injections, Intraventricular; Male; Motor Activity; Neurotransmitter Agents; Olanzapine; Pregnanolone; Rats; Rats, Sprague-Dawley; Risperidone; Social Isolation | 2004 |
COMT158 polymorphism and hostility.
Topics: Antipsychotic Agents; Benzodiazepines; Catechol O-Methyltransferase; Clozapine; Genotype; Haloperidol; Hostility; Humans; Methionine; Olanzapine; Polymorphism, Genetic; Risperidone; Schizophrenia; Schizophrenic Psychology; Valine | 2004 |
Reply to the comment by Skrobik et al.
Topics: Antipsychotic Agents; Benzodiazepines; Critical Illness; Delirium; Haloperidol; Humans; Olanzapine; Treatment Outcome | 2004 |
Effects of typical and atypical antipsychotics on human glycine transporters.
Topics: Amino Acid Transport Systems, Neutral; Animals; Antipsychotic Agents; Benzodiazepines; Brain; Chloride Channels; Choriocarcinoma; Clozapine; Female; Glycine; Glycine Plasma Membrane Transport Proteins; Haloperidol; Humans; Membrane Glycoproteins; Membrane Transport Modulators; Membrane Transport Proteins; Olanzapine; Rats; Receptors, N-Methyl-D-Aspartate; Risperidone; Schizophrenia; Sodium Channels; Synapses; Uterine Neoplasms | 2004 |
[Expectations and developments in atypical antipsychotics].
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Clozapine; Diabetes Complications; Haloperidol; Humans; Obesity; Olanzapine; Piperazines; Quinolones; Risk Factors; Schizophrenia; Weight Gain | 2004 |
[The value of publishing negative results from a randomized controlled trial: the Rosenheck's study].
Topics: Benzodiazepines; Haloperidol; Humans; Mental Disorders; Olanzapine; Publication Bias; Randomized Controlled Trials as Topic; Treatment Failure | 2004 |
Haloperidol and clozapine, but not olanzapine, induces oxidative stress in rat brain.
Topics: Animals; Benzodiazepines; Brain; Clozapine; Dose-Response Relationship, Drug; Haloperidol; Male; Olanzapine; Oxidative Stress; Rats; Rats, Wistar | 2004 |
EEG abnormalities under treatment with atypical antipsychotics: effects of olanzapine and amisulpride as compared to haloperidol.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Dose-Response Relationship, Drug; Electroencephalography; Female; Follow-Up Studies; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Schizophrenia; Sulpiride | 2004 |
Effects of clozapine, olanzapine and haloperidol on ethanol-induced ascorbic acid release in mouse striatum.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Ascorbic Acid; Benzodiazepines; Brain Chemistry; Central Nervous System Depressants; Clozapine; Dialysis; Ethanol; Haloperidol; Male; Mice; Neostriatum; Olanzapine; Serotonin Receptor Agonists | 2005 |
The impact of neuroleptic medication on seizure threshold and duration in electroconvulsive therapy.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Brain; Clopenthixol; Clozapine; Dibenzothiazepines; Electric Impedance; Electroconvulsive Therapy; Electroencephalography; Electromyography; Female; Fluphenazine; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Quetiapine Fumarate; Risperidone; Seizures; Sulpiride | 2004 |
Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats.
Topics: Analysis of Variance; Animals; Behavior, Animal; Benzodiazepines; Disease Models, Animal; Dopamine Antagonists; Drug Administration Routes; Dyskinesia, Drug-Induced; Haloperidol; Infusion Pumps; Male; Mastication; Olanzapine; Raclopride; Radioligand Assay; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Selective Serotonin Reuptake Inhibitors; Time Factors; Tritium | 2005 |
The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Brain; Fixatives; Haloperidol; Linear Models; Macaca fascicularis; Male; Olanzapine; Organ Size; Time Factors | 2005 |
Effects of chronic typical and atypical antipsychotic drug treatment on maternal behavior in rats.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Haloperidol; Maternal Behavior; Nesting Behavior; Olanzapine; Random Allocation; Rats; Rats, Sprague-Dawley | 2005 |
Functional effects of single dose first- and second-generation antipsychotic administration in subjects with schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Benzodiazepines; Brain; Cerebrovascular Circulation; Corpus Striatum; Drug Administration Schedule; Female; Gyrus Cinguli; Haloperidol; Humans; Male; Olanzapine; Prolactin; Schizophrenia | 2005 |
Body weight gain induced by a newer antipsychotic agent reversed as negative symptoms improved.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Diet; Exercise; Female; Haloperidol; Humans; Olanzapine; Schizophrenia; Weight Gain | 2005 |
Effects of chronic administration of olanzapine, amitriptyline, haloperidol or sodium valproate in naive and anhedonic rats.
Topics: Amitriptyline; Animals; Antidepressive Agents; Benzodiazepines; Eating; Haloperidol; Male; Olanzapine; Rats; Rats, Wistar; Self Administration; Sucrose; Valproic Acid | 2006 |
Neurotensin-deficient mice have deficits in prepulse inhibition: restoration by clozapine but not haloperidol, olanzapine, or quetiapine.
Topics: Amphetamine; Animals; Antipsychotic Agents; Benzodiazepines; Body Weight; Clozapine; Dibenzothiazepines; Female; Haloperidol; Male; Mice; Mice, Inbred C57BL; Neurotensin; Olanzapine; Quetiapine Fumarate; Reflex; Reflex, Startle | 2005 |
Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Controlled Clinical Trials as Topic; Dibenzothiazepines; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Risperidone; Schizophrenia; Thiazoles | 2005 |
Olanzapine and haloperidol for residual symptoms.
Topics: Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Haloperidol; Humans; Olanzapine; Receptors, Dopamine D2; Research Design; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2005 |
Effects of different antipsychotics and the antidepressant mirtazapine on glucose transporter mRNA levels in human blood cells.
Topics: Actins; Analysis of Variance; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Blood Cells; Clozapine; Glucose Transporter Type 3; Glucose Transporter Type 4; Glucose Transporter Type 5; Haloperidol; Humans; Mianserin; Mirtazapine; Olanzapine; RNA, Messenger; U937 Cells | 2006 |
Effects of chronic neuroleptic treatments on nutrient selection, body weight, and body composition in the male rat under dietary self-selection.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Blood Glucose; Body Composition; Body Weight; Diet; Dietary Proteins; Eating; Energy Intake; Food Preferences; Haloperidol; Male; Nutritional Status; Olanzapine; Plasma; Rats; Rats, Sprague-Dawley; Time Factors | 2005 |
Neurologic soft signs in schizophrenic patients treated with conventional and atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Haloperidol; Humans; Male; Nervous System Diseases; Neuropsychological Tests; Olanzapine; Risperidone; Schizophrenia; Severity of Illness Index | 2005 |
Olanzapine-induced suppression of cocaine self-administration in rhesus monkeys.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Cocaine-Related Disorders; Data Interpretation, Statistical; Dopamine; Dose-Response Relationship, Drug; Female; Fluoxetine; Haloperidol; Macaca mulatta; Male; Microdialysis; Olanzapine; Selective Serotonin Reuptake Inhibitors; Self Administration | 2006 |
Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study.
Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Chlorpromazine; Dopamine Antagonists; Drug Administration Schedule; Family Practice; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Risperidone; Schizophrenia; Sex Factors | 2005 |
Second-generation antipsychotic drugs, olanzapine, quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via PI3K/AKT, ERK, and pertussis toxin-sensitive pathways.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Chromones; Clozapine; Dibenzothiazepines; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Fluphenazine; Haloperidol; Humans; Morpholines; Nerve Growth Factor; Neurites; Olanzapine; PC12 Cells; Pertussis Toxin; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quetiapine Fumarate; Rats | 2005 |
Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: dopamine D2, serotonin 2A and NK-1 receptors as examples.
Topics: Animals; Antipsychotic Agents; Aprepitant; Benzodiazepines; Brain; Chromatography, High Pressure Liquid; Clozapine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Evaluation, Preclinical; Fluorobenzenes; Gerbillinae; Haloperidol; Male; Mass Spectrometry; Morpholines; Neurokinin-1 Receptor Antagonists; Olanzapine; Piperidines; Raclopride; Rats; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Receptors, Neurokinin-1; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Tetrazoles | 2005 |
Second-generation antipsychotics and risk of cerebrovascular accidents in the elderly.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Male; Odds Ratio; Olanzapine; Risperidone; Stroke | 2005 |
Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cerebrovascular Disorders; Cohort Studies; Dementia; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Haloperidol; Hospitalization; Humans; Male; Middle Aged; Olanzapine; Patient Admission; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Retrospective Studies; Risk Factors; Risperidone; Thiazoles | 2005 |
Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Female; Haloperidol; Humans; Linear Models; Male; Meta-Analysis as Topic; Middle Aged; Olanzapine; Placebo Effect; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome; Weight Gain | 2005 |
Clozapine and olanzapine, but not haloperidol, suppress serotonin efflux in the medial prefrontal cortex elicited by phencyclidine and ketamine.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Benzodiazepines; Brain Chemistry; Clozapine; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Amino Acid Antagonists; Haloperidol; Ketamine; Male; Microdialysis; Olanzapine; Phencyclidine; Prefrontal Cortex; Rats; Rats, Wistar; Serotonin; Time Factors | 2006 |
A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Olanzapine; Psychomotor Agitation; Randomized Controlled Trials as Topic; Retrospective Studies; Schizophrenia; Schizophrenic Psychology; Time Factors | 2005 |
[Treatment resistant schizophrenia, residual subtype: symptom improvement after additional treatment with amisulpride].
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Commitment of Mentally Ill; Drug Resistance; Drug Therapy, Combination; Follow-Up Studies; Haloperidol; Homicide; Humans; Insanity Defense; Male; Olanzapine; Prisoners; Schizophrenia, Paranoid; Sulpiride; Treatment Outcome | 2006 |
Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.
Topics: Antipsychotic Agents; Belgium; Benzodiazepines; Cost of Illness; Cost-Benefit Analysis; Decision Trees; Delayed-Action Preparations; Economics, Pharmaceutical; Haloperidol; Humans; Olanzapine; Risperidone; Schizophrenia | 2005 |
Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.
Topics: Administration, Oral; Antipsychotic Agents; Benzodiazepines; Cost of Illness; Cost-Benefit Analysis; Delayed-Action Preparations; Economics, Pharmaceutical; Germany; Haloperidol; Humans; Models, Economic; Olanzapine; Quality-Adjusted Life Years; Risperidone; Schizophrenia | 2005 |
Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain-Derived Neurotrophic Factor; Chlorpromazine; Corpus Striatum; Haloperidol; Hippocampus; Male; Nerve Growth Factor; Olanzapine; Rats; Rats, Wistar; Risperidone; Time | 2006 |
Neuropeptide Y mRNA expression levels following chronic olanzapine, clozapine and haloperidol administration in rats.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Female; Haloperidol; In Situ Hybridization; Mice; Neuropeptide Y; Olanzapine; Rats; RNA, Messenger | 2006 |
Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode.
Topics: Adult; Antipsychotic Agents; Attitude to Health; Benzodiazepines; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans; Male; Models, Psychological; Olanzapine; Patient Compliance; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology | 2006 |
Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
Topics: Antipsychotic Agents; Benzodiazepines; Computer Simulation; Cost of Illness; Cost-Benefit Analysis; Dibenzothiazepines; Drug Costs; Haloperidol; Health Care Costs; Humans; Models, Econometric; Olanzapine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Thailand; Thiazoles; Treatment Outcome | 2005 |
Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration.
Topics: Adipose Tissue; Animal Feed; Animals; Antipsychotic Agents; Benzodiazepines; Eating; Haloperidol; Male; Olanzapine; Organ Size; Random Allocation; Rats; Rats, Sprague-Dawley; Thermogenesis; Weight Gain | 2006 |
Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Chlorpromazine; Clozapine; Cross-Over Studies; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Haloperidol; Lipid Peroxidation; Male; Membrane Lipids; Olanzapine; Rats; Rats, Wistar; Risperidone; Schizophrenia; Superoxide Dismutase | 2007 |
Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade: experimental evidence.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antipsychotic Agents; Avoidance Learning; Benzodiazepines; Catalepsy; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Haloperidol; Idazoxan; Male; Microdialysis; Motor Activity; Nucleus Accumbens; Olanzapine; Prefrontal Cortex; Rats; Rats, Wistar | 2007 |
Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Amenorrhea; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Clozapine; Dibenzothiazepines; Female; Galactorrhea; Gynecomastia; Haloperidol; Humans; Hyperprolactinemia; Male; Olanzapine; Piperazines; Pituitary Neoplasms; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risperidone; Sex Factors; Thiazoles; United States; United States Food and Drug Administration | 2006 |
Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat.
Topics: Algorithms; Analysis of Variance; Animals; Antipsychotic Agents; Benzodiazepines; Binding, Competitive; Cerebellum; Corpus Striatum; Dose-Response Relationship, Drug; Haloperidol; Male; Olanzapine; Raclopride; Radioligand Assay; Rats; Rats, Wistar; Receptors, Dopamine D2; Risperidone; Tritium | 2006 |
Modification of spatial recognition memory and object discrimination after chronic administration of haloperidol, amitriptyline, sodium valproate or olanzapine in normal and anhedonic rats.
Topics: Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Conditioning, Operant; Discrimination, Psychological; Dose-Response Relationship, Drug; Food Preferences; Haloperidol; Male; Maze Learning; Memory; Olanzapine; Rats; Rats, Wistar; Recognition, Psychology; Space Perception; Stress, Psychological; Taste; Valproic Acid | 2007 |
Time course of the antipsychotic effect and the underlying behavioral mechanisms.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Benzodiazepines; Brain; Brain Chemistry; Chlordiazepoxide; Conditioning, Psychological; Dose-Response Relationship, Drug; Drug Resistance; Drug Tolerance; Haloperidol; Male; Models, Animal; Olanzapine; Rats; Rats, Sprague-Dawley; Reinforcement, Psychology; Risperidone; Time Factors | 2007 |
A model for antipsychotic-induced obesity in the male rat.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Body Composition; Body Weight; Circadian Rhythm; Diet; Disease Models, Animal; Dose-Response Relationship, Drug; Eating; Feeding Behavior; Haloperidol; Male; Obesity; Olanzapine; Piperazines; Rats; Rats, Sprague-Dawley; Thiazoles; Time Factors; Weight Gain | 2006 |
Effects of clozapine, olanzapine and haloperidol on nitric oxide production by lipopolysaccharide-activated N9 cells.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Cell Line; Cell Survival; Clozapine; Haloperidol; Lipopolysaccharides; Mice; Microglia; Nitric Oxide; Nitrites; Olanzapine | 2006 |
Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein.
Topics: Animals; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzodiazepines; Chlorpromazine; Clozapine; Cyclosporins; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Interactions; Flow Cytometry; Fluorescent Dyes; Haloperidol; Isoxazoles; Kidney; Liver; LLC-PK1 Cells; Olanzapine; Paliperidone Palmitate; Pyrimidines; Quetiapine Fumarate; Rhodamine 123; Risperidone; Swine; Transfection | 2006 |
Efficacy of olanzapine and haloperidol in an animal model of mania.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Bipolar Disorder; Disease Models, Animal; Drug Evaluation; Drug Interactions; Enzyme Inhibitors; Exploratory Behavior; Haloperidol; Male; Olanzapine; Ouabain; Rats; Rats, Sprague-Dawley | 2006 |
Differential effects of haloperidol, clozapine and olanzapine on learning and memory functions in mice.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Benzodiazepines; Clozapine; Haloperidol; Learning; Maze Learning; Memory; Mice; Models, Animal; Motor Activity; Olanzapine; Swimming | 2006 |
Effect of therapy with atypical antipsychotic drugs on prolactin concentration in patients with schizophrenia and schizoaffective disorders.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Haloperidol; Humans; Immunoenzyme Techniques; Male; Middle Aged; Olanzapine; Prolactin; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Sex Factors | 2005 |
Differential effects of haloperidol and olanzapine on levels of vascular endothelial growth factor and angiogenesis in rat hippocampus.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Blotting, Western; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Fluorescent Antibody Technique; Haloperidol; Hippocampus; Immunohistochemistry; Male; Neovascularization, Physiologic; Olanzapine; Rats; Rats, Sprague-Dawley; Time Factors; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Atypical antipsychotics, tardive dyskinesia, and D(2) receptors.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Receptors, Dopamine D2; Schizophrenia; Up-Regulation | 2006 |
Parallel regulation by olanzapine of the patterns of expression of 5-HT2A and D3 receptors in rat central nervous system and blood cells.
Topics: Animals; Benzodiazepines; Blood Cells; Blotting, Northern; Central Nervous System; Dopamine Antagonists; Gene Expression Regulation; Haloperidol; Ketanserin; Lymphocytes; Male; Olanzapine; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D3; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Tritium | 2006 |
Is the superior efficacy of new generation antipsychotics an artifact of LOCF?
Topics: Amisulpride; Artifacts; Benzodiazepines; Bias; Flupenthixol; Haloperidol; Humans; Olanzapine; Patient Dropouts; Psychiatric Status Rating Scales; Psychotropic Drugs; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Sulpiride; Treatment Outcome | 2007 |
Association between the interleukin-1 receptor antagonist gene and negative symptom improvement during antipsychotic treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Genotype; Haloperidol; Humans; Interleukin 1 Receptor Antagonist Protein; Male; Olanzapine; Polymorphism, Genetic; Risperidone; Schizophrenia; Spain; Tandem Repeat Sequences; Treatment Outcome; White People | 2006 |
Differential effects of haloperidol and olanzapine on the expression of erythropoietin and its receptor in rat hippocampus and striatum.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Blotting, Western; Corpus Striatum; Dose-Response Relationship, Drug; Endothelial Cells; Erythropoietin; Gene Expression; Glial Fibrillary Acidic Protein; Haloperidol; Hippocampus; Immunohistochemistry; Male; Olanzapine; Phosphopyruvate Hydratase; Rats; Receptors, Erythropoietin | 2006 |
No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Body Weight; Clozapine; Haloperidol; Humans; Olanzapine; Protein Binding; Radioligand Assay; Receptors, Cell Surface | 2007 |
Constructing an Index for the Subjective Well-being Under Neuroleptics scale (SWN), short form: applying structural equation modeling for testing reliability and validity of the index.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Germany; Haloperidol; Humans; Models, Statistical; Olanzapine; Personal Satisfaction; Prospective Studies; Psychometrics; Schizophrenia; Surveys and Questionnaires | 2006 |
The orexin-1 receptor antagonist SB-334867 blocks the effects of antipsychotics on the activity of A9 and A10 dopamine neurons: implications for antipsychotic therapy.
Topics: Action Potentials; Analysis of Variance; Animals; Antipsychotic Agents; Benzodiazepines; Benzoxazoles; Brain; Dopamine; Drug Interactions; Haloperidol; Intracellular Signaling Peptides and Proteins; Male; Naphthyridines; Neurons; Neuropeptides; Olanzapine; Orexin Receptors; Orexins; Rats; Rats, Sprague-Dawley; Receptors, G-Protein-Coupled; Receptors, Neuropeptide; Time Factors; Urea | 2007 |
Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys.
Topics: Algorithms; Animals; Antipsychotic Agents; Benzodiazepines; Cell Count; Endothelial Cells; Haloperidol; Macaca fascicularis; Male; Neuroglia; Neurons; Olanzapine; Parietal Lobe | 2007 |
Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Excitatory Amino Acid Antagonists; Haloperidol; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Models, Animal; Motor Activity; Olanzapine; Receptors, N-Methyl-D-Aspartate; Reflex, Startle; Risperidone | 2006 |
Relative risk of glucose elevation during antipsychotic exposure in a Veterans Administration population.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Chlorpromazine; Cohort Studies; Female; Fluphenazine; Haloperidol; Hospitals, Veterans; Humans; Hyperglycemia; Incidence; Male; Middle Aged; Olanzapine; Perphenazine; Retrospective Studies; Risk Assessment; Risk Factors; Risperidone; Southeastern United States; Time Factors; Veterans | 2007 |
Cost analysis of the treatment of schizophrenia in the UK: a comparison of olanzapine and haloperidol.
Topics: Benzodiazepines; Cost-Benefit Analysis; Costs and Cost Analysis; Decision Trees; Haloperidol; Health Care Costs; Humans; Olanzapine; Schizophrenia | 1998 |
The effects of antipsychotic drugs on GABAA receptor binding depend on period of drug treatment and binding site examined.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Binding, Competitive; Flunitrazepam; GABA Agonists; GABA Modulators; Haloperidol; Humans; Long-Term Care; Male; Muscimol; Olanzapine; Prefrontal Cortex; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, GABA-A; Schizophrenia | 2007 |
Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment.
Topics: Adipocytes; Animals; Antipsychotic Agents; Benzodiazepines; Cell Size; Drug Administration Schedule; Fatty Acid Synthases; Gene Expression Regulation; Glucose Transport Proteins, Facilitative; Haloperidol; Lipid Metabolism; Male; Obesity; Olanzapine; Piperazines; Rats; Rats, Sprague-Dawley; RNA; Statistics, Nonparametric; Sterol Esterase; Thiazoles; Weight Gain | 2007 |
The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Haloperidol; Male; Mice; Neural Inhibition; Olanzapine; Phencyclidine; Piperazines; Quinolones; Receptors, Dopamine D2; Reflex, Startle; Schizophrenia | 2007 |
Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Benzodiazepines; Brain; Dose-Response Relationship, Drug; Haloperidol; Ketanserin; Male; Olanzapine; Protein Binding; Rats; Rats, Sprague-Dawley; Receptor, Muscarinic M1; Receptors, Catecholamine; Receptors, Neurotransmitter; Receptors, Serotonin, 5-HT2; Risperidone | 2007 |
Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Atrophy; Benzodiazepines; Cerebral Cortex; Child; Cognition Disorders; Disease Progression; Haloperidol; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Magnetic Resonance Imaging; Neurodegenerative Diseases; Neuroprotective Agents; Neuropsychological Tests; Olanzapine; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Schizotypal Personality Disorder | 2007 |
Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis.
Topics: Adult; Affective Disorders, Psychotic; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Haloperidol; Humans; Male; Olanzapine; Perphenazine; Psychiatric Status Rating Scales; Reference Values; Risperidone; Schizophrenia; Weight Gain | 2007 |
Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats.
Topics: Animals; Antipsychotic Agents; Attention; Benzodiazepines; Clozapine; Cognition Disorders; Dibenzothiazepines; Disease Models, Animal; Dose-Response Relationship, Drug; Hallucinogens; Haloperidol; Impulsive Behavior; Male; Olanzapine; Phencyclidine; Quetiapine Fumarate; Rats; Rats, Wistar; Reaction Time; Risperidone; Schizophrenia | 2007 |
Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body Mass Index; Body Weight; Drug Administration Schedule; Drug Therapy, Combination; Female; Haloperidol; Hospitalization; Humans; Lithium Carbonate; Male; Obesity; Olanzapine; Risperidone; Smoking; Valproic Acid | 2008 |
Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Haloperidol; Humans; Models, Theoretical; Olanzapine; Risperidone; Schizophrenia; United States | 2007 |
Effects of antipsychotic treatments and D-serine supplementation on the electrophysiological activation of midbrain dopamine neurons induced by the noncompetitive NMDA antagonist MK 801.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Dizocilpine Maleate; Dopamine; Electrophysiology; Excitatory Amino Acid Antagonists; Glycine; Haloperidol; Male; Mesencephalon; Microelectrodes; Neurons; Olanzapine; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Serine | 2007 |
Fatal hyponatremia and other metabolic disturbances associated with psychotropic drug polypharmacy.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain Edema; Fatal Outcome; Fluphenazine; Haloperidol; Heart Arrest; Humans; Hyperglycemia; Hyponatremia; Inappropriate ADH Syndrome; Male; Mental Disorders; Olanzapine; Pancreatitis; Paroxetine; Polypharmacy; Selective Serotonin Reuptake Inhibitors | 2007 |
FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Brain; Cognition Disorders; Female; Fluorodeoxyglucose F18; Frontal Lobe; Haloperidol; Humans; Magnetic Resonance Imaging; Male; Neuropsychological Tests; Occipital Lobe; Olanzapine; Positron-Emission Tomography; Psychotic Disorders; Radiopharmaceuticals; Temporal Lobe | 2007 |
Effect of antipsychotic medication use on memory in patients with Alzheimer's disease: Assessing the potential risk for accelerated recent autobiographical memory loss.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Autobiographies as Topic; Benzodiazepines; Dibenzothiazepines; Drug Monitoring; Female; Geriatric Assessment; Haloperidol; Humans; Male; Memory; Mental Status Schedule; Neuropsychological Tests; Nursing Assessment; Olanzapine; Pilot Projects; Quetiapine Fumarate; Retrospective Studies; Risk Assessment; Risk Factors; Risperidone; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2007 |
In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Coagulation; Blood Platelets; Clozapine; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; In Vitro Techniques; Male; Middle Aged; Olanzapine; Partial Thromboplastin Time; Platelet Adhesiveness; Platelet Aggregation; Prothrombin Time; Risperidone; Thromboembolism; Venous Thrombosis | 2007 |
Drug challenges reveal differences in mediation of stress facilitation of voluntary alcohol drinking and withdrawal-induced anxiety in alcohol-preferring P rats.
Topics: Alcohol Drinking; Aminopyridines; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Benzodiazepines; Buspirone; Dopamine Antagonists; Ethanol; Flumazenil; GABA Modulators; Haloperidol; Indoles; Naloxone; Narcotic Antagonists; Olanzapine; Rats; Rats, Inbred Strains; Restraint, Physical; Serotonin Receptor Agonists; Stress, Physiological; Substance Withdrawal Syndrome | 2007 |
Discontinuation of risperidone, olanzapine, and haloperidol in first-episode psychosis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Male; Olanzapine; Psychiatric Status Rating Scales; Psychotic Disorders; Retrospective Studies; Risperidone | 2007 |
The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Behavior, Animal; Benzodiazepines; Benzoxazoles; Catalepsy; Haloperidol; Intracellular Signaling Peptides and Proteins; Locomotion; Male; Naphthyridines; Neuropeptides; Olanzapine; Orexins; Prolactin; Rats; Rats, Sprague-Dawley; Risperidone; Urea | 2007 |
Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Fetal Blood; Haloperidol; Humans; Infant, Low Birth Weight; Infant, Newborn; Intensive Care Units, Neonatal; Maternal-Fetal Exchange; Olanzapine; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Prospective Studies; Psychotic Disorders; Quetiapine Fumarate; Risperidone | 2007 |
Effect of antipsychotics on succinate dehydrogenase and cytochrome oxidase activities in rat brain.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Clozapine; Electron Transport Complex IV; Energy Metabolism; Haloperidol; Male; Olanzapine; Piperazines; Quinolones; Rats; Rats, Wistar; Succinate Dehydrogenase | 2007 |
Dopamine depletion of the prefrontal cortex induces dendritic spine loss: reversal by atypical antipsychotic drug treatment.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Dendritic Spines; Dopamine; Haloperidol; Male; Neurons; Olanzapine; Oxidopamine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley | 2008 |
Risk of death associated with antipsychotic drug dispensing in residential aged care facilities.
Topics: Aged; Anticonvulsants; Antipsychotic Agents; Australia; Benzodiazepines; Carbamazepine; Cause of Death; Chlorpromazine; Comorbidity; Cross-Sectional Studies; Death, Sudden; Female; Haloperidol; Homes for the Aged; Humans; Male; Nursing Homes; Olanzapine; Risk; Valproic Acid; Veterans | 2007 |
Lu 35-138 ((+)-(S)-3-{1-[2-(1-acetyl-2,3-dihydro-1H-indol-3-yl)ethyl]-3,6-dihydro-2H-pyridin-4-yl}-6-chloro-1H-indole), a dopamine D4 receptor antagonist and serotonin reuptake inhibitor: characterisation of its in vitro profile and pre-clinical antipsych
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Animals, Outbred Strains; Benzodiazepines; Cebus; Citalopram; Clozapine; Cognition; Dihydropyridines; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Haloperidol; Haplorhini; Humans; Indoles; Male; Mice; Molecular Structure; Motor Activity; Olanzapine; Piperazines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Dopamine D4; Risperidone; Selective Serotonin Reuptake Inhibitors; Sulfonamides | 2007 |
Sensitive liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissue.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Chromatography, Liquid; Clozapine; Haloperidol; Isoxazoles; Male; Olanzapine; Paliperidone Palmitate; Piperazines; Pyrimidines; Rats; Reproducibility of Results; Risperidone; Tandem Mass Spectrometry; Thiazoles | 2007 |
Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Female; Haloperidol; In Situ Hybridization; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, Muscarinic M1; RNA, Messenger; Time | 2008 |
Retrospective database analysis on the effectiveness of typical and atypical antipsychotic drugs in an outpatient clinic setting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Databases, Factual; Female; Haloperidol; Hospitals, University; Humans; Long-Term Care; Male; Middle Aged; Olanzapine; Outpatient Clinics, Hospital; Retrospective Studies; Risperidone; Schizophrenia; Treatment Outcome; Treatment Refusal; Turkey | 2007 |
Long-term effects of JL 13, a potential atypical antipsychotic, on ionotropic glutamate receptors.
Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Autoradiography; Benzodiazepines; Brain; Caudate Nucleus; Cerebral Cortex; Clozapine; Haloperidol; Hippocampus; Male; Olanzapine; Oxazepines; Piperazines; Putamen; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Risperidone; Tritium | 2007 |
Effects of haloperidol, clozapine and olanzapine on the survival of human neuronal and immune cells in vitro.
Topics: Adenosine Triphosphate; Antipsychotic Agents; Benzodiazepines; Cell Line, Tumor; Cell Survival; Clozapine; Dose-Response Relationship, Drug; Haloperidol; Humans; Monocytes; Neurons; Olanzapine; U937 Cells | 2007 |
Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol.
Topics: Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Cognition; Cognition Disorders; Emotions; Facial Expression; Female; Haloperidol; Humans; Male; Middle Aged; Neuropsychological Tests; Olanzapine; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Social Perception; Treatment Outcome | 2007 |
Comparing adherence to and persistence with antipsychotic therapy among patients with bipolar disorder.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Databases, Factual; Dibenzothiazepines; Female; Follow-Up Studies; Haloperidol; Humans; Male; Medicaid; Middle Aged; Olanzapine; Patient Compliance; Phenothiazines; Proportional Hazards Models; Quetiapine Fumarate; Retrospective Studies; Risperidone | 2007 |
Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys.
Topics: Animals; Antipsychotic Agents; Astrocytes; Benzodiazepines; Cell Count; Haloperidol; Macaca fascicularis; Male; Olanzapine; Oligodendroglia; Parietal Lobe | 2008 |
Antipsychotic medication dispensing and risk of death in veterans and war widows 65 years and older.
Topics: Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Antipsychotic Agents; Australia; Benzodiazepines; Carbamazepine; Cause of Death; Chlorpromazine; Cohort Studies; Dementia; Female; Haloperidol; Humans; Male; Mortality; Olanzapine; Proportional Hazards Models; Retrospective Studies; Risk; Risk Factors; Survival Rate; Valproic Acid; Veterans; Widowhood | 2007 |
Antipsychotic drug administration differentially affects [3H]muscimol and [3H]flunitrazepam GABA(A) receptor binding sites.
Topics: Animals; Antipsychotic Agents; Autoradiography; Benzodiazepines; Densitometry; Flunitrazepam; Haloperidol; Hippocampus; Humans; Male; Muscimol; Olanzapine; Prefrontal Cortex; Radionuclide Imaging; Rats; Rats, Sprague-Dawley; Receptors, GABA-A; Schizophrenia; Thalamus; Tissue Distribution; Tritium | 2008 |
Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Databases, Factual; Dementia, Vascular; Dibenzothiazepines; Female; Haloperidol; Humans; Kaplan-Meier Estimate; Male; Medicare Part A; Multivariate Analysis; Olanzapine; Quetiapine Fumarate; Risk Assessment; Risk Factors; Risperidone; Treatment Outcome; United States; United States Department of Veterans Affairs; Veterans | 2007 |
Effects of chronic treatment of olanzapine and haloperidol on peptide YY binding densities in the rat brain.
Topics: Animals; Antipsychotic Agents; Autoradiography; Benzodiazepines; Brain Chemistry; Female; Haloperidol; Olanzapine; Peptide YY; Rats; Rats, Sprague-Dawley | 2008 |
Delta9-Tetrahydrocannabinol-induced cognitive deficits are reversed by olanzapine but not haloperidol in rats.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Cognition Disorders; Dronabinol; Extracellular Space; Hallucinogens; Haloperidol; Hippocampus; Humans; Male; Marijuana Abuse; Maze Learning; Memory Disorders; Microdialysis; Olanzapine; Rats; Rats, Wistar | 2008 |
Protective effects of olanzapine and haloperidol on serum withdrawal-induced apoptosis in SH-SY5Y cells.
Topics: Analysis of Variance; Antipsychotic Agents; Apoptosis; Benzodiazepines; beta Catenin; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Gene Expression Regulation; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Haloperidol; Humans; Neuroblastoma; Olanzapine; Proto-Oncogene Proteins c-bcl-2; Serum; Tetrazolium Salts; Thiazoles | 2008 |
Repeated treatment with haloperidol, but not olanzapine, alters synaptic NMDA receptor composition in rat striatum.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antipsychotic Agents; Benzodiazepines; Calcium-Calmodulin-Dependent Protein Kinase Kinase; Corpus Striatum; Drug Administration Schedule; Gene Expression Regulation; Haloperidol; Male; Membrane Proteins; Olanzapine; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Synapses; Time Factors | 2008 |
Methamphetamine psychosis in which tardive dystonia was successfully treated with clonazepam.
Topics: Aged; Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Biperiden; Central Nervous System Stimulants; Clonazepam; Dyskinesia, Drug-Induced; Hallucinations; Haloperidol; Humans; Male; Methamphetamine; Olanzapine; Posture; Psychoses, Substance-Induced; Risperidone | 2007 |
Olanzapine monotherapy for late-onset vocal tics in a schizophrenic patient.
Topics: Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Magnetic Resonance Imaging; Middle Aged; Olanzapine; Schizophrenia; Schizophrenic Psychology; Tics | 2007 |
Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Dopamine D2 Receptor Antagonists; Female; Flupenthixol; Fluphenazine; Haloperidol; Humans; Magnetic Resonance Imaging; Male; Motivation; Neostriatum; Nucleus Accumbens; Olanzapine; Oxygen; Psychomotor Performance; Reaction Time; Receptors, Dopamine D2; Reward; Schizophrenia; Schizophrenic Psychology | 2008 |
Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research.
Topics: Benzodiazepines; Case-Control Studies; Ethics, Clinical; Feasibility Studies; Haloperidol; Humans; Olanzapine; Patient Dropouts; Pilot Projects; Randomized Controlled Trials as Topic; Registries; Risperidone; Schizophrenia; Time Factors | 2008 |
Neuroleptics and animal models: feasibility of oral treatment monitored by plasma levels and receptor occupancy assays.
Topics: Administration, Oral; Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Catalepsy; Clozapine; Dose-Response Relationship, Drug; Drinking; Haloperidol; Male; Models, Animal; Olanzapine; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Time Factors | 2008 |
Three cases of schizophrenia for which olanzapine was effective after early acute phase.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; Follow-Up Studies; Gambling; Haloperidol; Humans; Japan; Male; Mental Disorders; Middle Aged; Olanzapine; Patient Admission; Patient Compliance; Risperidone; Schizophrenia, Disorganized; Schizophrenia, Paranoid; Treatment Outcome | 2008 |
Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Basal Ganglia; Behavior, Animal; Benzodiazepines; Binding, Competitive; Clozapine; Conditioning, Psychological; Dopamine Antagonists; Haloperidol; Imidazoles; Indoles; Injections, Subcutaneous; Male; Models, Biological; Olanzapine; Protein Binding; Raclopride; Rats; Rats, Wistar; Receptors, Dopamine D2; Reproducibility of Results; Risperidone | 2008 |
Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Eating; Female; Haloperidol; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Histamine H1; RNA, Messenger; Time Factors; Ventromedial Hypothalamic Nucleus; Weight Gain | 2008 |
A case of paranoid schizophrenia complicated by scleroderma with associated esophageal dysmotility.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Case Management; Commitment of Mentally Ill; Cyclophosphamide; Diagnosis, Differential; Drug Interactions; Enteral Nutrition; Esophageal Achalasia; Female; Haloperidol; Humans; Immunosuppressive Agents; Olanzapine; Patient Acceptance of Health Care; Patient Care Team; Personality Assessment; Prednisone; Referral and Consultation; Schizophrenia, Paranoid; Scleroderma, Systemic; Treatment Refusal; Weight Loss | 2008 |
Antipsychotic-induced oxidative stress in rat brain.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Clozapine; Corpus Striatum; Haloperidol; Hippocampus; Male; Olanzapine; Oxidative Stress; Piperazines; Prefrontal Cortex; Quinolones; Rats; Rats, Wistar; Superoxides; Thiobarbituric Acid Reactive Substances | 2008 |
[Prescription of traditional neuroleptics in the remission period for schizophrenic patients with excess of body mass caused by atypical antipsychotics].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Drug Prescriptions; Female; Follow-Up Studies; Haloperidol; Humans; Male; Mental Status Schedule; Olanzapine; Overweight; Risperidone; Schizophrenia; Treatment Outcome; Trifluoperazine | 2007 |
[A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
Topics: Adult; Aggression; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dibenzothiazepines; Erectile Dysfunction; Female; Galactorrhea; Gynecomastia; Haloperidol; Humans; Hungary; International Cooperation; Libido; Male; Menstruation Disturbances; Middle Aged; Olanzapine; Outpatients; Patient Admission; Patient Compliance; Prospective Studies; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index | 2007 |
Did CATIE influence antipsychotic use?
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Therapy; Haloperidol; Humans; Olanzapine; Perphenazine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles | 2008 |
[Atypical antipsychotics in elderly patients with dementia].
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Dementia; Haloperidol; Humans; Methotrimeprazine; Middle Aged; Olanzapine; Risk Factors; Risperidone; Stroke | 2008 |
Lack of effect of antipsychotics on BNDF and NGF levels in hippocampus of Wistar rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain-Derived Neurotrophic Factor; Clozapine; Drug Administration Schedule; Haloperidol; Hippocampus; Male; Nerve Growth Factor; Olanzapine; Piperazines; Quinolones; Rats; Rats, Wistar; Time; Up-Regulation | 2008 |
Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Patient Compliance; Piperazines; Quality of Life; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles | 2008 |
Clozapine and olanzapine exhibit an intrinsic anxiolytic property in two conditioned fear paradigms: contrast with haloperidol and chlordiazepoxide.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Avoidance Learning; Benzodiazepines; Chlordiazepoxide; Clozapine; Conditioning, Psychological; Dose-Response Relationship, Drug; Fear; Haloperidol; Hypnotics and Sedatives; Male; Motor Activity; Olanzapine; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Vocalization, Animal | 2008 |
Cardiovascular variability during treatment with haloperidol, olanzapine or risperidone in recent-onset schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Pressure; Electrocardiography; Female; Haloperidol; Heart Rate; Hemodynamics; Humans; Male; Olanzapine; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Sex Characteristics; Smoking; Young Adult | 2009 |
Olanzapine, but not haloperidol, enhances PSA-NCAM immunoreactivity in rat prefrontal cortex.
Topics: Analysis of Variance; Animals; Benzodiazepines; Cell Count; Dopamine Antagonists; Haloperidol; Male; Neural Cell Adhesion Molecule L1; Olanzapine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Sialic Acids | 2008 |
Haloperidol both prevents and reverses quinpirole-induced nonregulatory water intake, a putative animal model of psychogenic polydipsia.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Benzodiazepines; Clomipramine; Clozapine; Disease Models, Animal; Dose-Response Relationship, Drug; Drinking; Haloperidol; Male; Olanzapine; Piperazines; Pyrroles; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Thiazepines | 2008 |
The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Benzofurans; Benzoxazoles; Benzylamines; Blood Glucose; Clozapine; Corticosterone; Cyclopentanes; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Haloperidol; Male; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Thiazoles | 2008 |
A comparison of the discriminative stimulus properties of the atypical antipsychotic drug clozapine in DBA/2 and C57BL/6 inbred mice.
Topics: Amphetamine; Animals; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Discrimination Learning; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Haloperidol; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Olanzapine; Risperidone | 2008 |
Role of serotonin-1A receptors in the action of antipsychotic drugs: comparison of prepulse inhibition studies in mice and rats and relevance for human pharmacology.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Haloperidol; Inhibition, Psychological; Male; Mice; Mice, Inbred Strains; Olanzapine; Piperazines; Quinolones; Rats; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Reflex, Startle; Risperidone; Serotonin Receptor Agonists; Species Specificity | 2008 |
Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation.
Topics: Acetylation; Animals; Benzodiazepines; Brain; Cell Adhesion Molecules, Neuronal; Clozapine; DNA Methylation; Extracellular Matrix Proteins; Glutamate Decarboxylase; Haloperidol; Histones; Lysine; Male; Mice; Nerve Tissue Proteins; Olanzapine; Promoter Regions, Genetic; Reelin Protein; Serine Endopeptidases; Sulpiride; Valproic Acid | 2008 |
Antipsychotics possessing antidepressive efficacy increase Golf protein in rat striatum.
Topics: Amisulpride; Animals; Antipsychotic Agents; Benzodiazepines; Blotting, Western; Clozapine; Corpus Striatum; Depressive Disorder; Dose-Response Relationship, Drug; GTP-Binding Protein alpha Subunits; Haloperidol; Injections, Intraperitoneal; Male; Olanzapine; Rats; Rats, Wistar; Risperidone; Sulpiride; Time Factors | 2008 |
Coregulation of genes in the mouse brain following treatment with clozapine, haloperidol, or olanzapine implicates altered potassium channel subunit expression in the mechanism of antipsychotic drug action.
Topics: Animals; Antipsychotic Agents; Base Sequence; Benzodiazepines; Blotting, Western; Brain; Clozapine; DNA Primers; Gene Expression Profiling; Gene Expression Regulation; Haloperidol; Male; Mice; Mice, Inbred C57BL; Models, Animal; Olanzapine; Oligonucleotide Array Sequence Analysis; Potassium Channels; Reverse Transcriptase Polymerase Chain Reaction | 2008 |
Antipsychotic drugs modulate Arc expression in the rat brain.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain Chemistry; Cytoskeletal Proteins; Dibenzothiazepines; Glyceraldehyde-3-Phosphate Dehydrogenases; Haloperidol; Male; Neostriatum; Nerve Tissue Proteins; Nuclease Protection Assays; Olanzapine; Prefrontal Cortex; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; RNA; RNA Probes; RNA, Messenger | 2009 |
Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting.
Topics: Administration, Intranasal; Animals; Antipsychotic Agents; Benzodiazepines; Brain; Drug Delivery Systems; Emulsions; Haloperidol; Injections, Intravenous; Male; Nanostructures; Olanzapine; Rats | 2008 |
Antipsychotic drugs inhibit nucleotide hydrolysis in zebrafish (Danio rerio) brain membranes.
Topics: 5'-Nucleotidase; Animals; Antipsychotic Agents; Benzodiazepines; Brain; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Haloperidol; Hydrolysis; Intracellular Membranes; Male; Nucleoside-Triphosphatase; Olanzapine; Sulpiride; Zebrafish | 2009 |
Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Cost of Illness; Dibenzothiazepines; Female; Follow-Up Studies; Haloperidol; Humans; Kaplan-Meier Estimate; Long-Term Care; Male; Middle Aged; Olanzapine; Prospective Studies; Psychiatric Status Rating Scales; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2008 |
Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Belgium; Benzodiazepines; Brief Psychiatric Rating Scale; Dyskinesia, Drug-Induced; Female; Haloperidol; Health Care Costs; Hospitalization; Humans; Male; Olanzapine; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Weight Gain | 2009 |
Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation.
Topics: Acute Disease; Administration, Oral; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Bipolar Disorder; Clopenthixol; Cross-Cultural Comparison; Female; Haloperidol; Hospitalization; Humans; Injections, Intramuscular; Male; Olanzapine; Psychiatric Status Rating Scales; Psychomotor Agitation; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2009 |
Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Cytokines; Haloperidol; Interleukin-10; Interleukin-6; Lipopolysaccharides; Male; Mice; Mice, Inbred BALB C; Olanzapine; Poly I-C; Risperidone; Serotonin Antagonists; Tumor Necrosis Factor-alpha | 2009 |
[The possibility of high-quality remission in the long chronic course of schizophrenia].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Disease Progression; Drug Therapy, Combination; Haloperidol; Hospitalization; Humans; Male; Olanzapine; Remission Induction; Schizophrenia; Schizophrenic Psychology | 2008 |
[Depression in schizophrenia].
Topics: Acute Disease; Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Data Interpretation, Statistical; Depressive Disorder; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Olanzapine; Psychometrics; Schizophrenia; Statistics, Nonparametric; Treatment Outcome | 2008 |
Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Brain; Caudate Nucleus; Dopamine; Dopamine Plasma Membrane Transport Proteins; Gene Expression Regulation, Enzymologic; Haloperidol; Limbic System; Nucleus Accumbens; Olanzapine; Piperazines; Putamen; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; RNA, Messenger; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase; Up-Regulation; Ventral Tegmental Area | 2009 |
Effects of antipsychotics and vitamin C on the formation of reactive oxygen species.
Topics: Animals; Antioxidants; Antipsychotic Agents; Ascorbic Acid; Benzodiazepines; Blood; Clozapine; Electron Spin Resonance Spectroscopy; Haloperidol; Olanzapine; Osmolar Concentration; Oxidative Stress; Rats; Reactive Oxygen Species | 2010 |
An investigation of the behavioral mechanisms of antipsychotic action using a drug-drug conditioning paradigm.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Benzodiazepines; Chlordiazepoxide; Conditioning, Psychological; Cues; Drug Interactions; Haloperidol; Male; Olanzapine; Rats; Rats, Sprague-Dawley | 2009 |
Avoidance-suppressing effect of antipsychotic drugs is progressively potentiated after repeated administration: an interoceptive drug state mechanism.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Benzodiazepines; Conditioning, Operant; Dose-Response Relationship, Drug; Haloperidol; Injections, Subcutaneous; Male; Memory; Olanzapine; Psychotropic Drugs; Rats; Rats, Sprague-Dawley; Risperidone | 2010 |
Haloperidol changes mRNA expression of a QKI splice variant in human astrocytoma cells.
Topics: Alternative Splicing; Antipsychotic Agents; Aripiprazole; Astrocytoma; Benzodiazepines; Cell Line, Tumor; Clozapine; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Haloperidol; Humans; Olanzapine; Piperazines; Quinolones; Receptors, Dopamine D2; Reverse Transcriptase Polymerase Chain Reaction; Risperidone; RNA-Binding Proteins; RNA, Messenger; Time Factors | 2009 |
Antipsychotic treatment alters protein expression associated with presynaptic function and nervous system development in rat frontal cortex.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Chromatography, Liquid; Detergents; Frontal Lobe; Haloperidol; Male; Mass Spectrometry; Nervous System; Olanzapine; Proteomics; Rats; Rats, Wistar; Synaptic Transmission | 2009 |
Typical and atypical antipsychotics alter acetylcholinesterase activity and ACHE expression in zebrafish (Danio rerio) brain.
Topics: Acetylcholinesterase; Animals; Antipsychotic Agents; Benzodiazepines; Brain; Dose-Response Relationship, Drug; Enzyme Activation; Female; Gene Expression Regulation, Enzymologic; Haloperidol; Male; Olanzapine; Zebrafish | 2009 |
Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Aripiprazole; Benzamides; Benzodiazepines; Benzoxazoles; Catalepsy; Clozapine; Dibenzothiazepines; Dioxanes; Dopamine Antagonists; Female; Haloperidol; Macaca fascicularis; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Remoxipride; Risperidone; Serotonin Receptor Agonists; Thiazoles; Tropanes; Video Recording | 2009 |
Targeting cognition in schizophrenia research: from etiology to treatment.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Cognition; Cognition Disorders; Dibenzothiazepines; Drug Administration Schedule; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Reaction Time; Schizophrenia; Sulpiride; Thiazoles | 2009 |
Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population.
Topics: Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Dibenzothiazepines; Dyslipidemias; Female; Haloperidol; Humans; Hypertriglyceridemia; Male; Olanzapine; Quetiapine Fumarate; Retrospective Studies; Risk Assessment; Risperidone; Time Factors; United States; United States Department of Veterans Affairs | 2009 |
Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine.
Topics: Adult; Antipsychotic Agents; Benzamides; Benzodiazepines; Clozapine; Female; Haloperidol; Humans; Iodine Radioisotopes; Male; Mesencephalon; Middle Aged; Olanzapine; Pyrrolidines; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia; Temporal Lobe; Tomography, Emission-Computed, Single-Photon | 2009 |
Prefrontal cortex and reversion of atropine-induced disruption of the degraded contingency effect by antipsychotic agents and N-desmethylclozapine in rats.
Topics: Animals; Antipsychotic Agents; Atropine; Benzodiazepines; Clozapine; Conditioning, Classical; Drug Interactions; Haloperidol; Male; Muscarinic Antagonists; Olanzapine; Prefrontal Cortex; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley | 2010 |
Early perturbation in feeding behaviour and energy homeostasy in olanzapine-treated rats.
Topics: Adiposity; Animals; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Eating; Energy Metabolism; Feeding Behavior; Glucose Tolerance Test; Haloperidol; Male; Olanzapine; Rats; Rats, Sprague-Dawley; Schizophrenic Psychology; Time Factors; Weight Gain | 2009 |
Intramuscular haloperidol versus intramuscular olanzapine for treatment of acute agitation: a cost-minimization study.
Topics: Acute Disease; Adult; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Cohort Studies; Combined Modality Therapy; Drug Costs; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Olanzapine; Patient Isolation; Practice Patterns, Physicians'; Psychomotor Agitation; Restraint, Physical; Time Factors | 2009 |
Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System.
Topics: Antipsychotic Agents; Benzodiazepines; Brazil; Cost-Benefit Analysis; Drug Costs; Haloperidol; Humans; Markov Chains; Medication Adherence; Olanzapine; Quality of Life; Quality-Adjusted Life Years; Recurrence; Risperidone; Schizophrenia | 2009 |
The effects of the second generation antipsychotics and a typical neuroleptic on collagen-induced platelet aggregation in vitro.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Collagen; Female; Haloperidol; Humans; In Vitro Techniques; Male; Olanzapine; Platelet Activation; Platelet Aggregation; Risperidone | 2010 |
Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors.
Topics: Analysis of Variance; Animals; Behavior, Animal; Benzodiazepines; Dopamine Antagonists; Drug Interactions; Female; Haloperidol; Histamine H1 Antagonists; Indoles; Olanzapine; Pyridines; Pyrilamine; Rats; Receptor, Serotonin, 5-HT2C; Receptors, Histamine H1; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Agonists; Time Factors; Weight Gain | 2009 |
Fatal pulmonary embolism following antipsychotic treatment and physical restraint.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Fatal Outcome; Female; Haloperidol; Heart Arrest; Heart Failure; Humans; Hypnotics and Sedatives; Lorazepam; Olanzapine; Practice Guidelines as Topic; Pulmonary Artery; Pulmonary Embolism; Restraint, Physical; Schizophrenia, Paranoid; Venous Thromboembolism | 2009 |
[Complex therapy of schizophrenia].
Topics: Adolescent; Adult; Antipsychotic Agents; Art Therapy; Benzodiazepines; Clinical Trials as Topic; Clozapine; Cognitive Behavioral Therapy; Combined Modality Therapy; Dance Therapy; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Middle Aged; Music Therapy; Occupational Therapy; Olanzapine; Psychotherapy; Quetiapine Fumarate; Retrospective Studies; Risperidone; Schizophrenia; Schizophrenic Psychology; Single-Blind Method; Suicide; Treatment Outcome; Young Adult | 2009 |
Different antipsychotics elicit different effects on magnocellular oxytocinergic and vasopressinergic neurons as revealed by Fos immunohistochemistry.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Haloperidol; Hypothalamus; Immunohistochemistry; Male; Neurons; Olanzapine; Oxytocin; Paraventricular Hypothalamic Nucleus; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Risperidone; Supraoptic Nucleus; Vasopressins | 2010 |
The effects of antipsychotic drugs administration on 5-HT1A receptor expression in the limbic system of the rat brain.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Binding Sites; Female; Haloperidol; Limbic System; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Serotonin, 5-HT1; RNA, Messenger | 2009 |
Early exposure to haloperidol or olanzapine induces long-term alterations of dendritic form.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Benzodiazepines; Cell Shape; Dendrites; Female; Frontal Lobe; Haloperidol; Mice; Neuronal Plasticity; Neurons; Nucleus Accumbens; Olanzapine; Parietal Lobe; Silver Staining; Time | 2010 |
Antipsychotic-induced gene regulation in multiple brain regions.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Gene Expression Profiling; Gene Expression Regulation; Haloperidol; Male; Neurotransmitter Agents; Olanzapine; Oligonucleotide Array Sequence Analysis; Rats; Rats, Sprague-Dawley; Receptors, G-Protein-Coupled; Signal Transduction; Transcription Factors | 2010 |
Expression changes of serotonin receptor gene subtype 5HT3a in peripheral blood mononuclear cells from schizophrenic patients treated with haloperidol and Olanzapin.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Leukocytes, Mononuclear; Olanzapine; Receptors, Serotonin, 5-HT3; Schizophrenia | 2009 |
Characteristics and mortality among hospitalized patients treated with intramuscular antipsychotics: analysis of a United States hospital database.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Databases, Factual; Female; Haloperidol; Hospital Mortality; Humans; Injections, Intramuscular; Male; Olanzapine; Piperazines; Thiazoles; United States; Young Adult | 2010 |
Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Brain-Derived Neurotrophic Factor; Case-Control Studies; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Risperidone; Schizophrenia; Sulpiride; Treatment Failure | 2010 |
The first- and second-generation antipsychotic drugs affect ADP-induced platelet aggregation.
Topics: Adenosine Diphosphate; Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Haloperidol; Humans; Male; Olanzapine; Platelet Activation; Platelet Aggregation; Risperidone | 2010 |
Haloperidol induces higher Homer1a expression than risperidone, olanzapine and sulpiride in striatal sub-regions.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain Mapping; Carrier Proteins; Corpus Striatum; Gene Expression Regulation; Haloperidol; Homer Scaffolding Proteins; Male; Olanzapine; Random Allocation; Rats; Rats, Sprague-Dawley; Risperidone; RNA, Messenger; Sulpiride | 2010 |
Comparison of short-acting intramuscular antipsychotic medication: impact on length of stay and cost.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cohort Studies; Drug Costs; Female; Haloperidol; Humans; Injections, Intramuscular; Length of Stay; Male; Middle Aged; Olanzapine; Piperazines; Psychomotor Agitation; Quinolones; Retrospective Studies; Schizophrenia; Thiazoles | 2011 |
Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Carbon Radioisotopes; Cerebellar Cortex; Cerebral Cortex; Computer Graphics; Dopamine Antagonists; Dose-Response Relationship, Drug; Haloperidol; Humans; Hyperprolactinemia; Male; Mathematical Computing; Middle Aged; Olanzapine; Pituitary Gland; Positron-Emission Tomography; Prolactin; Pyrrolidines; Receptors, Dopamine D2; Risperidone; Salicylamides; Schizophrenia; Statistics as Topic; Sulpiride; Temporal Lobe; Young Adult | 2010 |
In vivo temporal EPR study using a region-selected intensity determination method to estimate cerebral reducing ability in rats treated with olanzapine.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Blood-Brain Barrier; Cerebral Cortex; Corpus Striatum; Cyclic N-Oxides; Electron Spin Resonance Spectroscopy; Half-Life; Haloperidol; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Magnetic Resonance Spectroscopy; Male; Models, Animal; Olanzapine; Oxidation-Reduction; Prefrontal Cortex; Pyrrolidines; Rats; Rats, Wistar | 2010 |
The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro.
Topics: Animals; Antipsychotic Agents; Autoradiography; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Haloperidol; Humans; In Vitro Techniques; Male; Olanzapine; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Risperidone; Tritium; Vitamin K 1 | 2010 |
Disruption of conditioned reward association by typical and atypical antipsychotics.
Topics: Animals; Antipsychotic Agents; Association Learning; Benzodiazepines; Conditioning, Operant; Haloperidol; Male; Olanzapine; Rats; Rats, Sprague-Dawley; Reward | 2010 |
Acute respiratory distress due to antipsychotic drugs.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Drug Therapy, Combination; Dystonia; Fatal Outcome; Haloperidol; Humans; Larynx; Male; Olanzapine; Respiratory Distress Syndrome; Respiratory Insufficiency; Risperidone; Schizophrenia | 2010 |
Atypical anti-psychotics in delusional parasitosis: a retrospective case series of 20 patients.
Topics: Antipsychotic Agents; Benzodiazepines; Ectoparasitic Infestations; Female; Fluoxetine; Haloperidol; Humans; Imipramine; Male; Middle Aged; Olanzapine; Pimozide; Retrospective Studies; Risperidone; Schizophrenia, Paranoid; Sertraline | 2010 |
Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia?
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Comorbidity; Dementia; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Olanzapine; Proportional Hazards Models; Quetiapine Fumarate; Retrospective Studies; Risk Factors; Risperidone; Sex Factors; Veterans | 2010 |
Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Carnitine; Clozapine; Energy Metabolism; Fatty Acids, Nonesterified; Female; Haloperidol; Insulin Resistance; Lipolysis; Male; Malonyl Coenzyme A; Mice; Olanzapine; Piperazines; Rats; Rats, Sprague-Dawley; Risperidone; Thiazoles; Vitamin B Complex | 2012 |
A prospective longitudinal study of cholesterol and aggression in patients randomized to clozapine, olanzapine, and haloperidol.
Topics: Aggression; Benzodiazepines; Cholesterol; Clozapine; Cross-Sectional Studies; Double-Blind Method; Haloperidol; Humans; Longitudinal Studies; Olanzapine; Prospective Studies; Randomized Controlled Trials as Topic | 2010 |
Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics.
Topics: Adult; Antioxidants; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Glutathione Peroxidase; Haloperidol; Humans; Lipid Peroxidation; Malondialdehyde; Middle Aged; Olanzapine; Oxidative Stress; Quetiapine Fumarate; Risperidone; Schizophrenia; Superoxide Dismutase | 2010 |
Olanzapine-induced accumulation of adipose tissue is associated with an inflammatory state.
Topics: Adipose Tissue; Analysis of Variance; Animals; Antipsychotic Agents; Benzodiazepines; Cytokines; Glucose; Haloperidol; Immunoassay; Inflammation; Insulin Resistance; Leptin; Lipid Metabolism; Liver; Male; Olanzapine; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
Distinct neural mechanisms underlying acute and repeated administration of antipsychotic drugs in rat avoidance conditioning.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Benzodiazepines; Clozapine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drug Administration Schedule; Haloperidol; Male; Olanzapine; Rats; Rats, Sprague-Dawley; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists | 2010 |
Extrapyramidal side-effects and dopamine D(2/3) receptor binding in substantia nigra.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain Mapping; Clozapine; Female; Haloperidol; Humans; Magnetic Resonance Imaging, Interventional; Male; Olanzapine; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia; Substantia Nigra; Tomography, Emission-Computed, Single-Photon | 2010 |
Olanzapine increases cell mitotic activity and oligodendrocyte-lineage cells in the hypothalamus.
Topics: Adipocytes; Animals; Antimetabolites; Antipsychotic Agents; Benzodiazepines; Biomarkers; Body Temperature; Body Weight; Bromodeoxyuridine; Cell Lineage; Cell Proliferation; Cell Size; Eating; Energy Metabolism; Female; Haloperidol; Hypothalamus; Immunohistochemistry; Mice; Mice, Inbred C57BL; Mitosis; Motor Activity; Olanzapine; Oligodendroglia | 2010 |
Identification and quantification of 30 antipsychotics in blood using LC-MS/MS.
Topics: Analysis of Variance; Antipsychotic Agents; Autopsy; Benzodiazepines; Butyrophenones; Calibration; Chemical Fractionation; Chromatography, High Pressure Liquid; Drug Stability; Haloperidol; Humans; Linear Models; Olanzapine; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2010 |
Alterations in metabotropic glutamate receptor 1α and regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Lipoprotein Lipase; Macaca fascicularis; Male; Middle Aged; Monoacylglycerol Lipases; Olanzapine; Prefrontal Cortex; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; RGS Proteins; Schizophrenia | 2010 |
Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzodiazepines; Choice Behavior; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Glutamic Acid; Haloperidol; Impulsive Behavior; Male; Microdialysis; Neuropsychological Tests; Olanzapine; Piperazines; Prefrontal Cortex; Quinolones; Rats; Reaction Time; Schizophrenia; Serotonin; Time Factors | 2011 |
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 3. Rapid tranquilisation in acute psychotic agitation.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Emergencies; Emergency Medicine; Emergency Service, Hospital; Evidence-Based Medicine; Haloperidol; Humans; Injections, Intramuscular; Olanzapine; Psychomotor Agitation; Schizophrenia; Treatment Outcome; United Kingdom; Young Adult | 2011 |
Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study.
Topics: Adolescent; Adult; Affect; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Psychotic Disorders; Receptors, Dopamine D2; Risperidone; Schizophrenia; Self Report; Severity of Illness Index; Young Adult | 2011 |
Protective effects of atypical antipsychotic drugs against MPP(+)-induced oxidative stress in PC12 cells.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antipsychotic Agents; Aripiprazole; bcl-2-Associated X Protein; Benzodiazepines; Blotting, Western; Cell Survival; Haloperidol; Herbicides; Olanzapine; Oxidative Stress; PC12 Cells; Piperazines; Quinolones; Rats; Reactive Oxygen Species; Superoxide Dismutase; Thiazoles | 2011 |
Quetiapine, olanzapine and haloperidol affect human plasma lipid peroxidation in vitro.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Haloperidol; Humans; In Vitro Techniques; Lipid Peroxidation; Male; Olanzapine; Plasma; Quetiapine Fumarate; Spectrophotometry; Thiobarbituric Acid Reactive Substances | 2011 |
Folie à deux: double case-report of shared delusions with a fatal outcome.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Clozapine; Combined Modality Therapy; Epilepsy; Fatal Outcome; Female; Haloperidol; Humans; Nordazepam; Olanzapine; Patient Compliance; Psychotherapy; Psychotic Disorders; Schizophrenia, Paranoid; Shared Paranoid Disorder; Sibling Relations; Suicide; Valproic Acid | 2011 |
Differential effects of antipsychotic medications on polyunsaturated fatty acid biosynthesis in rats: Relationship with liver delta6-desaturase expression.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Drinking Water; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Fatty Acids, Unsaturated; Haloperidol; Isoxazoles; Linoleoyl-CoA Desaturase; Liver; Male; Olanzapine; Paliperidone Palmitate; Pyrimidines; Quetiapine Fumarate; Rats; Rats, Long-Evans; Risperidone; RNA, Messenger | 2011 |
A comparison of the safety of olanzapine and haloperidol in combination with benzodiazepines in emergency department patients with acute agitation.
Topics: Acute Disease; Adult; Alcoholic Intoxication; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Blood Pressure; Drug Interactions; Drug Therapy, Combination; Emergency Service, Hospital; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Oxygen; Psychomotor Agitation; Retrospective Studies | 2012 |
Hypersexual features in Huntington's disease.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Huntington Disease; Olanzapine; Sexual Behavior; Sexual Dysfunction, Physiological; Sexual Dysfunctions, Psychological; Treatment Outcome | 2011 |
Antagonist functional selectivity: 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo.
Topics: Animals; Behavior, Animal; Benzodiazepines; Blotting, Western; Clozapine; Dopamine Antagonists; Dose-Response Relationship, Drug; Haloperidol; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Motor Activity; Olanzapine; Phencyclidine; Radioligand Assay; Receptor, Serotonin, 5-HT2A; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Antagonists; Serotonin Receptor Agonists; Stereotyped Behavior; Up-Regulation | 2011 |
A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cost-Benefit Analysis; Economics, Pharmaceutical; Female; Haloperidol; Humans; Imidazoles; Indoles; Male; Models, Economic; National Health Programs; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia; Sweden | 2011 |
Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Databases, Factual; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Administration Routes; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pharmacovigilance; Quetiapine Fumarate; Risk Factors; World Health Organization | 2011 |
Cortical opioid markers in schizophrenia and across postnatal development.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Enkephalins; Female; Haloperidol; Humans; Macaca fascicularis; Male; Middle Aged; Olanzapine; Polymerase Chain Reaction; Prefrontal Cortex; Protein Precursors; Receptors, Opioid, delta; Receptors, Opioid, mu; RNA, Messenger; Schizophrenia | 2012 |
Olanzapine stimulates proliferation but inhibits differentiation in rat oligodendrocyte precursor cell cultures.
Topics: Animals; Benzodiazepines; Cell Differentiation; Cell Proliferation; Cells, Cultured; Haloperidol; Neural Stem Cells; Olanzapine; Oligodendroglia; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors | 2011 |
Effects of antipsychotics with different weight gain liabilities on human in vitro models of adipose tissue differentiation and metabolism.
Topics: Adipocytes; Adipogenesis; Adipose Tissue; Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Haloperidol; Humans; Olanzapine; Piperazines; Thiazoles; Weight Gain | 2011 |
[Clinical characteristics of cannabis-induced schizophrenia spectrum disorder].
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Hallucinations; Haloperidol; Humans; Hungary; Male; Marijuana Abuse; Olanzapine; Paranoid Disorders; Piperazines; Psychomotor Performance; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risperidone; Schizophrenia; Schizophrenic Psychology | 2011 |
Effects of antipsychotic drugs on BDNF, GSK-3β, and β-catenin expression in rats subjected to immobilization stress.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; beta Catenin; Blotting, Western; Brain-Derived Neurotrophic Factor; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Haloperidol; Hippocampus; Male; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Restraint, Physical; Schizophrenia; Stress, Psychological | 2011 |
Continuation of ECT after recovery from transient, ECT-induced, postictal cortical blindness.
Topics: Adolescent; Anti-Dyskinesia Agents; Antipsychotic Agents; Atropine; Benzodiazepines; Blindness, Cortical; Electroconvulsive Therapy; Female; Glycopyrrolate; Haloperidol; Humans; Muscarinic Antagonists; Olanzapine; Panic; Schizophrenia, Paranoid; Treatment Outcome; Trihexyphenidyl | 2012 |
Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antipsychotic Agents; Avoidance Learning; Benzodiazepines; Catalepsy; Drug Synergism; Glutamic Acid; Glycine Plasma Membrane Transport Proteins; Haloperidol; Male; Membrane Potentials; Olanzapine; Oxadiazoles; Piperidines; Prefrontal Cortex; Rats; Rats, Wistar; Receptors, AMPA; Risperidone; Synaptic Transmission; Tetrahydronaphthalenes | 2012 |
MK-801 alters Na+, K+-ATPase activity and oxidative status in zebrafish brain: reversal by antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain Chemistry; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Female; Fluoresceins; Haloperidol; Lipid Peroxidation; Male; Membranes; Nerve Tissue Proteins; Olanzapine; Oxidative Stress; Reactive Nitrogen Species; Reactive Oxygen Species; Sodium-Potassium-Exchanging ATPase; Sulpiride; Thiobarbituric Acid Reactive Substances; Zebrafish | 2012 |
Contextual and behavioral control of antipsychotic sensitization induced by haloperidol and olanzapine.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Benzodiazepines; Conditioning, Psychological; Dose-Response Relationship, Drug; Haloperidol; Male; Motor Activity; Olanzapine; Phencyclidine; Rats; Rats, Sprague-Dawley | 2012 |
Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Medical Records; Olanzapine; Perphenazine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Sulpiride; Thiazoles; Time Factors; Treatment Outcome | 2011 |
Risk of mortality among individual antipsychotics in patients with dementia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Dementia; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Olanzapine; Propensity Score; Quetiapine Fumarate; Retrospective Studies; Risk; Risperidone; Time Factors; Valproic Acid | 2012 |
Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs.
Topics: Adult; Amisulpride; Analysis of Variance; Antipsychotic Agents; Attention; Benzodiazepines; Dibenzothiazepines; Emotions; Fluphenazine; Haloperidol; Humans; Memory; Middle Aged; Olanzapine; Perazine; Perphenazine; Quetiapine Fumarate; Recognition, Psychology; Risperidone; Schizophrenia; Sulpiride | 2012 |
Perphenazine suspension: a new, old treatment, side effects and continuous use.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Clinical Trials as Topic; Drug Compounding; Drug Delivery Systems; Female; Fluphenazine; Haloperidol; Hospitals, Psychiatric; Humans; Male; Movement Disorders; Olanzapine; Patient Discharge; Perphenazine; Risperidone; Suspensions; Treatment Outcome | 2012 |
Effectiveness of sulpiride in adult patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Proportional Hazards Models; Retrospective Studies; Risperidone; Schizophrenia; Sulpiride; Treatment Outcome; Young Adult | 2013 |
Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Benzodiazepines; Brain; Catalepsy; Cells, Cultured; CHO Cells; Cricetinae; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Female; Haloperidol; Humans; Ligands; Locomotion; Male; Olanzapine; Piperidines; Prolactin; Pyridazines; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Dopamine D2; Schizophrenia; Serotonin | 2012 |
A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emergency Service, Hospital; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Medical Records; Middle Aged; Olanzapine; Psychomotor Agitation; Retrospective Studies; Substance-Related Disorders | 2012 |
Reduction in tardive dyskinesia symptoms during treatment with olanzapine or haloperidol.
Topics: Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Drug Monitoring; Haloperidol; Humans; Middle Aged; Olanzapine; Psychotic Disorders; Randomized Controlled Trials as Topic; Retrospective Studies; Schizophrenia; Severity of Illness Index; Time Factors; Young Adult | 2012 |
A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Attention; Benzodiazepines; Body Weight; Cocaine; Conditioning, Operant; Depression; Disease Models, Animal; Dopamine Uptake Inhibitors; Electroencephalography; Hallucinogens; Haloperidol; Humans; Macaca fascicularis; Magnetic Resonance Imaging; Male; Mental Recall; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microinjections; Motor Activity; Mutation; Olanzapine; Oocytes; Oxazoles; Phencyclidine; Phenethylamines; Protein Binding; Pyrrolidinones; Rats; Rats, Wistar; Receptors, G-Protein-Coupled; Reinforcement, Psychology; Schizophrenia; Swimming; Telemetry; Tritium; Xenopus | 2013 |
Parametric studies of antipsychotic-induced sensitization in the conditioned avoidance response model: roles of number of drug exposure, drug dose, and test-retest interval.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Benzodiazepines; Conditioning, Psychological; Dose-Response Relationship, Drug; Haloperidol; Male; Olanzapine; Rats; Rats, Sprague-Dawley; Time Factors | 2012 |
Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophrenia.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Benzodiazepines; Citalopram; Conditioning, Psychological; Disease Models, Animal; Drug Interactions; Drug Therapy, Combination; Haloperidol; Male; Olanzapine; Polypharmacy; Random Allocation; Rats; Rats, Sprague-Dawley; Schizophrenia | 2012 |
Nitric oxide in patients with schizophrenia: the relationship with the severity of illness and the antipsychotic treatment.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Female; Haloperidol; Humans; Male; Middle Aged; Nitrates; Nitric Oxide; Olanzapine; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Severity of Illness Index; Young Adult | 2012 |
Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: implications for substance abuse in schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Conditioning, Classical; Cues; Diagnosis, Dual (Psychiatry); Dopamine; Dopamine Agents; Drug-Seeking Behavior; Haloperidol; Male; Motivation; Neostriatum; Olanzapine; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Reward; Schizophrenia; Schizophrenic Psychology; Substance-Related Disorders | 2013 |
Clozapine regulation of p90RSK and c-Fos signaling via the ErbB1-ERK pathway is distinct from olanzapine and haloperidol in mouse cortex and striatum.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Clozapine; Corpus Striatum; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Haloperidol; Mice; Olanzapine; Phosphorylation; Proto-Oncogene Proteins c-fos; Ribosomal Protein S6 Kinases, 90-kDa; Signal Transduction | 2013 |
Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Benzodiazepines; Glycogen Synthase Kinase 3; Haloperidol; Insulin; Insulin Receptor Substrate Proteins; Intra-Abdominal Fat; Liver; Magnetic Resonance Imaging; Male; Models, Animal; Olanzapine; Phosphorylation; Rats; Rats, Sprague-Dawley | 2013 |
Consensus statement on the use of intramuscular aripiprazole for the rapid control of agitation in bipolar mania and schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Haloperidol; Humans; Hypnotics and Sedatives; Olanzapine; Piperazines; Psychomotor Agitation; Quinolones; Schizophrenia; Tranquilizing Agents | 2013 |
Atypical neuroleptic malignant syndrome in H1N1 pneumonia.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Creatine Kinase; Haloperidol; Humans; Influenza A Virus, H1N1 Subtype; Male; Middle Aged; Neuroleptic Malignant Syndrome; Olanzapine; Pneumonia, Viral; Schizophrenia; Treatment Outcome; Valproic Acid; Withholding Treatment | 2013 |
White-matter microstructure in previously drug-naive patients with schizophrenia after 6 weeks of treatment.
Topics: Adolescent; Adult; Anisotropy; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Brain Mapping; Case-Control Studies; Dibenzothiazepines; Diffusion Tensor Imaging; Female; Frontal Lobe; Gyrus Cinguli; Haloperidol; Humans; Image Processing, Computer-Assisted; Male; Nerve Fibers, Myelinated; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride; Treatment Outcome; Young Adult | 2013 |
Psychotic disorder after contact with a potentially rabid animal and post-exposure prophylactic anti-rabies treatment.
Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Clonazepam; Diagnosis, Differential; Dibenzothiazepines; Female; Haloperidol; Humans; Lorazepam; Olanzapine; Psychotic Disorders; Quetiapine Fumarate; Rabies; Rabies Vaccines; Young Adult | 2014 |
Adherence challenges and long-acting injectable antipsychotic treatment in patients with schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Fluphenazine; Haloperidol; Humans; Injections; Isoxazoles; Medication Adherence; Olanzapine; Paliperidone Palmitate; Palmitates; Risperidone; Schizophrenia | 2013 |
Endocannabinoid metabolism in the prefrontal cortex in schizophrenia.
Topics: Adolescent; Adult; Age Factors; Animals; Antipsychotic Agents; Benzodiazepines; Berberine; Calcium Channel Blockers; Endocannabinoids; Female; Gene Expression Regulation; Haloperidol; Humans; Macaca fascicularis; Male; Middle Aged; Monoacylglycerol Lipases; Olanzapine; Prefrontal Cortex; Schizophrenia; Young Adult | 2013 |
Opposite effects of typical and atypical anti-psychotic drugs on sensitized dopamine receptors: sub-chronic low dose Olanzapine exposure reverses sensitization but a similar regimen of low dose haloperidol potentiates sensitization effects.
Topics: Animals; Antipsychotic Agents; Apomorphine; Benzodiazepines; Conditioning, Psychological; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Haloperidol; Male; Olanzapine; Rats; Rats, Wistar | 2013 |
Antipsychotics promote the differentiation of oligodendrocyte progenitor cells by regulating oligodendrocyte lineage transcription factors 1 and 2.
Topics: 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase; Animals; Antipsychotic Agents; Basic Helix-Loop-Helix Transcription Factors; Benzodiazepines; Cell Differentiation; Cell Line; Cell Proliferation; Dibenzothiazepines; Gene Expression; Haloperidol; Humans; Mice; Nerve Tissue Proteins; Neural Stem Cells; Olanzapine; Oligodendrocyte Transcription Factor 2; Oligodendroglia; Quetiapine Fumarate; Rats; Schizophrenia | 2013 |
Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Delirium; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Prospective Studies; Quetiapine Fumarate; Risperidone; Treatment Outcome | 2013 |
Effect of olanzapine on scopolamine induced deficits in differential reinforcement of low rate 72s (DRL-72s) schedule in rats: involvement of the serotonergic receptors in restoring the deficits.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Cholinesterase Inhibitors; Conditioning, Operant; Donepezil; Haloperidol; Impulsive Behavior; Indans; Male; Muscarinic Antagonists; Olanzapine; Piperidines; Quinolines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Reinforcement, Psychology; Scopolamine; Serotonin Antagonists; Sulfones | 2013 |
Reduced cortical volume and elevated astrocyte density in rats chronically treated with antipsychotic drugs-linking magnetic resonance imaging findings to cellular pathology.
Topics: Animals; Antipsychotic Agents; Astrocytes; Atrophy; Benzodiazepines; Cell Count; Cerebral Cortex; Haloperidol; Magnetic Resonance Imaging; Male; Neuroimaging; Neurons; Olanzapine; Rats | 2014 |
Elevated viral restriction factor levels in cortical blood vessels in schizophrenia.
Topics: Adult; Animals; Antigens, Differentiation; Antipsychotic Agents; Benzodiazepines; Female; GABAergic Neurons; Haloperidol; Humans; Macaca fascicularis; Male; Middle Aged; Olanzapine; Prefrontal Cortex; RNA, Messenger; Schizophrenia | 2014 |
Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cost of Illness; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Costs; Female; Haloperidol; Health Care Costs; Hospitalization; Humans; Isoxazoles; Male; Middle Aged; Models, Econometric; Olanzapine; Paliperidone Palmitate; Palmitates; Quality-Adjusted Life Years; Risperidone; Schizophrenia; Sweden | 2014 |
Evaluation of the potential of antipsychotic agents to induce catalepsy in rats: assessment of a new, commercially available, semi-automated instrument.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Catalepsy; Clozapine; Haloperidol; Hand Strength; Male; Olanzapine; Posture; Psychology, Experimental; Rats; Rats, Sprague-Dawley | 2014 |
Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain-Derived Neurotrophic Factor; Clozapine; Female; Genetic Association Studies; Genotype; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pharmacogenetics; Polymorphism, Single Nucleotide; Predictive Value of Tests; Risperidone; Schizophrenia; Treatment Outcome | 2014 |
Despite expert recommendations, second-generation antipsychotics are not often prescribed in the emergency department.
Topics: Administration, Oral; Adult; Alcoholic Intoxication; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Droperidol; Drug Prescriptions; Drug Therapy, Combination; Emergency Service, Hospital; Female; Haloperidol; Hospitals, University; Humans; Male; Middle Aged; Olanzapine; Piperazines; Practice Guidelines as Topic; Practice Patterns, Physicians'; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles | 2014 |
[Emergency psychopharmacotherapy in Hungary -- preliminary data].
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clopenthixol; Droperidol; Drug Prescriptions; Drug Therapy, Combination; Emergency Treatment; Female; Haloperidol; Humans; Hungary; Male; Middle Aged; Olanzapine; Piperazines; Practice Patterns, Physicians'; Promethazine; Psychiatry; Psychomotor Agitation; Psychotic Disorders; Quinolones; Surveys and Questionnaires | 2014 |
[Antipsychotic-induced priapism and management challenges: a case report].
Topics: Antipsychotic Agents; Benzodiazepines; Drug Substitution; Follow-Up Studies; Haloperidol; Hospitals, Psychiatric; Humans; Male; Morocco; Olanzapine; Priapism; Recurrence; Schizophrenia; Schizophrenic Psychology; Treatment Refusal; Young Adult | 2014 |
Effects of antipsychotic drugs on insight in schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Awareness; Benzodiazepines; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Thiazoles | 2014 |
Effect of environmental cues on the behavioral efficacy of haloperidol, olanzapine, and clozapine in rats.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Cues; Drug Tolerance; Environment; Excitatory Amino Acid Antagonists; Haloperidol; Housing, Animal; Hyperkinesis; Male; Motor Activity; Olanzapine; Phencyclidine; Random Allocation; Rats, Sprague-Dawley | 2014 |
Generalized estimating equation model and long-term exposure effect of antipsychotics on SH-SY5Y cells against oxidative stressors.
Topics: 1-Methyl-4-phenylpyridinium; Amyloid beta-Peptides; Antipsychotic Agents; Benzodiazepines; Cell Line, Tumor; Cell Survival; Glutathione; Haloperidol; Humans; Hydrogen Peroxide; Models, Biological; Neuroprotective Agents; Olanzapine; Oxidative Stress; Paliperidone Palmitate; Peptide Fragments; Protein Carbonylation; Risperidone | 2014 |
Examining dopamine D3 receptor occupancy by antipsychotic drugs via [3H]7-OH-DPAT ex vivo autoradiography and its cross-validation via c-fos immunohistochemistry in the rat brain.
Topics: Animals; Antipsychotic Agents; Autoradiography; Benzodiazepines; Clozapine; Dopamine Antagonists; Haloperidol; Indoles; Islands of Calleja; Male; Nitriles; Olanzapine; Piperidines; Proto-Oncogene Proteins c-fos; Radiography; Rats, Wistar; Receptors, Dopamine D2; Receptors, Dopamine D3; Tetrahydroisoquinolines; Tetrahydronaphthalenes | 2014 |
Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Delirium; Dementia; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Risperidone | 2015 |
Glutamate receptor 1 phosphorylation at serine 845 contributes to the therapeutic effect of olanzapine on schizophrenia-like cognitive impairments.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Cognition Disorders; Disease Models, Animal; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Haloperidol; Hippocampus; Male; Memory, Short-Term; Neuronal Plasticity; Olanzapine; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Schizophrenia; Spatial Learning | 2014 |
Comparative analysis of the treatment of chronic antipsychotic drugs on epileptic susceptibility in genetically epilepsy-prone rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Disease Models, Animal; Epilepsy; Haloperidol; Mental Disorders; Olanzapine; Quetiapine Fumarate; Rats; Risperidone; Seizures | 2015 |
Novel Therapeutic Strategies for Delirium in Patients With Cancer: A Preliminary Study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cross-Sectional Studies; Delirium; Female; Half-Life; Haloperidol; Humans; Male; Middle Aged; Neoplasms; Olanzapine; Quetiapine Fumarate; Risperidone; Severity of Illness Index | 2016 |
Differential effects of short- and long-term antipsychotic treatment on the expression of neuregulin-1 and ErbB4 receptors in the rat brain.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cerebral Cortex; Female; Haloperidol; Hippocampus; Neuregulin-1; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, ErbB-4; Schizophrenia; Signal Transduction; Time Factors; Up-Regulation | 2015 |
Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database.
Topics: Algorithms; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Data Mining; Databases, Factual; Dibenzothiazepines; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Thiazoles | 2015 |
Temporal and spatial transcriptional fingerprints by antipsychotic or propsychotic drugs in mouse brain.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Dizocilpine Maleate; Gene Expression Profiling; Gene Expression Regulation; Hallucinogens; Haloperidol; Methamphetamine; Mice; Olanzapine; Phencyclidine; Receptors, Dopamine D2 | 2015 |
Are reduplicative paramnesia and clonal pluralization overlapping constructs?
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Capgras Syndrome; Clozapine; Diagnosis, Differential; Haloperidol; Humans; Identification, Psychological; Male; Olanzapine; Psychiatric Status Rating Scales; Schizophrenia, Paranoid; Treatment Outcome | 2015 |
Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm.
Topics: Aged; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Dementia; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Psychotropic Drugs; Quetiapine Fumarate; Registries; Retrospective Studies; Risk; Risperidone; United States; Veterans | 2015 |
Risk of ischemic stroke associated with the use of antipsychotic drugs in elderly patients: a retrospective cohort study in Korea.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Cohort Studies; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Olanzapine; Proportional Hazards Models; Quetiapine Fumarate; Republic of Korea; Retrospective Studies; Risk; Stroke; Time Factors | 2015 |
Antipsychotic treatment leading to dopamine supersensitivity persistently alters nucleus accumbens function.
Topics: Amphetamine; Animals; Antipsychotic Agents; Benzodiazepines; Conditioning, Operant; Dopamine; Dopamine Agonists; Drug Resistance; GABA Agonists; Haloperidol; Male; Motor Activity; Nucleus Accumbens; Olanzapine; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, GABA; Reward | 2015 |
Effect of short and long-term treatment with antipsychotics on orexigenic/anorexigenic neuropeptides expression in the rat hypothalamus.
Topics: alpha-MSH; Animals; Antipsychotic Agents; Benzodiazepines; Calcium-Binding Proteins; Chlorpromazine; DNA-Binding Proteins; Drug Administration Schedule; Haloperidol; Hypothalamus; Male; Nerve Tissue Proteins; Neuropeptide Y; Nucleobindins; Olanzapine; Orexin Receptors; Orexins; Pro-Opiomelanocortin; Rats; Rats, Sprague-Dawley; Receptor, Melanocortin, Type 4; Receptors, G-Protein-Coupled; Receptors, Neuropeptide | 2015 |
A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Cost-Benefit Analysis; Drug Costs; Haloperidol; Health Care Costs; Humans; Middle Aged; Olanzapine; Quality-Adjusted Life Years; Risperidone; Schizophrenia; Uganda | 2015 |
Altered expression of CDC42 signaling pathway components in cortical layer 3 pyramidal cells in schizophrenia.
Topics: Adult; Animals; Antipsychotic Agents; Benzodiazepines; cdc42 GTP-Binding Protein; Cytoskeletal Proteins; Female; Gene Expression Regulation; GTP-Binding Protein Regulators; Haloperidol; Humans; Laser Capture Microdissection; Lim Kinases; Macaca fascicularis; Male; Middle Aged; Olanzapine; p21-Activated Kinases; Prefrontal Cortex; rho GTP-Binding Proteins; rho Guanine Nucleotide Dissociation Inhibitor alpha; RNA-Binding Proteins; Schizophrenia; Signal Transduction | 2015 |
Metabotropic glutamate receptor 5, and its trafficking molecules Norbin and Tamalin, are increased in the CA1 hippocampal region of subjects with schizophrenia.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; CA1 Region, Hippocampal; Carrier Proteins; Chlorpromazine; Dimerization; Female; Haloperidol; Humans; Immunoblotting; Male; Membrane Proteins; Middle Aged; Nerve Tissue Proteins; Neuropeptides; Olanzapine; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Schizophrenia | 2015 |
Investigation into effects of antipsychotics on ectonucleotidase and adenosine deaminase in zebrafish brain.
Topics: Adenosine Deaminase; Adenosine Triphosphatases; Animals; Antipsychotic Agents; Benzodiazepines; Brain; Female; Haloperidol; Hydrolysis; Male; Olanzapine; Sulpiride; Zebrafish; Zebrafish Proteins | 2015 |
Effects of antipsychotic drugs on the expression of synapse-associated proteins in the frontal cortex of rats subjected to immobilization stress.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; beta Catenin; Blotting, Western; Brain-Derived Neurotrophic Factor; Disks Large Homolog 4 Protein; Frontal Lobe; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Haloperidol; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Olanzapine; Rats; Rats, Sprague-Dawley; Stress, Physiological; Synapses; Synaptophysin | 2015 |
Microglial activation in the rat brain following chronic antipsychotic treatment at clinically relevant doses.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Calcium-Binding Proteins; Cell Count; Cell Proliferation; Haloperidol; Immunohistochemistry; Male; Microfilament Proteins; Microglia; Neuroimmunomodulation; Olanzapine; Random Allocation; Rats, Sprague-Dawley | 2015 |
Olanzapine Is Faster than Haloperidol in Inducing Metabolic Abnormalities in Schizophrenic and Bipolar Patients.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Female; Follow-Up Studies; Haloperidol; Humans; Male; Metabolic Diseases; Middle Aged; Olanzapine; Psychiatric Status Rating Scales; Retrospective Studies; Schizophrenia; Severity of Illness Index | 2015 |
Effects of long-term treatment with the neuroleptics haloperidol, clozapine and olanzapine on immunoexpression of NMDA receptor subunits NR1, NR2A and NR2B in the rat hippocampus.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; CA1 Region, Hippocampal; CA2 Region, Hippocampal; CA3 Region, Hippocampal; Clozapine; Dentate Gyrus; Haloperidol; Hippocampus; Male; Olanzapine; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Signal Transduction | 2015 |
Effects of neuroleptics administration on adult neurogenesis in the rat hypothalamus.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Doublecortin Protein; Haloperidol; Hypothalamus; Male; Neurogenesis; Neurons; Olanzapine; Rats | 2015 |
Tyrosine hydroxylase localization in the nucleus accumbens in schizophrenia.
Topics: Adult; Animals; Antipsychotic Agents; Benzodiazepines; Dopamine; Female; Haloperidol; Humans; Male; Middle Aged; Nucleus Accumbens; Olanzapine; Rats; Rats, Sprague-Dawley; Schizophrenia; Tyrosine 3-Monooxygenase | 2016 |
The atypical antipsychotic, olanzapine, potentiates ghrelin-induced receptor signaling: An in vitro study with cells expressing cloned human growth hormone secretagogue receptor.
Topics: Antipsychotic Agents; Benzodiazepines; Cell Line; Ghrelin; Haloperidol; Humans; In Vitro Techniques; MAP Kinase Signaling System; Olanzapine; Receptors, Ghrelin | 2016 |
In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions: link to spatial receptor occupancy.
Topics: Animals; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B; Benzodiazepines; Blood-Brain Barrier; Brain; Cerebrospinal Fluid; Clozapine; Haloperidol; Male; Neuropharmacology; Olanzapine; Paliperidone Palmitate; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Risperidone | 2016 |
Antipsychotic Drugs Differentially Affect mRNA Expression of Genes Encoding the Neuregulin 1-Downstream ErbB4-PI3K Pathway.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Cell Line, Tumor; Cell Survival; Clozapine; Gene Expression Regulation; Haloperidol; Humans; Neuregulin-1; Olanzapine; Phosphatidylinositol 3-Kinases; Quetiapine Fumarate; Receptor, ErbB-4; RNA, Messenger; Schizophrenia; Sulpiride | 2016 |
Altered expression of developmental regulators of parvalbumin and somatostatin neurons in the prefrontal cortex in schizophrenia.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Disease Models, Animal; Female; Gene Expression; Haloperidol; Humans; Macaca fascicularis; MafB Transcription Factor; Male; Middle Aged; Neurons; Olanzapine; Parvalbumins; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Prefrontal Cortex; Receptor, Fibroblast Growth Factor, Type 1; RNA, Messenger; Schizophrenia; Somatostatin | 2016 |
[Plasma levels of antipsychotics and the severity of side-effects in the treatment of schizophrenia exacerbation].
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapine; Depression; Drug Therapy, Combination; Female; Haloperidol; Humans; Hyperprolactinemia; Male; Middle Aged; Olanzapine; Prolactin; Risperidone; Schizophrenia; Schizophrenic Psychology; Young Adult | 2015 |
Patient-oriented randomisation: A new trial design applied in the Neuroleptic Strategy Study.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Studies as Topic; Flupenthixol; Haloperidol; Humans; Olanzapine; Patient-Centered Care; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Research Design; Schizophrenia | 2016 |
Multiple Long-Acting Injectable Antipsychotics for Treatment-Resistant Schizophrenia: Case Report.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Drug Therapy, Combination; Haloperidol; Humans; Injections, Intramuscular; Male; Olanzapine; Schizophrenia | 2016 |
Reversal of evoked gamma oscillation deficits is predictive of antipsychotic activity with a unique profile for clozapine.
Topics: Amino Acids; Animals; Antipsychotic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heterocyclic; Clozapine; Disease Models, Animal; Dizocilpine Maleate; Electroencephalography; Haloperidol; Ketamine; Male; Olanzapine; Prepulse Inhibition; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Reflex, Startle; Schizophrenia | 2016 |
Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cost-Benefit Analysis; Delayed-Action Preparations; Haloperidol; Hospitalization; Humans; Olanzapine; Paliperidone Palmitate; Portugal; Quality-Adjusted Life Years; Recurrence; Risperidone; Schizophrenia | 2016 |
The predictive value of early treatment response in antipsychotic-naive patients with first-episode psychosis: Haloperidol versus olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Female; Haloperidol; Humans; Male; Olanzapine; Outcome Assessment, Health Care; Prognosis; Psychiatric Status Rating Scales; Psychotic Disorders; Young Adult | 2016 |
Clozapine and olanzapine are better antioxidants than haloperidol, quetiapine, risperidone and ziprasidone in in vitro models.
Topics: Antioxidants; Antipsychotic Agents; Benzodiazepines; Biphenyl Compounds; Clozapine; Free Radical Scavengers; Haloperidol; Humans; Models, Biological; Neutrophil Activation; Neutrophils; Olanzapine; Picrates; Piperazines; Quetiapine Fumarate; Reactive Oxygen Species; Risperidone; Tetradecanoylphorbol Acetate; Thiazoles | 2016 |
Delirium associated with olanzapine use in the elderly.
Topics: Aged; Antipsychotic Agents; Aortic Aneurysm; Benzodiazepines; Delirium; Haloperidol; Humans; Male; Olanzapine; Postoperative Complications; Treatment Outcome | 2017 |
Extended neuroleptic administration modulates NMDA-R subunit immunoexpression in the rat neocortex and diencephalon.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Diencephalon; Down-Regulation; Haloperidol; Hippocampus; Hypothalamus; Male; N-Methylaspartate; Neocortex; Olanzapine; Protein Subunits; Rats; Rats, Sprague-Dawley; Up-Regulation | 2016 |
Chronic exposure to haloperidol and olanzapine leads to common and divergent shape changes in the rat hippocampus in the absence of grey-matter volume loss.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Female; Gray Matter; Haloperidol; Hippocampus; Magnetic Resonance Imaging; Male; Olanzapine; Organ Size; Rats | 2016 |
First and second generation antipsychotics differentially affect structural and functional properties of rat hippocampal neuron synapses.
Topics: Animals; Antipsychotic Agents; Astrocytes; Benzodiazepines; Cells, Cultured; Coculture Techniques; Female; Haloperidol; Hippocampus; Neurons; Olanzapine; Rats; Schizophrenia; Synapses | 2016 |
Re-arrangements of gene transcripts at glutamatergic synapses after prolonged treatments with antipsychotics: A putative link with synaptic remodeling.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Dibenzocycloheptenes; Disks Large Homolog 4 Protein; Gene Expression; Haloperidol; Heterocyclic Compounds, 4 or More Rings; Male; Neostriatum; Nerve Tissue Proteins; Neuronal Plasticity; Olanzapine; Post-Synaptic Density; Rats; Rats, Sprague-Dawley | 2017 |
Time-dependent sensitization of antipsychotic effect in adolescent male and female rats.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Drug Tolerance; Excitatory Amino Acid Antagonists; Female; Haloperidol; Male; Motor Activity; Olanzapine; Phencyclidine; Random Allocation; Rats, Sprague-Dawley; Sex Characteristics; Time Factors | 2017 |
Pharmacoepigenomic responses of antipsychotic drugs on pharmacogenes are likely to be modulated by miRNAs.
Topics: Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B; Benzodiazepines; Case-Control Studies; Clozapine; Cytochrome P-450 CYP3A; Epigenesis, Genetic; Haloperidol; Hep G2 Cells; Humans; MicroRNAs; Olanzapine; Promoter Regions, Genetic; Schizophrenia | 2017 |
Comparative effects of sertraline, haloperidol or olanzapine treatments on ketamine-induced changes in mouse behaviours.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Anxiety; Behavior, Animal; Benzodiazepines; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Exploratory Behavior; Grooming; Haloperidol; Interpersonal Relations; Ketamine; Male; Memory Disorders; Memory, Short-Term; Mice; Motor Activity; Olanzapine; Sertraline | 2017 |
Ketamine-induced behavioural and brain oxidative changes in mice: an assessment of possible beneficial effects of zinc as mono- or adjunct therapy.
Topics: Anesthetics, Dissociative; Animals; Antioxidants; Antipsychotic Agents; Benzodiazepines; Brain; Drug Therapy, Combination; Haloperidol; Interpersonal Relations; Ketamine; Male; Maze Learning; Mice; Olanzapine; Oxidative Stress; Schizophrenia; Treatment Outcome; Zinc | 2017 |
Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study.
Topics: Adult; Antipsychotic Agents; Belgium; Benzodiazepines; Delayed-Action Preparations; Drug Administration Schedule; Female; Haloperidol; Humans; Medication Adherence; Netherlands; Olanzapine; Paliperidone Palmitate; Retrospective Studies; Risperidone; Schizophrenia; Treatment Outcome | 2017 |
Oral haloperidol or olanzapine intake produces distinct and region-specific increase in cannabinoid receptor levels that is prevented by high fat diet.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Autoradiography; Benzodiazepines; Brain; Diet, High-Fat; Drinking Water; Exploratory Behavior; Haloperidol; Male; Motor Activity; Olanzapine; Random Allocation; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Recognition, Psychology; Up-Regulation | 2017 |
Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cost-Benefit Analysis; Delayed-Action Preparations; Haloperidol; Humans; Netherlands; Olanzapine; Paliperidone Palmitate; Quality-Adjusted Life Years; Recurrence; Risperidone; Schizophrenia | 2017 |
Effects of haloperidol, olanzapine, ziprasidone, and PHA-543613 on spatial learning and memory in the Morris water maze test in naïve and MK-801-treated mice.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, Animal; Haloperidol; Male; Maze Learning; Memory; Mice; Mice, Inbred C57BL; Olanzapine; Piperazines; Quinuclidines; Schizophrenia; Spatial Learning; Thiazoles; Treatment Outcome | 2017 |
Chronic atypical antipsychotics, but not haloperidol, increase neurogenesis in the hippocampus of adult mouse.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bromodeoxyuridine; Cell Count; Clozapine; Haloperidol; Hippocampus; Immunohistochemistry; Male; Mice, Inbred C57BL; Neurogenesis; Neurons; Olanzapine; Quetiapine Fumarate | 2017 |
The antipsychotic drugs olanzapine and haloperidol modify network connectivity and spontaneous activity of neural networks in vitro.
Topics: Antipsychotic Agents; Cluster Analysis; gamma-Aminobutyric Acid; Haloperidol; Humans; Immunohistochemistry; Neural Pathways; Neurons; Olanzapine; Synapses | 2017 |
Understanding the influence of antipsychotic drugs on global methylation events and its relevance in treatment response.
Topics: 5-Methylcytosine; Adult; Antipsychotic Agents; Case-Control Studies; Clozapine; Cytosine; DNA; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Epigenesis, Genetic; Female; Haloperidol; Hep G2 Cells; Humans; Male; MicroRNAs; Olanzapine; Pharmacogenetics; Schizophrenia; Treatment Outcome | 2018 |
Combined treatment with a selective PDE10A inhibitor TAK-063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic-like effects without affecting plasma prolactin levels and cataleptic responses in rodents.
Topics: Administration, Oral; Akathisia, Drug-Induced; Animals; Antipsychotic Agents; Benzodiazepines; Catalepsy; Corpus Striatum; Dendritic Spines; Disease Models, Animal; Dopamine Antagonists; Drug Synergism; Drug Therapy, Combination; Haloperidol; Humans; Male; Methamphetamine; Mice; Mice, Inbred ICR; Neurons; Olanzapine; Phosphodiesterase Inhibitors; Prolactin; Pyrazoles; Pyridazines; Rats; Rats, Sprague-Dawley; Synaptic Potentials; Treatment Outcome | 2018 |
Predictors of remission during acute treatment of first-episode schizophrenia patients involuntarily hospitalized and treated with algorithm-based pharmacotherapy: Secondary analysis of an observational study.
Topics: Administration, Oral; Adult; Algorithms; Antipsychotic Agents; Clozapine; Commitment of Mentally Ill; Drug Therapy, Combination; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Methotrimeprazine; Olanzapine; Psychotic Disorders; Quetiapine Fumarate; Retrospective Studies; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Failure; Treatment Outcome | 2019 |
Dantrolene for Treatment of Suspected Neuroleptic Malignant Syndrome.
Topics: Analgesics, Opioid; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Dantrolene; Diagnosis, Differential; Fentanyl; Haloperidol; Humans; Levetiracetam; Male; Middle Aged; Neuroleptic Malignant Syndrome; Olanzapine; Phenytoin; Piracetam | 2018 |
[The effect of antipsychotic drug on monoamine receptors in peripheral blood mononuclear cells: affinity linked mechanism].
Topics: Antipsychotic Agents; Cytokines; Haloperidol; Humans; Leukocytes, Mononuclear; Olanzapine; Receptors, Dopamine D1; Receptors, Serotonin, 5-HT2; Schizophrenia | 2018 |
Effects of chronic antipsychotic drug exposure on the expression of Translocator Protein and inflammatory markers in rat adipose tissue.
Topics: Adipose Tissue; Adiposity; Animals; Antigens, Differentiation; Antipsychotic Agents; Biomarkers; Carrier Proteins; Cytokines; Gene Expression; Haloperidol; Inflammation; Insulin Resistance; Interleukin-6; Intra-Abdominal Fat; Macrophages; Male; Obesity; Olanzapine; Rats; Rats, Sprague-Dawley; Receptors, GABA-A | 2018 |
Parenteral Antipsychotic Choice and Its Association With Emergency Department Length of Stay for Acute Agitation Secondary to Alcohol Intoxication.
Topics: Adult; Alcoholic Intoxication; Antipsychotic Agents; Droperidol; Drug Delivery Systems; Emergency Service, Hospital; Female; Haloperidol; Humans; Length of Stay; Male; Middle Aged; Olanzapine; Psychomotor Agitation; Retrospective Studies | 2019 |
Intramuscular Midazolam, Olanzapine, Ziprasidone, or Haloperidol for Treating Acute Agitation in the Emergency Department.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Cohort Studies; Emergency Medical Services; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Mental Status and Dementia Tests; Midazolam; Middle Aged; Olanzapine; Piperazines; Prospective Studies; Psychomotor Agitation; Thiazoles; Treatment Outcome; Young Adult | 2018 |
Ethics and Regulatory Barriers to Research in Emergency Settings.
Topics: Emergency Service, Hospital; Haloperidol; Midazolam; Olanzapine; Piperazines; Thiazoles | 2018 |
Involvement of vascular endothelial growth factor (VEGF) and mitogen-activated protein kinases (MAPK) in the mechanism of neuroleptic drugs.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Cell Line, Tumor; Haloperidol; Humans; Mitogen-Activated Protein Kinases; Neuroprotective Agents; Olanzapine; Pituitary Adenylate Cyclase-Activating Polypeptide; Signal Transduction; Sulpiride; Vascular Endothelial Growth Factor A | 2018 |
Effects of olanzapine and haloperidol on mTORC1 signaling, dendritic outgrowth, and synaptic proteins in rat primary hippocampal neurons under toxic conditions.
Topics: Animals; Antipsychotic Agents; Dendrites; Female; Haloperidol; Hippocampus; Mechanistic Target of Rapamycin Complex 1; Neurites; Neuronal Plasticity; Neurons; Olanzapine; Rats, Sprague-Dawley; Signal Transduction | 2018 |
Antipsychotics and pituitary tumors: an analysis of the European pharmacovigilance database (EudraVigilance).
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Child; Databases, Factual; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Paliperidone Palmitate; Pharmacovigilance; Pituitary Neoplasms; Pregnancy; Quetiapine Fumarate; Retrospective Studies; Risperidone; Sulpiride; Young Adult | 2019 |
Rescue Sedation When Treating Acute Agitation in the Emergency Department With Intramuscular Antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Droperidol; Emergency Service, Hospital; Female; Haloperidol; Humans; Hypnotics and Sedatives; Injections, Intramuscular; Male; Midazolam; Middle Aged; Minnesota; Olanzapine; Psychomotor Agitation; Retrospective Studies | 2019 |
Intramuscular Midazolam, Olanzapine, Ziprasidone, or Haloperidol for Treating Acute Agitation.
Topics: Emergency Service, Hospital; Haloperidol; Midazolam; Olanzapine; Piperazines; Thiazoles | 2019 |
In reply.
Topics: Emergency Service, Hospital; Haloperidol; Midazolam; Olanzapine; Piperazines; Thiazoles | 2019 |
Chronic Antipsychotic Treatment Modulates Aromatase (CYP19A1) Expression in the Male Rat Brain.
Topics: Animals; Antipsychotic Agents; Aromatase; Brain; Clozapine; Haloperidol; Male; Olanzapine; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2019 |
Acute Agitation and the Exception From Informed Consent Requirements.
Topics: Emergency Service, Hospital; Haloperidol; Informed Consent; Midazolam; Olanzapine; Piperazines; Thiazoles | 2019 |
In reply.
Topics: Emergency Service, Hospital; Haloperidol; Midazolam; Olanzapine; Piperazines; Thiazoles | 2019 |
In reply.
Topics: Emergency Service, Hospital; Haloperidol; Midazolam; Olanzapine; Piperazines; Thiazoles | 2019 |
Risk Factors for Noncompliance with Antipsychotic Medication in Long-Term Treated Chronic Schizophrenia Patients.
Topics: Antipsychotic Agents; Clozapine; Haloperidol; Humans; Olanzapine; Patient Compliance; Risk Factors; Schizophrenia; Schizophrenic Psychology | 2019 |
Two cases report of epidemic stress disorder to novel coronavirus pneumonia.
Topics: Aged; Antipsychotic Agents; Betacoronavirus; China; Coronavirus Infections; COVID-19; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pandemics; Pneumonia, Viral; SARS-CoV-2; Stress Disorders, Traumatic, Acute | 2020 |
Situational analysis of prevailing practices in the management of first-episode psychosis in Chennai, India.
Topics: Haloperidol; Humans; India; Olanzapine; Psychotic Disorders; Risperidone | 2021 |
The Effects of Antipsychotics on the Synaptic Plasticity Gene
Topics: Animals; Antipsychotic Agents; Brain; Brain Mapping; Dibenzocycloheptenes; Dose-Response Relationship, Drug; Duration of Therapy; Haloperidol; Heterocyclic Compounds, 4 or More Rings; Homer Scaffolding Proteins; Humans; In Situ Hybridization; Models, Animal; Neuronal Plasticity; Olanzapine; Post-Synaptic Density; Rats; Tissue Distribution | 2020 |
Metabolic profile of methylazoxymethanol model of schizophrenia in rats and effects of three antipsychotics in long-acting formulation.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Female; Haloperidol; Lipid Metabolism; Male; Metabolome; Methylazoxymethanol Acetate; Olanzapine; Rats, Sprague-Dawley; Risperidone; Schizophrenia | 2020 |
Three Cases of COVID-19-related First Onset Brief Reactive Psychosis.
Topics: Adult; Antipsychotic Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Delusions; Haloperidol; Humans; Involuntary Treatment; Lorazepam; Male; Olanzapine; Pandemics; Paranoid Behavior; Pneumonia, Viral; Psychotic Disorders; SARS-CoV-2; Social Isolation; Treatment Outcome | 2020 |
Interacting effects of the MAM model of schizophrenia and antipsychotic treatment: Untargeted proteomics approach in adipose tissue.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Disease Models, Animal; Female; Haloperidol; Intra-Abdominal Fat; Methylazoxymethanol Acetate; Olanzapine; Pregnancy; Prenatal Exposure Delayed Effects; Proteomics; Rats; Rats, Sprague-Dawley; Risperidone; Schizophrenia; Signal Transduction; TOR Serine-Threonine Kinases | 2021 |
Postpartum psychosis in mothers with SARS-CoV-2 infection: A case series from India.
Topics: Antipsychotic Agents; Asymptomatic Infections; COVID-19; Delusions; Female; Hallucinations; Haloperidol; Humans; India; Olanzapine; Psychotic Disorders; Puerperal Disorders; Restraint, Physical; Self-Injurious Behavior; Trihexyphenidyl; Young Adult | 2020 |
Exploring a Safety Signal of Antipsychotic-Associated Pneumonia: A Pharmacovigilance-Pharmacodynamic Study.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antipsychotic Agents; Clozapine; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pharmacovigilance; Pneumonia; Pneumonia, Aspiration; Receptors, Muscarinic; United States; United States Food and Drug Administration; Young Adult | 2021 |
A Retrospective Comparison of the Effectiveness and Safety of Intravenous Olanzapine Versus Intravenous Haloperidol for Agitation in Adult Intensive Care Unit Patients.
Topics: Adult; Antipsychotic Agents; Haloperidol; Humans; Intensive Care Units; Olanzapine; Retrospective Studies | 2022 |
Risk and Prevention of Aggression in Patients With Psychotic Disorders.
Topics: Aggression; Clozapine; Conduct Disorder; Haloperidol; Humans; Olanzapine; Psychotic Disorders; Schizophrenia; Violence | 2021 |
Dispersive Liquid-Liquid Microextraction Based Preconcentration of Selected Pesticides and Escitalopram Oxalate, Haloperidol, and Olanzapine from Wastewater Samples Prior to Determination by GC-MS.
Topics: Citalopram; Gas Chromatography-Mass Spectrometry; Haloperidol; Humans; Limit of Detection; Liquid Phase Microextraction; Olanzapine; Pesticides; Wastewater; Water Pollutants, Chemical | 2021 |
Clinical practice guideline on pharmacological and psychological management of adult patients with schizophrenia spectrum disorders and a comorbid substance use.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Nicotine; Olanzapine; Practice Guidelines as Topic; Schizophrenia; Substance-Related Disorders | 2022 |
Extrapyramidal Symptoms Induced by Treatment for Delirium: A Case Report.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Intensive Care Units; Male; Middle Aged; Olanzapine | 2021 |
Therapeutic potential of TAK-071, a muscarinic M
Topics: Allosteric Regulation; Animals; Antipsychotic Agents; CHO Cells; Cognition; Cognitive Dysfunction; Cricetulus; Disease Models, Animal; Haloperidol; Humans; Memory, Short-Term; Mice; Mice, Transgenic; MicroRNAs; Muscarinic Agonists; Olanzapine; Quetiapine Fumarate; Receptor, Muscarinic M1; Recombinant Proteins; Schizophrenia; Social Behavior | 2021 |
The first patient to receive olanzapine: A recollection.
Topics: Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Haloperidol; Humans; Olanzapine | 2021 |
Olanzapine intramuscular shows better efficacy than zuclopenthixol acetate intramuscular in reducing the need for restraint, but not in comparison to haloperidol intramuscular.
Topics: Antipsychotic Agents; Benzodiazepines; Clopenthixol; Haloperidol; Humans; Injections, Intramuscular; Olanzapine; Psychomotor Agitation; Psychotic Disorders | 2022 |
Gene expression changes following chronic antipsychotic exposure in single cells from mouse striatum.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Gene Expression; Haloperidol; Humans; Male; Mice; Mice, Inbred C57BL; Olanzapine; RNA | 2022 |
Chronic oral olanzapine treatment but not haloperidol decreases [
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Diet; Dizocilpine Maleate; Haloperidol; Male; Olanzapine; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Substantia Nigra | 2022 |
Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Clozapine; Drug-Related Side Effects and Adverse Reactions; Haloperidol; Humans; Olanzapine; Paliperidone Palmitate; Quetiapine Fumarate; Retrospective Studies; Risperidone; Schizophrenia | 2022 |
Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Topics: Adenosine Monophosphate; Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Clopenthixol; Clozapine; Flupenthixol; Fluphenazine; Haloperidol; Humans; Olanzapine; Paliperidone Palmitate; Pharmaceutical Preparations; Pimozide; Quetiapine Fumarate; Risperidone; Sulpiride; Trifluoperazine | 2022 |
[Neuroleptic malignant syndrome caused by olanzapine, risperidone and haloperidol].
Topics: Adult; Antipsychotic Agents; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome; Olanzapine; Risperidone | 2022 |
Interhemispheric differences of pyramidal cells in the primary motor cortices of schizophrenia patients investigated postmortem.
Topics: Aged; Aged, 80 and over; Aging; Animals; Antipsychotic Agents; Autopsy; Datasets as Topic; Disease Models, Animal; Female; Functional Laterality; Haloperidol; Humans; Immunohistochemistry; Intermediate Filaments; Male; Middle Aged; Motor Cortex; Olanzapine; Parvalbumins; Pyramidal Cells; Rats; Rats, Sprague-Dawley; Regression Analysis; Schizophrenia | 2023 |
Practice of prescribing antipsychotics in schizophrenia during 2013-2018 based on data from the National Health Fund.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Olanzapine; Risperidone; Schizophrenia | 2022 |
Comparative Safety Analysis of Oral Antipsychotics for In-Hospital Adverse Clinical Events in Older Adults After Major Surgery : A Nationwide Cohort Study.
Topics: Aged; Antipsychotic Agents; Cohort Studies; Emergence Delirium; Female; Haloperidol; Hospital Mortality; Hospitals; Humans; Ischemic Attack, Transient; Male; Olanzapine; Quetiapine Fumarate; Retrospective Studies; Risperidone | 2023 |
Second International Consensus Study of Antipsychotic Dosing (ICSAD-2).
Topics: Antipsychotic Agents; Delayed-Action Preparations; Haloperidol; Humans; Olanzapine; Psychotic Disorders; Schizophrenia | 2023 |